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Chapter 1
Introduction
As early as the 13th century, we are aware that ‘an ounce of prevention is worth a pound of 
cure’ 1. Disease prevention plays an important role in modern day medicine. The World 
Health Organization has put prevention forward as it is the most cost-effective long-term 
strategy for the control of disease 2. Prevention of diseases increases quality of life and 
reduces health care costs.
This thesis concentrates on prevention. Part I deals with the prevention of 
the most prevalent and detrimental complication of endoscopic retrograde 
cholangiopancreatography (ERCP): post-ERCP pancreatitis (PEP) 3. The core of Part I is 
the FLUYT trial, a large scale randomized controlled trial that investigates periprocedural 
hydration in the prevention of PEP. In Part II, prevention is approached from a different 
angle and the scope is widened to acute pancreatitis (AP) of all aetiologies: how can we 
predict the disease course of acute pancreatitis? Through early prognostication it may 
be possible to influence the disease course of AP and prevent patients from reaching the 
severest disease stages with necrosis and organ failure. This requires accurate predictive 
algorithms and identification of factors that are associated with a severe disease course. 
Table 1 summarizes the research questions addressed in this thesis and subsequent 
paragraphs will discuss the underlying rationale. 
Table 1: Summary of research questions addressed in this thesis
Part I: Prevention of post-ERCP pancreatitis
Which classification system (consensus or revised Atlanta) is the most accurate reflection of 
PEP severity?
How can severe post-ERCP pancreatitis be predicted?
What is the evidence for periprocedural hydration to prevent post-ERCP pancreatitis?
Does periprocedural hydration with lactated Ringer’s solution reduce the incidence of post-
ERCP pancreatitis in moderate-high risk patients undergoing ERCP who already receive 
prophylactic rectal NSAIDs?
Part II: Prediction of AP disease course
What is the association between portal system vein diameter and severity of acute 
pancreatitis?
What is the evidence for angiography and perfusion computed tomography for predicting 
severity of acute pancreatitis?
What is the association between obesity and outcomes in acute pancreatitis?
AP: acute pancreatitis. ERCP: endoscopic retrograde cholangiopancreatography. NSAID: non-
steroidal anti-inflammatory drugs. PEP: post-ERCP pancreatitis.
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Part I: Prevention of post-ERCP pancreatitis
Endoscopic retrograde cholangiopancreatography 
Endoscopic retrograde cholangiopancreatography (ERCP) is a procedure to treat diseases 
of the pancreatobiliary system, such as choledocholithiasis and chronic pancreatitis 
4. A flexible endoscope is passed through the mouth, stomach and first part of the 
duodenum to papilla of Vater, the entrance to the common bile duct and pancreatic 
duct (figure 1). The system is visualized through contrast injection and subsequent 
X-ray and by instrumentation diseases can be treated. ERCP is mainly performed by 
gastroenterologists, although surgeons can be involved as well 5.
Figure 1: Endoscopic retrograde cholangiopancreatography6. Panel A displays the anatom-
ical relationship between duodenum, gallbladder, bile duct and pancreatic duct. Panel B and C 
show how instruments such as guidewires can aide in treating diseases of the pancreatobiliary 
tree. In this case, a gallstone is removed. 
The first peroral cannulation of the ampulla of Vater was reported in 1965 7. After 
its introduction, ERCP evolved from a diagnostic to a therapeutic procedure 8. ERCP 
utilization in the United States (US) increased with 24% between 2000 and 2010 to 288,715 
procedures yearly 9. A minimum of 200 procedures is necessary before credentials are 
1
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Chapter 1
provided 10. ERCP has a steep learning curve and is therefore rightfully regarded as 
‘advanced’ endoscopy, not in the least due to the high complication rate involved.
Complications of ERCP
Indeed, from the earliest days of ERCP physicians are aware that the procedure carries a 
substantial risk of complications. In the first reported series of endoscopic cannulation 
in 50 patients, McCune mentions that ‘the danger of producing pancreatitis […] has been in 
our minds’ 11. ERCP bears the highest complication rate of all endoscopic procedures of 7% 
and an ERCP-related mortality of 0.33% 12. Complications include bleeding, perforation, 
infection and instrument impaction 13. However, the most prevalent and most serious 
complication is PEP: it encompasses 51% of all ERCP-related complications and 33% of 
ERCP-related deaths 12. 
Post-ERCP pancreatitis
Post-ERCP pancreatitis is an inflammatory process of the pancreas. The reason why an 
ERCP can induce acute pancreatitis can be understood from the anatomical relationship 
between the biliary system and the adjacent pancreas (figure 1, panel A). One can imagine 
that procedures performed in close proximity of the pancreas can lead to irritation and 
subsequent inflammation of the organ. Indeed, PEP is thought to arise from a combination 
of mechanical (e.g. increased intraductal pressure by instrumentation), chemical (through 
contrast media used during ERCP), enzymatic (reflux of activated intestinal enzymes) 
and microbiological (i.e. reflux of intestinal bacteria) factors 14. However, the exact 
mechanisms underlying PEP remain poorly understood. 
Overall, PEP has an incidence of 3.5% 12, but it approaches 15% in high-risk patients 
3. The classic high-risk patient is a young woman met a suspicion of sphincter of Oddi 
dysfunction 15. PEP is characterized clinically by severe abdominal pain radiating to the 
back and a rise in serum amylase or lipase (digestive enzymes produced by the pancreas). 
It is often accompanied by nausea and vomiting. The disease course is mild, moderate or 
severe in 60%, 30% and 10% of patients, respectively (table 2). The overall mortality rate 
is 0.7% 3. In patients with a mild disease course, the inflammatory process is confined 
to the pancreas itself and these patients recover uneventful in the span of a few days. 
However, in some patients the disease progresses to necrotizing pancreatitis with an 
systemic inflammatory response that can lead to failure of distant organ systems 16. 
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Definition of post-ERCP pancreatitis
Both abdominal pain and hyperamylasemia are common after ERCP 17. This makes it 
difficult to distinguish transient pain after ERCP from a clinically relevant PEP. In 1991, 
an influential meeting was held to provide investigators and endoscopists with guidelines 
to categorize and treat ERCP complications 13. There it was decided that for a diagnosis of 
PEP both abdominal pain and hyperamylasemia should be present at more than 24 hours 
after ERCP and hospitalization should be prolonged for at least two days. At the same 
conference, PEP severity was defined as mild, moderate or severe primarily on the basis 
of length of hospital stay (table 2). 
Table 2: Definition of post-ERCP pancreatitis and its severity 13
Mild New or increased abdominal pain consistent with pancreatitis
Serum amylase/lipase ≥3xULN at more than 24 hours after ERCP
Admission or prolongation of planned admission for 2-3 days
Moderate Hospitalization of 4-10 days
Severe Hospitalization of >10 days, or 
Hemorrhagic pancreatitis, phlegmon, pseudocyst, or 
Intervention (percutaneous drainage or surgery)
ERCP: endoscopic retrograde cholangiopancreatography. ULN: upper limit of normal.
Adequate stratification of disease severity is important to predict prognosis. It enables 
researchers and clinicians to compare the efficacy of prophylactic measures that prevent 
PEP or reduce its severity. The question is whether length of hospital stay accurately 
reflects disease severity. In acute pancreatitis, hospital stay is influenced by comorbidity, 
department, fasting period and diagnostics 18. In general, hospital stay is dependent on 
cultural and institutional policies 19. Also, competing diagnoses and logistic issues (e.g. 
transfer to care home) could influence length of stay. Finally, it must be noted that acute 
pancreatitis of other aetiology is defined according to the revised Atlanta classification, 
which hampers comparison with other aetiologies 20. These observations led to the 
following research question:
Which classification system (consensus or revised Atlanta) is the most accurate 
reflection of PEP severity? (Chapter 2)
Our hypothesis is that the revised Atlanta criteria are a better reflection of PEP severity. 
We will investigate this in a multicenter retrospective cohort study. The multicenter 
design allows us to create a large PEP cohort that will contain enough severe cases for 
an adequate comparison. 
1
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Prevention of post-ERCP pancreatitis
Due to the high complication rate that accompanies PEP, many studies have focused on 
identification of risk factors and design of prophylactic measures. Risk factors are used 
for identifying patients that benefit most from ERCP, thereby justifying their exposure 
to complications 21. Alternatively, in patients with an unfavourable risk/benefit ratio, 
clinicians can resort to less invasive procedures such as endoscopic ultrasound (EUS) 
or magnetic resonance cholangiopancreatography (MRCP) 22,23. The PEP risk of ERCP 
techniques is the subject of investigation in order to establish an atraumatic ERCP practice 
with a low risk of PEP. In 2014, the European Society of Gastrointestinal Endoscopy (ESGE) 
summarized the evidence for ERCP risk factors (table 3) 24.  
Table 3: Risk factors for post-ERCP pancreatitis 24
Patient related Procedure related
Suspected SOD
Female gender
Previous pancreatitis
Previous PEP
Younger age
Nondilated extrahepatic bile ducts
Absence of chronic pancreatitis
Normal serum bilirubin
Cannulation attempts duration >10 minutes
Pancreatic guidewire passage >1
Pancreatic injection
Precut sphincterotomy
Pancreatic sphincterotomy
Biliary balloon sphincter dilation
Failure to clear bile duct stones
Intraductal ultrasound
PEP: post-ERCP pancreatitis. SOD: Sphincter of Oddi dysfunction. 
Apart from risk factor identification, efforts have been made to identify prophylactic 
measures for PEP. At least 28 pharmacologic agents have been  tested in randomized 
controlled trials 25. Despite these efforts only two prophylactics have been judged to be 
effective in reducing PEP: rectal nonsteroidal anti-inflammatory drugs (NSAIDs) and 
pancreatic duct (PD) stents 26–28. 
Many efforts have been directed to introduce measures to prevent PEP, while less attention 
went to studies that focus on reduction of PEP severity. The relative contribution of 
patient- and procedure-related factors and prophylactics in the prediction of PEP severity 
has not been investigated to date. Therefore, we formulated the following research 
question: 
How can severe post-ERCP pancreatitis be predicted? (Chapter 3)
Our hypothesis is that traditional patient- and ERCP-related risk factors for PEP are 
also associated with severe PEP. Furthermore, we hypothesize that rectal NSAIDs and 
526323-L-bw-Smeets
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PD-stents will reduce severe PEP. We will investigate this in a multicenter retrospective 
cohort study through multivariable logistic regression analysis and creation of a 
prediction model. 
Periprocedural hydration to prevent post-ERCP pancreatitis
In 2014 a pilot study was published that investigated periprocedural hydration with 
lactated Ringer’s solution to prevent PEP 29. This strategy was designed to preserve 
adequate pancreatic perfusion and tissue oxygenation during ERCP. The thinking was that 
early pancreatic microcirculatory perfusion disturbances are correlated with severity of 
acute pancreatitis 30. Circumstantial evidence supporting this theory is that an increased 
level of pre-procedural blood urea nitrogen, a marker of haemoconcentration, has been 
associated with PEP development and severity 31,32. The results were promising with 
17% PEP in the control group against 0% in the intervention group. However, the trial 
was inadequately powered and the included patients did not receive prophylactic rectal 
NSAIDs. These cannot be withheld from patients due to the clear evidence in favour of 
their use. These observations led to the third and fourth research question of this thesis: 
What is the evidence for periprocedural hydration to prevent post-ERCP pancreatitis? 
(Chapter 4)
Our hypothesis is that periprocedural hydration significantly reduces the incidence of 
post-ERCP pancreatitis. In a systematic review we will summarize the evidence for this 
hypothesis to ensure we identify all studies to date on this subject. In that way, a reliable 
overview of evidence to date can be given 33. 
Does periprocedural hydration with lactated Ringer’s solution reduce the incidence of 
post-ERCP pancreatitis in moderate-high risk patients undergoing ERCP who already 
receive prophylactic rectal NSAIDs? (Chapters 5 and 6)
Our hypothesis is that periprocedural hydration significantly reduces the incidence 
of post-ERCP pancreatitis and PEP severity. We will investigate this by conducting a 
multicenter, parallel group, superiority randomized controlled trial in 826 patients from 
20 hospitals of the Dutch Pancreatitis Study Group. We chose this design because an RCT 
offers the highest level of evidence concerning effectiveness of treatments 34,35.
1
526323-L-bw-Smeets
Processed on: 22-11-2018 PDF page: 14
14
Chapter 1
Part II: Prediction of AP disease course
Disease progression of acute pancreatitis
The disease course of AP represents a continuum from mild, interstitial pancreatitis to 
fulminant necrotizing pancreatitis. The mortality rate of interstitial AP is below 2%, but 
it increases rapidly once necrosis and organ failure develop 16,36,37. Necrotizing pancreatitis 
occurs in 15% of cases, a third of which becomes infected with an associated mortality 
rate up to 30% 38. Persistent organ failure early in the disease course has an associated 
mortality up to 50% 20. 
One of the pathophysiological hallmarks of AP is extravasation of fluids to the third 
space due to increased endothelial permeability and circulatory stasis 39. The median 
fluid sequestration in the first 48 hours is 3.2L 40. It leads to reduced intravascular volume 
and can result in hypovolemic shock 41. Blood flow to vital organs is maintained at the 
expense of the gastrointestinal system through vasoconstriction of the splanchnic 
circulation (blood flow of the gut, spleen, pancreas and liver). This results in ischemia 
of the mesenteric organs 42–44. The circulatory changes are involved in development of 
local complications such as necrosis, as well as systemic complications like organ failure 
30. These processes are the rationale behind aggressive fluid hydration as the cornerstone 
of early AP treatment or as a prophylactic measure to prevent post-ERCP pancreatitis.   
Prediction of disease progression
Because the circulatory changes in AP are present within hours of disease onset 45, they 
can serve as a starting point for prognostication of disease severity. Early prognostication 
can guide clinicians in their choices regarding aggressiveness of fluid resuscitation, 
transfer to an intensive care unit for close monitoring or referral to a tertiary care centre 
for specialized treatment. A myriad of prognostic scoring systems is available, but their 
predictive performance often leaves much to be desired with areas under the curve (AUC) 
as low as 0.57 46–48. Therefore, it can be useful to optimize existing scoring systems or 
identify new ways of predicting severity. 
A prospective cohort of patients with severe AP reported that non-visualisation of the 
portal and splenic vein (due to a supposed smaller vein diameter) was associated with 
increased disease severity 49. This led us to the fifth research question of this thesis:
526323-L-bw-Smeets
Processed on: 22-11-2018 PDF page: 15
15
Introduction
What is the association between portal system vein diameter and severity of acute 
pancreatitis? (Chapter 7)
We hypothesize that smaller portal system vein diameter (portal, splenic and superior 
mesenteric veins) is associated with severe acute pancreatitis. We will conduct a post-
hoc analysis of prospective data to investigate this hypothesis. By using existing data, 
we can first build an evidence base for our theory before conducting a prospective study 
that exposes patients to radiation. The use of data from randomized trials ensures that 
endpoints are defined and collected prospectively, increasing the reliability of results.
The microvasculature changes within the pancreas itself can be used for prognostication 
as well. Microcirculatory derangements correlate with disease severity 50,51. Early changes 
in microcirculation can be visualized with perfusion computed tomography (PCT) and 
angiography, but the prognostic performance of these measures have not been critically 
evaluated to date. This led us to formulate the sixth research question of this thesis: 
What is the evidence for angiography and perfusion computed tomography for 
predicting severity of acute pancreatitis? (Chapter 8)
Our hypothesis is that perfusion computed tomography and angiography can accurately 
predict necrosis. We will conduct a systematic review to summarize the evidence for this 
hypothesis. In that way, we can identify current knowledge gaps and provide an overview 
of the techniques and parameters that are used in PCT and angiography, as these are 
expected to vary widely. 
There are data to suggest that obesity plays a role in AP disease progression as well 52. 
Pancreatic enzymes released in AP are thought to digest adipocytes, causing an outflux 
of unsaturated fatty acids that aggravate local and systemic complications 53. However, 
evidence to date is mostly from small cohorts that report only unadjusted outcomes 54. 
Therefore, whether obesity is independently associated with outcomes in AP is open to 
debate. This led us to the seventh and final research question of this thesis:
What is the association between obesity and outcomes in acute pancreatitis? (Chapter 9)
Our hypothesis is that obesity is independently associated with mortality in acute 
pancreatitis. We will investigate this by means of an individual patient data meta-analysis 
(IPDMA) of prospective cohorts. This design allows us to address the methodological 
shortcomings of individual studies and meta-analyses already published 55,56.
1
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ABSTRACT
Background and Aims
Post endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the 
most prevalent complication after ERCP with an incidence of 3.5% and mortality of 3%. 
PEP severity is classified according to the consensus or revised Atlanta criteria. The 
consensus criteria use length of stay as a differentiator, while the revised Atlanta criteria 
focus on local and systemic adverse events. We question whether length of stay accurately 
reflects disease severity. In this real-life, international cohort study we investigated which 
classification is the strongest predictor of PEP-related mortality. 
Methods
We reviewed 13,384 consecutive ERCPs performed between 2012-2017 in 8 hospitals. 
We reviewed records of PEP patients for evaluation of all pancreatitis-related adverse 
events and compared the predictive capabilities of both classifications for PEP-related 
mortality. Furthermore, we investigated the correlation between the two classifications 
and identified reasons underlying length of stay.
Results
The total sample consisted of 387 patients. The revised Atlanta criteria have a higher 
sensitivity (100 vs. 55%), specificity (98 vs. 72%) and positive predictive value (58 vs. 5%). 
There is a significant difference (p<0.001) between the consensus and revised Atlanta 
criteria, with 112 (29%) and 19 (5%) severe patients, respectively. In 124 patients (32%), 
the length of stay was influenced by concomitant diseases.
Conclusions
The revised Atlanta classification is superior in predicting mortality and better reflects 
PEP severity. This has important implications for researchers, clinicians and patients. 
For the diagnosis of post-ERCP pancreatitis, the consensus criteria remain the golden 
standard. However, the revised Atlanta criteria are the preferable for defining PEP 
severity. 
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INTRODUCTION
Post endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the 
most prevalent complication after ERCP with an overall incidence of 3.5%. In high risk 
patients, particularly those with sphincter of Oddi dysfunction, the PEP rate is 15%1,2. In 
up to 3% of patients PEP is fatal2.
Adequate assessment of PEP severity is important to predict prognosis. It enables 
researchers and clinicians to compare the efficacy of prophylactic measures that prevent 
PEP or reduce its severity. Currently, there are two classification systems to assess PEP 
severity: the consensus criteria and revised Atlanta criteria3,4. The consensus criteria stem 
from an expert meeting in 1991 that defined ERCP-related adverse events and discussed 
technical considerations as well as management3. The consensus criteria are widely 
used in ERCP guidelines5,6, landmark trials on PEP prophylaxis7,8 and epidemiological 
studies1,2. The revised Atlanta criteria from 2012 are an update of the 1992 Atlanta criteria 
for defining and treating acute pancreatitis regardless of aetiology4. Both classification 
systems distinguish three categories of disease severity: mild, moderate or severe PEP. 
The main difference between both criteria is that the consensus criteria use length of 
hospital stay as a discriminative element, while the revised Atlanta criteria focus on the 
development of local and systemic adverse events (Supplementary Table 1). 
In acute pancreatitis the development of persistent organ failure is the main driver 
of mortality9. The question is whether length of hospital stay accurately reflects 
disease severity. Variables associated with length of hospital stay in acute pancreatitis 
are comorbidity, department, fasting period, diet reintroduction and diagnostics10. 
Furthermore, hospital stay is dependent on culture, practice styles and institutional 
policies11. For instance, in the United States the length of hospital stay decreased 0.2 
percent per year between 2003 and 201212. Finally, competing diagnoses may increase 
the length of stay as well.
We created an international, multicenter, real-life cohort of PEP patients with all 
parameters to assess local and systemic adverse events of PEP, reasons underlying length 
of hospital stay and PEP-related mortality. This allows us to compare both classification 
systems. Our aims were to determine: 1) which system (consensus or revised Atlanta) is 
the strongest predictor of PEP-related mortality, 2) the correlation between the consensus 
2
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and revised Atlanta criteria in defining PEP severity and 3) the effect of concomitant 
diseases or other factors on length of stay in PEP. 
METHODS
In this study we adhered to the Strengthening The Reporting of Observational studies 
in Epidemiology (STROBE) guidelines13. The study was approved by the Medical Ethics 
Committee of the Radboud University Medical Center on December 1st 2016 (nr. 2016-2974) 
and follows the declaration of Helsinki. 
Study design and setting
We created a multicenter retrospective cohort of patients with PEP by reviewing all 
ERCPs that were performed between 2012 and 2017 from 7 Dutch and 1 US hospitals. 
The hospitals consisted of 2 university medical centers (one Dutch, one US) and 6 large 
teaching hospitals. We reviewed all hospital contacts up to 48 hours after ERCP in order 
to discover incident cases with PEP. In the participating centers it is common practice 
that patients with symptoms suggestive for adverse events present to the same hospital 
in which they received their ERCP.
Participants
We included patients if they met the consensus or revised Atlanta criteria for acute 
pancreatitis (see Supplementary Table 2). We included patients who fulfilled the revised 
Atlanta criteria for pancreatitis if they had a hospital stay of at least two additional nights. 
Their clinical course was comprehensively reviewed in order to assess pancreatitis-related 
adverse events up to discharge. In patients with necrotizing pancreatitis or organ failure 
during the initial admission, we checked hospital contacts up to 1 year after discharge to 
detect readmissions for the same disease process. Patients with acute pancreatitis prior 
to ERCP were excluded. 
Endpoints
The primary endpoint of the study is PEP-related mortality. The secondary endpoint is 
PEP severity, defined according to the consensus criteria and the revised Atlanta criteria 
(see Supplementary Table 1). We defined local adverse events as an acute peripancreatic 
fluid collection, pancreatic pseudocyst or necrotizing pancreatitis (parenchymal or 
peripancreatic)4,14. An intervention was defined as any drainage (percutaneous or 
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endoscopic) or necrosectomy (surgical or endoscopic) for treating PEP. We defined organ 
failure as follows15: 
 - Pulmonary: PaO2<60 mm Hg, despite FiO2 of 0.30, or need for mechanical ventilation, 
 - Circulatory: systolic blood pressure <90 mm Hg, despite adequate fluid resuscitation, 
or need for inotropic catecholamine support or 
 - Renal: creatinine >177 umol/liter after rehydration or new need for hemofiltration 
or haemodialysis
Multi-organ failure is defined as failure of two organ systems at the same time. Persistent 
organ failure is defined as organ failure lasting >48 hours. 
Other variables
Other variables we collected were age, gender, American Society of Anesthesiologists 
(ASA) score, ERCP indication (adopted from ASGE16), ICU admission, length of ICU stay 
and length of hospital stay. We calculated length of hospital stay in two ways. The total 
length of hospital stay was calculated as the number of days from ERCP to discharge, 
regardless of any concomitant disorders. Where possible, we separated this from the 
length of stay for PEP: the number of days from ERCP until PEP subsided. We defined this 
as minimal pain medication requirement (non-opioids) and normal diet tolerance. Doubts 
in the distinction between PEP and other reasons for hospital stay were discussed with 
the local investigator and, in case of disagreement, resolved after discussion with the 
lead investigator (E.v.G.). Finally, we scored all concomitant diseases and other reasons 
for a (prolonged) hospital stay during the initial admission for PEP. 
Analyses and statistics
In the primary analysis we investigated the predictive capabilities of both severity 
definitions for PEP-related mortality. First, we dichotomized both classification systems 
into mild/moderate or severe PEP. We expressed diagnostic performance in terms of 
sensitivity, specificity, positive predictive value (PPV) and negative predictive value 
(NPV). In the secondary analysis we investigated the correlation between consensus and 
revised Atlanta criteria. To that end, we tested their correlation by chi-square. Finally, we 
investigated the effect of concomitant diseases or other reasons on the length of hospital 
stay. We checked if the PEP disease course could be separated from other reasons for 
hospital stay. 
All analyses were performed by using IBM SPSS version 25. A two-sided P-value below 
0.05 will be regarded as significant. 
2
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RESULTS
Flow chart
The 8 participating centres performed a total of 13,384 ERCPs during the inclusion period 
(see figure 1). The inclusion criteria were met in 396 patients (3%). After excluding 9 
patients who had acute pancreatitis prior to ERCP, the final study population consisted 
of 387 PEP cases. No patients were lost to follow-up.
Figure 1: Flow chart. ERCP: endoscopic retrograde cholangiopancreatography. PEP: post-ERCP 
pancreatitis.
Baseline characteristics
The baseline characteristics of the 387 PEP cases are summarized in table 1. Patients had 
a mean age of 57 years (SD: 18) and 114 (30%) were male. A total of 317 patients (82%) 
had ASA class II or higher. The leading indication for ERCP was choledocholithiasis (259 
cases, 67%). Thirty patients (8%) developed necrotizing pancreatitis. Organ failure was 
seen in 22 cases (6%) and in 19 cases (86%) organ failure persisted beyond 48 hours. 
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Ultimately, 11 patients (3%) died. Some 112 patients (29%) had severe PEP according to 
the consensus criteria, versus 19 patients (5%) according to the revised Atlanta criteria.
 
Table 1: Baseline characteristics
Age, mean (SD) 57 (18)
Male gender, n (%) 114 (30%)
ASA score, n (%)
 I
 II
 III
 IV
70 (18%)
205 (53%)
110 (28%)
2 (0.5%)
ERCP indication, n (%)
  Biliary stone extraction
 Stent placement for malignancy
 Postoperative bile leak treatment
259 (67%)
62 (16%)
17 (4%)
Necrosis*, n (%) 30 (8%)
Organ failure, n (%) 22 (6%)
Multi-organ failure, n (%) 15 (4%)
Persistent organ failure, n (%) 19 (5%)
Intervention 11 (3%)
ICU admission, n (%)
Length of ICU stay, median (IQR; range)
16 (4%)
2.5 (12; 1-76)
Total length of stay, median (IQR; range) 7 (6; 2-231)
Mortality, n (%) 11 (3%)
Consensus criteria severity
 Mild
 Moderate
 Severe
46 (12%)
229 (59%)
112 (29%)
Revised Atlanta severity
 Mild
 Moderate
 Severe
315 (81%)
53 (14%)
19 (5%)
ASA: American Society of Anesthesiologists. ERCP: endoscopic retrograde cholangiopancreatog-
raphy. ICU: intensive care unit. IQR: interquartile range. SD: standard deviation. *In 257 patients 
(66%), the presence of pancreatic necrosis could not be determined as performance of CT scan was 
left to the discretion of the treating physician.
Prediction of PEP-related mortality
Table 2 summarizes the sensitivity, specificity, PPV and NPV of the consensus and revised 
Atlanta criteria for predicting mortality. The revised Atlanta criteria have a higher 
sensitivity (100% vs. 55%), specificity (98% vs. 72%) and PPV (58% vs. 5%). The NPV was 
similar (100% vs. 98%). 
2
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Table 2: Prediction of mortality
Consensus Revised Atlanta
Sensitivity 55% 100%
Specificity 72% 98%
Positive predictive value 5% 58%
Negative predictive value 98% 100%
Correlation between the consensus and revised Atlanta criteria
The correlation between the consensus and revised Atlanta criteria is displayed in figure 
2. There is a significant difference between the two classifications (p<0.001). 
Figure 2: Correlation between consensus and revised Atlanta criteria for PEP severity. 
Values depict number of cases (percentage of total sample). P<0.001 (Pearson χ2).
The consensus criteria labelled five cases (1%) as mild or moderate, while the revised 
Atlanta criteria labelled them as severe. All five patients had fatal persistent organ failure. 
None of them met the severe consensus criteria because PEP was fatal within 10 days, 
necrosis was not yet visible on CT scan and none of them had an intervention. 
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Furthermore, 98 patients (25%) had a severe course according to the consensus criteria, 
but a mild or moderate course according to revised Atlanta. In 76 of those patients (78%), 
the only reason for a severe consensus label was a hospital stay exceeding 10 days. In 
the remaining 22 patients (22%), reasons for assigning a severe consensus label were 
development of necrosis (in all cases) or an intervention (in 6 cases). None of these 98 
patients had persistent organ failure or died. 
Hospitalization and concomitant diseases 
We identified reasons for the length of stay in our cohort (figure 3). In 263 of the 387 
patients (68%), the length of hospital stay was explained solely by PEP. In the remaining 
124 patients (32%), the length of stay was influenced by concomitant diseases in 86 
patients (69%). In 51 patients (59%), the PEP course could not be distinguished from 
concomitant disorders. The most prevalent concomitant diseases were cholangitis (n=33; 
38%) and perforation (n=15; 17%).  In 38 patients (31%), prolonged stay was due to other 
reasons, mainly waitlisted for cholecystectomy (n=22; 58%) or diagnostic procedures 
(n=12; 32%). 
Figure 3: Reasons for length of hospital stay in cohort. LoS: length of stay. PEP: post-ERCP 
pancreatitis. *Cholangitis (n=33), perforation (n=15), other inflammatory process (e.g. pneumo-
nia) (n=13), post-operative bile leak (n=10), post-ERCP bleeding (n=7), cholecystitis (n=6), renal 
insufficiency (n=2). ^Pending cholecystectomy (n=22), diagnostics for other disease (n=12), logis-
tic/transfer issues (n=4). #Defined as absence of necrosis, organ failure or death.
2
526323-L-bw-Smeets
Processed on: 22-11-2018 PDF page: 32
26
Chapter 2
The majority of patients in our PEP cohort had no adverse events (n=343; 89%). However, 
75 (22%) were labelled as severe according to the consensus criteria because the length of 
stay exceeded 10 days. In the cohort of patients who did not have another diagnosis apart 
from PEP, the prolonged stay was due to persistent pain, failure to thrive and problems 
with oral refeeding.
DISCUSSION
Our analysis establishes that the diagnostic performance of the revised Atlanta criteria 
for PEP-related mortality is better than the consensus criteria in terms of sensitivity, 
specificity and PPV. The NPV was similar, although 3 patients with mild PEP according 
to the consensus criteria died. This means that patients who are labelled as severe by 
the consensus criteria often run a benign course, while those labelled as mild might die. 
There is a statistically significant discrepancy between both classifications.   
This study identifies four main reservations that come with the use of the consensus 
criteria to define PEP severity. First, these criteria do not capture the patient category 
with early persistent organ failure, known to have an especially high mortality rate up 
to 36%17,18. In our cohort, 5 of the 11 deceased patients (45%) developed such a disease 
course. Second, length of hospital stay was influenced by reasons other than PEP (e.g. 
concomitant diseases) in 124 patients (32%). This results in a biased assessment of PEP 
severity. Third, in the majority of patients (n=343; 89%), length hospital of stay was 
dictated by persistent pain, failure to thrive or problems with oral refeeding, not by severe 
morbidity prognosticating mortality. Fourth, from a methodological point of view, length 
of hospital stay is subjective and dependent on the treating physician. This could lead to 
important bias in unblinded studies19,20.  
The difficulties with defining PEP severity according to the consensus criteria were 
highlighted by two other studies as well21,22. The first study21 reported a smaller discrepancy 
between the two definitions. According to the consensus criteria, 64 cases were mild, 11 
moderate and 3 severe. When assessed by the revised Atlanta, 76 cases were mild and 2 
were severe. However, the incidence of mild PEP in that cohort is probably overestimated, 
because the study defined PEP as pancreatic pain and hyperamylasaemia (>3x upper 
limit of normal), without including the criterion of prolongation of hospitalization (>2 
days). Furthermore, because our larger sample size allowed us to identify more patients 
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with a severe disease course, we believe our study was better equipped to point out 
the differences between the definitions. The second study22 found a large discrepancy 
between the consensus criteria and the Ranson score, which is a severity prediction score. 
In a cohort of 25 PEP cases, 11 had a mild PEP and 14 had a moderate PEP by following 
the consensus criteria, whereas all episodes were mild by applying the Ranson score. 
Our results are comparable because we also showed that the consensus criteria have 
low predictive properties. However, our study also identified the reasons behind the low 
prognostic accuracy and, more importantly, how this relates to the worth of the consensus 
criteria as a definition. 
Our findings are important from several perspectives. First of all, from a scientific point of 
view it is necessary to adopt objective definitions that are related to clinically important 
outcomes. In that way, a reported reduction in PEP severity parallels a reduction in 
morbidity and mortality. With this study we showed that the revised Atlanta criteria 
are capable of meeting these requirements better than the consensus criteria. A further 
advantage would be that PEP severity can be more easily compared to AP of other 
aetiology, which is reported according to the revised Atlanta criteria. Nevertheless, 
adopting the revised Atlanta criteria will have a profound influence on the feasibility of 
PEP studies, because severe PEP will then be an even rarer occurrence: in our PEP cohort, 
only 19 patients (5%) had severe PEP according to revised Atlanta, against 112 (29%) if the 
consensus criteria are used. Therefore, it will be exceedingly difficult for studies to detect 
a difference in PEP severity with sufficient statistical power. This calls for alternative 
methods such as individual patient data meta-analyses or composite endpoints. 
Second, from a clinical perspective our results shed light on how to value PEP prophylaxis 
efficacy. Major PEP trials report relative risk reductions in moderate-severe PEP of up to 
50%7,8. Because they adopted the consensus criteria, this mainly translates to a reduction 
in hospital stays from ≥4 days to <4 days, not necessarily in a reduction of clinically 
important outcomes such as (persistent) organ failure23. This is important when assessing 
the cost-benefit ratio of conducting an ERCP and in the informed consent procedure for 
patients undergoing ERCP.  
Despite the issues raised above, it must be stressed that the consensus criteria are valuable 
from a patient and societal perspective, since longer hospital stays lead to reductions in 
quality of life and higher costs and odds of mortality24–26. Additionally, although problems 
like oral refeeding are clearly distinct from adverse events like organ failure, they probably 
2
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carry significant meaning from a patient’s view. That is important in light of patient 
reported outcome measures and patient centred care27,28. Because of that, there is perhaps 
a role for both systems in defining PEP severity. At the very least, the issues raised by this 
study justify reporting both classifications.   
Some limitations might be important for the interpretation of our results. First, our 
study is retrospective. However, data collection was complete and there were no losses 
to follow-up. We may have missed patients with subclinical pancreatic necrosis as it is 
common clinical practice to only perform a CT scan in case of clinical deterioration. This 
could lead to an underestimation of necrotizing PEP in our cohort and result in a lower 
incidence of severe PEP according to the consensus criteria. On the other hand, this 
would have increased the discrepancy between the two definitions. A second limitation 
is our relatively limited sample size (i.e. only 11 deaths). However, our cohort is one of 
the largest reported and is well equipped to point out the main differences between the 
two definitions.  
In conclusion, the revised Atlanta classification is the preferable system to define a PEP 
disease course and is superior in predicting PEP-related mortality. This has important 
implications for researchers, clinicians and patients. For the diagnosis of post-ERCP 
pancreatitis, the consensus criteria remain the golden standard. 
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SUPPLEMENTARY MATERIAL
Supplementary table 1: Diagnostic criteria for severity of PEP
Cotton 3 Revised Atlanta 4
Mild Hospitalization of 2-3 days • No organ failure
• No local or systemic complications
Moderate Hospitalization of 4-10 days • Organ failure that resolves within 
48h (transient organ failure) and/or
• Local or systemic complications 
without persistent organ failure
Severe Hospitalization of >10 days, or hem-
orrhagic pancreatitis, phlegmon, or 
pseudocyst, or intervention (percutane-
ous drainage or surgery)*
Persistent organ failure (>48h)
• Single organ failure
• Multiple organ failure
*Hemorrhagic pancreatitis was defined as necrotizing pancreatitis and the term ‘phlegmon’ was 
abandoned 14.
Supplementary table 2: Diagnostic criteria for PEP
Cotton Revised Atlanta
 - New or increased abdominal pain consistent with 
pancreatitis 
 - Serum amylase/lipase ≥3x ULN at more than 24 
hours after ERCP
 - Admission or prolongation of planned admission 
for at least 2 days
 - Abdominal pain
 - Serum amylase/lipase >3x ULN
 - Acute pancreatitis on CE-CT, MRI 
or US
CE-CT: contrast enhanced computed tomography scan. ERCP: endoscopic retrograde cholan-
giopancreatography. MRI: magnetic resonance imaging. ULN: upper limit of normal. US: ultra-
sound.
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ABSTRACT
Background & Aims
Post endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the 
most serious ERCP complication, with a severe course in 11% of patients and a 0.7% 
mortality rate. The incidence of severe PEP is rising due to increasing ERCP utilization 
and a shift to therapeutic procedures. Prediction of PEP severity may alleviate disease 
course through guidance of clinicians in post-procedural monitoring, hospitalization 
and pre-emptive hydration. To date, no specific model for severe PEP exists. Therefore, 
we used data from an international PEP cohort to develop a prediction model for severe 
PEP: the PEP severity index (PEPSI). 
Methods
We created a PEP cohort by reviewing 13,384 consecutive ERCPs from 8 hospitals. Data 
on established risk factors for PEP were collected and entered in a backward logistic 
regression analysis. The primary outcome was severe PEP according to the consensus 
criteria. Regression coefficients were converted into an easy to use prediction rule 
(PEPSI). Finally, we tested the correlation between PEPSI and necrosis, organ failure, 
intensive care unit (ICU) admission, length of stay and mortality.
Results
The cohort consisted of 387 cases. The parameters age, sex, history of acute pancreatitis, 
pancreatic contrast injection and pancreatic sphincterotomy were retained in the final 
model. The PEPSI score had an AUC of 0.63 (0.57-0.69) and categorizes patients into low 
or high risk of severe PEP with a sensitivity of 90%. PEPSI was significantly associated 
with necrosis, organ failure, ICU admission and length of stay. 
Conclusions
We developed a scoring system for severe PEP that allows swift and easy stratification of 
patients directly after ERCP to guide the decision-making process surrounding ERCPs.
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INTRODUCTION
Post endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the 
most serious ERCP complication. PEP is associated with a severe disease course in 11% of 
patients and a mortality rate of 0.7%1,2. PEP has substantial social and economic impact, 
with health care expenditures of up to 200 million dollar per year in the United States 
(US)1. Moreover, two developments will likely result in a higher incidence of severe PEP. 
First, ERCP utilization is increasing. In the US alone, 290,000 procedures were performed 
in 2010, an increase of 24% in 10 years3. Second, there is a shift from diagnostic to 
therapeutic ERCPs, that bear a higher complication rate4. 
It is therefore imperative to reduce the incidence of severe PEP. This may be accomplished 
through the use of prophylactic measures for PEP, which are associated with relative 
risk reductions in moderate-severe PEP of up to 50%5. Another potential strategy is 
early prediction of disease severity to guide clinical decision-making that surrounds the 
intensity of post-procedural monitoring, hospitalization of ambulatory patients and pre-
emptive hydration. As such, it may affect disease course. Because PEP is a complication 
that develops within 2-6 hours after ERCP in over 70% of patients6, early risk stratification 
is crucial. To date, no specific prognostic model for PEP severity exists. 
We therefore aimed to develop a prediction model for severe PEP using objective and 
routinely available parameters for risk stratification of patients immediately after ERCP. 
To that end, we used data from an international, multicenter cohort of PEP patients. 
METHODS
We adhered to the Transparent Reporting of multivariable prediction model for Individual 
Prognosis or Diagnosis guidelines (see supplement)7. The Medical Ethics Committee of 
the Radboud University Medical Center approved the study prior to data collection (nr. 
2016-2974). This study follows the declaration of Helsinki.
Study design and participants
We identified patients with PEP, defined according to consensus criteria8, by retrospective 
evaluation of hospital records of all ERCPs that were conducted between 2012 and 2017 in 
7 Dutch (1 university and 6 teaching hospitals) and 1 US university hospital. All hospital 
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contacts of patients that underwent ERCP were reviewed up to 48 hours after ERCP for 
signs of PEP. We excluded patients with acute pancreatitis (AP) prior to ERCP. We screened 
all hospital records for complications up to discharge. In patients with necrotizing 
pancreatitis or organ failure during the primary admission, we reviewed hospital contacts 
up to 1 year after discharge for readmissions. 
Outcome measure
We initially planned to use the revised Atlanta criteria9 to define severe PEP, because 
they are a better reflection of the PEP phenotype compared to the consensus criteria. 
However, only 19 patients in our cohort had a severe disease course according to revised 
Atlanta. This would restrict our power to a significant degree and probably result in an 
inaccurate prediction model. Therefore, we defined severe PEP according to the consensus 
criteria8 as hospitalization of >10 days, hemorrhagic pancreatitis, phlegmon, pseudocyst 
or invasive intervention for PEP. We defined an invasive intervention as any drainage 
(endoscopic or percutaneous) or necrosectomy (endoscopic or surgical) for treating PEP. 
We dichotomized the endpoint into mild/moderate and severe PEP. 
Potential prognostic factors
Sixteen patient- and ERCP-related parameters are recognized as independent risk factors 
for PEP and could play a role in its severity10,11. Moreover, these factors are thought to 
act synergistically and thereby increase the risk of severe PEP12. For this reason, and 
because the parameters are available for early prognostication immediately after ERCP, 
we used these risk factors as the basis of our prognostic factor selection. Additionally, 
candidate factors had to be unambiguous and objective and be measured routinely in 
clinical practice13. 
We omitted intraductal ultrasound because evidence for its value was based on only one 
retrospective study14. We excluded bile duct width, duration of cannulation attempts 
and bile stone clearance as these are prone to subjectivity and measurement error. We 
excluded serum bilirubin as this is not routinely measured before ERCP. Specifically, 
cannulation difficulty is not routinely and objectively quantified in clinical practice and 
was not available in our data set for this analysis. Because studies suggest that biliary 
decompression, achieved through biliary sphincterotomy, could ameliorate the disease 
course of AP15, we included previous biliary sphincterotomy. Finally, we added the use of 
prophylactic rectal non-steroidal anti-inflammatory drugs (NSAIDs) and pancreatic duct 
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(PD) stents as these are thought to alleviate disease severity5,16. An overview of candidate 
prognostic factors is given in table 1. 
Table 1: Potential prognostic factors
Prognostic factor Definition
Procedural characteristics
  Pancreatic guidewire pas-
sage
Any number of pancreatic guidewire passages, including those 
for pancreatic guidewire assisted cannulation.
  Pancreatic contrast injec-
tion
Any pancreatic contrast injection, regardless of acinarization.
  Previous biliary sphincter-
otomy
A history of biliary sphincterotomy or signs of previous 
sphincterotomy during ERCP. 
 Precut sphincterotomy Regardless of conventional technique or fistulotomy.
 Pancreatic sphincterotomy Any pancreatic sphincterotomy, including transpancreatic 
sphincterotomy.
  Biliary balloon sphincter 
dilation
Any balloon dilation, regardless of duration. 
Patient characteristics
 Age Age at the time of ERCP. 
 Sex Male, female
 History of AP History of any AP (defined according to revised Atlanta 9), in-
cluding post-ERCP pancreatitis (defined according to consen-
sus criteria 8).
  Suspected) sphincter of 
Oddi dysfunction
Defined according to Rome III criteria 30.
Prophylactics
 Rectal NSAID use Any prophylactic rectal NSAID used, regardless type, timing 
and dose.
 PD-stent Any successful pancreatic duct stent placement.
AP: acute pancreatitis. ERCP: endoscopic retrograde cholangiopancratography. NSAID: nonsteroi-
dal anti-inflammatory drug. PD: pancreatic duct. With the exception of the predictive factor age, all 
categories were dichotomous (either yes/no or male/female). 
Statistics
Descriptive statistics were used to summarize the data. Data were missing for 10 of the 23 
baseline variables, ranging between 0.3% and 66% of cases (table 2). These missing data 
were imputed using multiple imputation by chained equations procedure (predictive mean 
matching)17. Missing data were assumed to be missing at random. We created twenty-five 
imputed datasets.
Thereafter, we calculated the individual contribution of all potential prognostic factors 
by univariable logistic regression analysis. We used multivariable logistic regression with 
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backward selection by Akaike’s information criterion13 to achieve the most parsimonious 
combination of predictors. Model performance was assessed on calibration with 
Hosmer-Lemeshow goodness-of-fit test and a calibration plot to estimate its reliability. 
Discrimination was estimated as the area under the receiver operating characteristic 
curve (AUC). Prediction models derived with multivariable regression analyses are known 
for overfitting18. Therefore, the model was validated internally using bootstrapping 
techniques. Five hundred samples were drawn with replacement from the development 
sample. We used the logistic regression formula to construct a simple score: the post-
ERCP pancreatitis severity index (PEPSI). We divided the adjusted regression coefficients 
by the lowest coefficient and rounded them to the nearest integer. For simplicity we 
categorized patients into low or high risk of severe PEP. The cut-off value was chosen 
such that a sensitivity of at least 90% would be achieved, as we deemed it most important 
not to miss severe cases. 
Finally, we tested the association between PEPSI category and five clinically important 
outcomes in PEP: necrotizing pancreatitis9, organ failure (defined as pulmonary, 
circulatory or renal according to Bradley19), intensive care unit (ICU) admission, total 
length of hospital stay and mortality. Binary outcomes were compared by χ2 test, 
continuous by student’s T-test.  
A two-sided P-value below 0.05 was regarded as statistically significant. All analyses were 
performed using SPSS version 25 and R version 3.4.4.
RESULTS
Baseline characteristics
A total of 13,384 ERCPs were performed during the inclusion period. In total, 387 patients 
(3%) developed PEP. No patients were lost to follow-up. The baseline characteristics of 
our study population are summarized in table 2. The sample consisted mainly of women 
(n=273, 71%) and patients had a mean age of 57 years (range: 18-94). A history of AP was 
present in 33 patients (9%), sphincter of Oddi dysfunction in 9 patients (2%). The leading 
indication for ERCP was choledocholithiasis in 259 patients (67%). In 249 ERCPs (64%) 
the pancreas was manipulated, mainly through cannulation. A pre-cut was performed 
in 81 patients (21%). Most patients (n=287, 74%) received PEP prophylaxis. Finally, 112 
patients (29%) had severe PEP according to the consensus criteria. 
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Table 2: Baseline characteristics
Total 
cohort
Mild/ moder-
ate PEP
(n=275)
Severe PEP
(n=112)
Missing
Age (years)† 57 (18-94) 56 (18-94) 59 (22-89) 0 (0%)
Female sex 273 (71%) 202 (73%) 71 (63%) 0 (0%)
ASA-score 0 (0%)
 I 70 (18%) 52 (19%) 18 (16%)
 II 205 (53%) 143 (52%) 62 (55%)
 III 110 (28%) 78 (28%) 32 (29%)
 IV 2 (0.5%) 2 (1%) 0 (0%)
History of AP 33 (9%) 27 (10%) 6 (5%) 0 (0%)
History of SOD 9 (2%) 7 (3%) 2 (2%) 0 (0%)
ERCP indication
 Biliary stone extraction 259 (67%) 181 (66%) 78 (70%) 0 (0%)
 Stent placement for malignancy 62 (16%) 45 (16%) 17 (15%) 0 (0%)
 Postoperative bile leak 17 (4%) 10 (4%) 0 (0%)
Pancreatic manipulation
 Pancreatic guidewire passage 226 (58%) 156 (57%) 70 (64%) 5 (1%)
 Pancreatic contrast injection 118 (31%) 77 (28%) 41 (38%) 7 (2%)
 Pancreatic sphincterotomy 22 (6%) 12 (4%) 10 (9%) 2 (0.5%)
Biliary sphincter manipulation
 Previous sphincterotomy 36 (9%) 26 (10%) 10 (9%) 1 (0.3%)
 Precut sphincterotomy 81 (21%) 59 (22%) 22 (20%) 1 (0.3%)
 Balloon dilation 32 (8%) 20 (7%) 12 (11%) 2 (0.5%)
Rectal NSAID use 236 (61%) 170 (66%) 66 (66%) 28 (7%)
PD-stent use 62 (16%) 45 (17%) 17 (15%) 4 (1%)
Combination therapy^ 39 (10%) 30 (11%) 9 (8%) 4 (1%)
Necrosis 30 (8%) 0 (0%) 30 (37%) 257 (66%)*
Organ failure 22 (6%) 7 (3%) 15 (13%) 0 (0%)
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Table 2. Continued
Total 
cohort
Mild/moder-
ate PEP
(n=275)
Severe PEP
(n=112)
Missing
Persistent organ failure 19 (5%) 5 (2%) 14 (13%) 0 (0%)
ICU admission 16 (4%) 6 (2%) 10 (9%) 0 (0%)
Total length of stay (days)† 7 (2-231) 6 (2-10) 15 (5-231) 0 (0%)
Mortality 11 (3%) 5 (2%) 6 (5%) 0 (0%)
Consensus criteria severity
 Mild 46 (12%) 0 (0%)
 Moderate 229 (59%) 0 (0%)
 Severe 112 (29%) 0 (0%)
All values represent n (%), unless stated otherwise. †Median (min-max). ^Defined as a combination 
of rectal NSAID and PD-stent. *The presence of pancreatic necrosis could not be determined as 
performance of CT scan was left to the discretion of the treating physician. ASA: American Society 
of Anesthesiologists. AP: acute pancreatitis. ERCP: endoscopic retrograde cholangiopancreatogra-
phy. ICU: intensive care unit. NSAID: nonsteroidal anti-inflammatory drugs. PD: pancreatic duct. 
SD: standard deviation. SOD: sphincter of Oddi dysfunction. 
Model development and performance
Sex and pancreatic contrast injection were significantly associated with severe PEP 
in univariable analysis (table 3). After backward selection, five prognostic factors 
were retained in the model: age, sex, history of AP, pancreatic contrast injection and 
pancreatic sphincterotomy. Female sex and a history of AP were associated with a lower 
odds of severe PEP, whereas higher age, pancreatic contrast injection and pancreatic 
sphincterotomy increased the odds of severe PEP. However, none of these variables 
reached statistical significance in the multivariable analysis. The AUC was 0.62 (95% CI: 
0.56-0.68), the calibration slope 1.01 (95% CI: 0.50-1.52) and the Hosmer-Lemeshow test 
was not statistically significant (p=0.58), indicating a good model fit. 
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Table 3: Univariable and multivariable analyses of prognostic factors
Univariable 
OR (95% CI) P-value
Multivariable 
OR (95% CI) P-value
Regression 
coeffi-
cients*
Age 1.44 (0.99-2.09) 0.05 1.44 (0.96-2.14) 0.07 0.01
Female sex 0.63 (0.39-0.99) 0.05 0.67 (0.41-1.11) 0.12 -0.23
History of AP 0.52 (0.21-1.30) 0.16 0.44 (0.17-1.16) 0.10 -0.48
History of SOD 0.70 (0.14-3.40) 0.65
Pancreatic guidewire 
passage
1.32 (0.84-2.08) 0.23
Pancreatic contrast 
injection
1.64 (1.02-2.61) 0.04 1.63 (0.97-2.74) 0.06 0.29
Previous biliary 
sphincterotomy
0.94 (0.44-2.01) 0.87
Precut sphincterot-
omy
0.89 (0.52-1.55) 0.69
Pancreatic sphincter-
otomy
2.12 (0.89-5.06) 0.09 2.06 (0.79-5.36) 0.14 0.42
Biliary balloon 
sphincter dilation
1.52 (0.72-3.23) 0.27
Rectal NSAID use 0.95 (0.58-1.54) 0.83
PD-stent use 0.96 (0.52-1.75) 0.88
AP: acute pancreatitis. CI: confidence interval. NSAID: nonsteroidal anti-inflammatory drugs. OR: 
Odds ratio. PD: pancreatic duct. SOD: sphincter of Oddi dysfunction. *After internal validation with 
a shrinkage factor of 0.58. Regression coefficient of intercept was -1.26. 
Through bootstrapping we obtained a shrinkage factor of 0.58. We multiplied all 
regression coefficients with this factor and re-evaluated the model’s performance. The 
AUC of the final model was 0.63 (95% CI: 0.57-0.69), the calibration slope 1.29 (95% CI: 
0.65-1.93) and the Hosmer-Lemeshow test had a p-value of 0.71, indicating a good model 
fit (figure 1). 
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Figure 1: Calibration plot of model after internal validation. The distribution of predicted 
probabilities is shown separately for patients with and without severe PEP. Triangles indicate 
observed proportions of severe PEP by tenths of predicted probability.
Model use and correlation analysis
Ultimately, the model was used to construct a prediction model for severe PEP: the PEPSI 
score (table 4). The total risk score for each individual patient can be obtained by assigning 
points for each predictor and totaling the results. Patients with a PEPSI score above 
15 have a high risk of a severe disease course. With this cut-off value, the sensitivity, 
specificity, positive predictive value and negative predictive value are 90%, 27%, 33% 
and 88%, respectively. 
Table 4: Post-ERCP Pancreatitis Severity Index (PEPSI)
Predictor Weight to risk score Risk score
Age Age in years …
Female sex -32 …
History of acute pancreatitis -65 …
Pancreatic contrast injection +40 …
Pancreatic sphincterotomy +60 …
+ Total risk score
For example, a 40-year old female without a history of acute pancreatitis, without a pancreatic contrast 
injection but with a pancreatic sphincterotomy has total risk score of 40 – 32 + 60 = 68. This amounts to 
a high risk of severe PEP. The predicted probability of severe PEP can be calculated by the following for-
mula: P = 1/[1+ exp (-(-1.26 + 0.01 * Age – 0.23 * Female sex – 0.48 * History of acute pancreatitis + 0.29 * 
Pancreatic contrast injection + 0.42 * Pancreatic sphincterotomy))]. 
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The mean risk score of patients was 45 (SD: 39). Eighty-five patients (22%) were 
categorized as having a low risk of severe PEP, 302 (78%) were categorized as high risk. We 
tested the association between the two risk categories and five clinical endpoints (table 
5). The high-risk group had significantly higher percentages of necrotizing pancreatitis 
(p=0.016), organ failure (p=0.042) and ICU stay (p=0.030). Also, the hospital stay was 
significantly longer in the high-risk group with a mean difference of 5 days (95% CI: 3-7; 
p<0.001). There was no significant difference in mortality between the PEPSI groups 
(p=0.295). 
Table 5: Correlation between PEPSI category and clinical endpoints
Low risk (PEPSI≤15)
(n=85)
High risk (PEPSI>15)
(n=302)
P-value
Necrosis 1 (1%) 29 (10%) 0.02
Organ failure 1 (1%) 21 (7%) 0.04
ICU stay 0 (0%) 16 (5%) 0.03
Length of stay (days) 7 (2-33) 8.5 (2-231) <0.001
Mortality 1 (1%) 10 (3%) 0.30
Values depict number of patients with endpoint (percentage of total in PEPSI category). Length of 
stay values designate median (min-max). ICU: intensive care unit.
DISCUSSION
We developed a prediction model tailored to identification of severe post-ERCP 
pancreatitis. It incorporates age, sex, history of AP, pancreatic contrast injection and 
pancreatic sphincterotomy. The PEPSI score stratifies patients into high and low risk 
groups and allows for identification of patients at increased risk for necrosis, organ failure, 
ICU admission and prolonged hospital stay. 
We identify three clinical domains that benefit from the use of the PEPSI score. First, it 
can guide clinicians in their choices concerning discharge and referral. In tertiary care 
centers that perform ERCPs as an ambulatory service for referring community hospitals, a 
high PEPSI score could alert physicians that patients are best kept at the specialised center 
for adequate treatment of a potentially severe disease. Second, it can guide clinicians in 
their choice for prophylactic measures. Data suggest that PD-stents, compared to rectal 
NSAIDs, are better at preventing moderate-severe PEP20. This could be an argument to 
at least place a prophylactic PD-stent in patients that combine a high risk of PEP with 
a high risk of severe PEP. Third, early risk stratification by PEPSI allows physicians to 
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take advantage of the early therapeutic window in AP. This is the time frame in which 
the third space losses that characterize the disease may still be reversible21,22. More 
aggressive fluid resuscitation at that stage might prevent necrosis and organ failure, 
the main determinants of mortality23. Apart from clinical implications, the significant 
association between PEPSI and length of hospital stay is important from a patient and 
societal perspective: longer hospital stays lead to reduced quality of life and higher odds 
of mortality24,25.
Compared to general AP scoring systems, PEPSI has potential advantages and 
disadvantages. The main advantage of PEPSI is that it can be calculated immediately 
after PEP diagnosis. This is problematic for the currently available general AP scores. 
For example, the Glasgow-Imrie score require data input from additional physical 
examinations and laboratory tests that take up to 48 hours to complete26. Also, PEPSI 
relies on simple and objective parameters. General AP scoring systems are complex and 
rely on many parameters not routinely measured after ERCP. For instance, the widely 
used Acute Physiology and Chronic Health Evaluation (APACHE) II score27 requires the 
measurement of 5 physiological and 7 laboratory parameters. A disadvantage of PEPSI 
is that it cannot be repeated to improve predictive accuracy or monitor treatment, which 
does come with many general AP scoring systems because they incorporate parameters 
that reflect the physiological state of a patient.       
 
In addition to the results of the PEPSI score, our multivariable analysis sheds light 
on individual prognostic factors for severe PEP. We found no statistically significant 
differences in established risk factors and PEP prophylactics between mild/moderate and 
severe PEP, which is in line with another study on this subject28. This did not hamper the 
development of our prediction model, because statistical significance is not a prerequisite 
for prognostication13. Still, our results contradict the established belief that PEP risk 
factors act synergistically to increase the risk of severe PEP, especially in young women 
with a clinical suspicion of sphincter of Oddi dysfunction12. However, these observations 
were never subjected to statistical scrutiny. 
A strength of our study is that we created one of the largest PEP cohorts reported to 
date. Our cohort is derived from eight centres (university medical centres as well as 
teaching hospitals) in two different countries, which increases the external validity of 
our results. However, some potential limitations are relevant to interpretation of our 
results. First, we used the consensus criteria to define severe PEP. Adopting the revised 
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Atlanta criteria might have led to a more valuable prediction model, because the revised 
Atlanta criteria better reflect the PEP phenotype. However, we showed that PEPSI has a 
significant association with necrosis, organ failure and ICU stay, all of which are important 
hallmarks of a PEP disease course. A second limitation is that our study was retrospective. 
Therefore, we were unable to collect data on some important prognostic factors, such 
as difficult cannulation11. The predictive accuracy of PEPSI might have been greater if 
we could have incorporated these in our analyses. However, general AP scoring systems 
have AUCs ranging from 0.57 to 0.7429. Therefore, it seems that our model’s performance 
is comparable. Furthermore, the retrospective design did allow us to create one of the 
largest PEP cohorts reported. In a prospective setting it would have been exceedingly 
difficult to collect data of more than 13,000 ERCPs. Future studies should validate the 
PEPSI score in an external cohort. Also, it could be worthwhile to identify additional 
prognostic factors and incorporate these into PEPSI to enhance its discrimination. In that 
way, it would be possible to better discriminate between true and false positive patients.
In conclusion, the PEPSI score allows for prognostication of severe PEP immediately 
after ERCP. As such, it can guide clinicians in their choices regarding PEP prophylaxis, 
post-procedural monitoring, aggressiveness of hydration and decisions with respect to 
discharge and referral of patients. 
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SUPPLEMENTARY MATERIAL
Supplementary table 1: TRIPOD checklist
Section/ Topic Item Checklist Item Page
Title and abstract
Title 1 D;V Identify the study as developing and/
or validating a multivariable prediction 
model, the target population, and the 
outcome to be predicted.
1
Abstract 2 D;V Provide a summary of objectives, study 
design, setting, participants, sample size, 
predictors, outcome, statistical analysis, 
results, and conclusions.
5, 6
Introduction
Background and 
objectives
3a D;V Explain the medical context (including 
whether diagnostic or prognostic) and 
rationale for developing or validating the 
multivariable prediction model, including 
references to existing models.
7
3b D;V Specify the objectives, including whether 
the study describes the development or 
validation of the model or both.
7
Methods
Source of data 4a D;V Describe the study design or source of data 
(e.g., randomized trial, cohort, or registry 
data), separately for the development and 
validation data sets, if applicable.
8
4b D;V Specify the key study dates, including start 
of accrual; end of accrual; and, if applica-
ble, end of follow-up. 
8
Participants 5a D;V Specify key elements of the study setting 
(e.g., primary care, secondary care, general 
population) including number and location 
of centres.
8
5b D;V Describe eligibility criteria for partici-
pants. 
8
5c D;V Give details of treatments received, if 
relevant. 
n.a.
Outcome 6a D;V Clearly define the outcome that is predict-
ed by the prediction model, including how 
and when assessed. 
8, 9
6b D;V Report any actions to blind assessment of 
the outcome to be predicted. 
n.a.
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Supplementary table 1: Continued
Section/ Topic Item Checklist Item Page
Title and abstract
Predictors 7a D;V Clearly define all predictors used in de-
veloping or validating the multivariable 
prediction model, including how and when 
they were measured.
9, table 1
7b D;V Report any actions to blind assessment 
of predictors for the outcome and other 
predictors. 
n.a.
Sample size 8 D;V Explain how the study size was arrived at. n.a.
Missing data 9 D;V Describe how missing data were handled 
(e.g., complete-case analysis, single impu-
tation, multiple imputation) with details 
of any imputation method. 
10
Statistical analy-
sis methods
10a D Describe how predictors were handled in 
the analyses. 
10
10b D Specify type of model, all model-building 
procedures (including any predictor selec-
tion), and method for internal validation.
10
10c V For validation, describe how the predic-
tions were calculated. 
n.a.
10d D;V Specify all measures used to assess model 
performance and, if relevant, to compare 
multiple models. 
10
10e V Describe any model updating (e.g., reca-
libration) arising from the validation, if 
done.
n.a.
Risk groups 11 D;V Provide details on how risk groups were 
created, if done. 
10
Development vs. 
validation
12 V For validation, identify any differences 
from the development data in setting, eli-
gibility criteria, outcome, and predictors. 
n.a.
Results
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Supplementary table 1: Continued
Section/ Topic Item Checklist Item Page
Title and abstract
Participants 13a D;V Describe the flow of participants through 
the study, including the number of partic-
ipants with and without the outcome and, 
if applicable, a summary of the follow-up 
time. A diagram may be helpful. 
12
13b D;V Describe the characteristics of the par-
ticipants (basic demographics, clinical 
features, available predictors), including 
the number of participants with missing 
data for predictors and outcome. 
12, table 2
13c V For validation, show a comparison with 
the development data of the distribution 
of important variables (demographics, 
predictors and outcome). 
n.a.
Model develop-
ment 
14a D Specify the number of participants and 
outcome events in each analysis. 
Table 2
14b D If done, report the unadjusted association 
between each candidate predictor and 
outcome.
Table 3
Model specifica-
tion
15a D Present the full prediction model to allow 
predictions for individuals (i.e., all regres-
sion coefficients, and model intercept or 
baseline survival at a given time point).
Table 3 & 4
15b D Explain how to the use the prediction 
model.
Table 4
Model perfor-
mance
16 D;V Report performance measures (with CIs) 
for the prediction model.
12, 13
Model-updating 17 V If done, report the results from any model 
updating (i.e., model specification, model 
performance).
n.a.
Discussion
Limitations 18 D;V Discuss any limitations of the study (such 
as nonrepresentative sample, few events 
per predictor, missing data). 
16
Interpretation 19a V For validation, discuss the results with ref-
erence to performance in the development 
data, and any other validation data. 
n.a.
19b D;V Give an overall interpretation of the re-
sults, considering objectives, limitations, 
results from similar studies, and other 
relevant evidence. 
14-16
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Supplementary table 1: Continued
Section/ Topic Item Checklist Item Page
Title and abstract
Implications 20 D;V Discuss the potential clinical use of 
the model and implications for future 
research. 
14-16
Other information
Supplementary 
information
21 D;V Provide information about the availability 
of supplementary resources, such as study 
protocol, Web calculator, and data sets. 
n.a.
Funding 22 D;V Give the source of funding and the role of 
the funders for the present study. 
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ABSTRACT
Background & Aims
With an overall incidence of 3.5%, pancreatitis is the most frequent complication of 
endoscopic retrograde cholangiopancreatography (ERCP). Periprocedural hydration 
may prevent post-ERCP pancreatitis by maintaining pancreatic microperfusion, 
thereby inhibiting the pancreatic inflammatory response. However, the evidence for 
periprocedural hydration as a preventive measure is unclear. We conducted a systematic 
review to assess the evidence regarding periprocedural hydration as a preventive measure 
for post-ERCP pancreatitis.
Methods
We searched PubMed and EMBASE databases and adhered to the PRISMA guidelines. We 
included studies addressing periprocedural hydration as a preventive measure to reduce 
frequency and severity of post-ERCP pancreatitis. Study quality was assessed by using 
the MINORS and Cochrane Collaboration’s tool. 
Results
Six studies with a total of 1102 patients were included. Two randomized controlled trials 
reported a decreased incidence of post-ERCP pancreatitis after hydration: 0% vs. 17% 
(P=0.016) and 5.3% vs. 22.7% (P=0.002). A third trial and two case-controls studies did 
not report significant differences. Two retrospective studies found that patients with 
mild post-ERCP pancreatitis had received significantly more fluids during (mean 940mL 
vs. 810mL; P=0.031) or after ERCP (median 2834mL vs. 2044mL; P <0.02) compared to 
patients with moderate/severe disease. Adverse events of periprocedural hydration were 
not reported in any of the included studies. The different methodologies of the included 
studies precluded a formal data synthesis.
Conclusions
There is some evidence to suggest that hydration affords protection against post-ERCP 
pancreatitis, but study heterogeneity precludes firm conclusions. Adequately powered 
randomized trials are needed to evaluate the preventive effect of periprocedural hydration. 
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INTRODUCTION
Endoscopic retrograde cholangiopancreatography (ERCP) is widely used as a therapeutic 
procedure to treat diseases of the pancreaticobiliary tree. Though very effective, ERCP 
comes with an overall complication rate ranging from 4.0-15.9% and a mortality rate 
between 0.06-1.0%1–4. The most frequent complication of ERCP is post-ERCP pancreatitis 
(PEP). It has a reported overall incidence of 3.5%, that approaches 15% in high-risk 
populations2,5. PEP leads to prolonged hospitalization with substantial economic impact6,7. 
A number of possible pathophysiological pathways have been postulated8,9, all sharing 
the concept that damage to the pancreas induces premature, intracellular activation of 
zymogens. This results in autodigestion of the pancreas with ensuing inflammation. 
Numerous prophylactic agents have been studied10,11, but based on the available 
literature two preventive measures are currently advocated by the European Society 
for Gastrointestinal Endoscopy12. First, rectal non-steroidal anti-inflammatory drugs 
(NSAIDs) curtail the inflammatory response that accompanies PEP4,6. These drugs are 
recommended for all patients subjected to ERCP. Second, prophylactic pancreatic duct 
stents are thought to prevent pancreatic duct obstruction and subsequent mechanical 
trauma to the pancreas. Their placement is recommended in high-risk patients. 
Recently, a third potential method has gained attention: intensive periprocedural 
fluid resuscitation may inhibit the pancreatic inflammatory response by maintaining 
pancreatic microperfusion. Disturbances in the microcirculation are probably aggravated 
by the relatively dehydrated state of patients undergoing ERCP. Circumstantial evidence 
to support this theory is that elevated preprocedural blood urea nitrogen levels, as a 
measure of hydration status, are associated with development of PEP13,14. Furthermore, 
intensive periprocedural hydration could influence PEP severity. The pancreatic 
inflammatory response causes vasodilatation with intravascular volume depletion, end-
organ hypoperfusion and ultimately ischemia. Periprocedural hydration could counteract 
this pathway, thereby preventing necrosis and organ failure, the major complications 
defining severe pancreatitis15.
The evidence supporting periprocedural fluid resuscitation as a preventive measure for 
PEP is unclear. Therefore, we conducted a systematic review to determine the effect of 
periprocedural hydration on incidence and severity of PEP in patients subjected to ERCP. 
4
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METHODS
Literature search
A systematic search was conducted with the aid of an expert librarian in the electronic 
databases PubMed and Embase in February 2016 (see Supplement 1 for full electronic 
search strategy). We adhered to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines16. No search restrictions regarding year of 
publication or publication type were applied. Two authors (X.S. and D.d.C.) independently 
scanned the resulting titles and abstracts to judge if inclusion or exclusion criteria were 
met. After excluding papers based on title and abstract, the eligibility of the remaining 
articles was assessed by reading the full text papers. A manual cross-reference check of 
included studies was performed to scan for other eligible studies. Disagreements were 
resolved after discussion with a third author (E.v.G.). 
Inclusion and exclusion criteria
We included studies written in English addressing periprocedural fluid resuscitation to 
prevent PEP or its effect on PEP severity. Studies without original data, such as reviews, 
were excluded, as well as studies evaluating non-post-ERCP pancreatitis or other 
preventive strategies. Articles discussing measures of hemoconcentration (blood urea 
nitrogen, hematocrit) were excluded as well, as these provide only indirect evidence for 
periprocedural fluid resuscitation. 
Data extraction
Two authors (X.S. and D.d.C.) independently collected the data from the included studies. 
Disagreements were resolved after discussion with a third author (E.v.G.). General study 
characteristics that were obtained included first author, year of publication and location 
of research. To assess the external validity of the studies, we extracted the study design, 
time period, inclusion and exclusion criteria, number of participants, definition of PEP, 
incidence of PEP and PEP severity. PEP severity was considered to be related to either 
length of hospitalization and/or complications of PEP. With regard to periprocedural 
fluid resuscitation we obtained the following data: type of fluid used, duration of fluid 
infusion, rate of infusion, timing of infusion (during ERCP, after ERCP or both) and 
the total volume administered. We defined periprocedural fluids as intravenous fluids 
administered at the start of ERCP and in the 24 hours after the procedure, at which 
time post-ERCP pancreatitis can be diagnosed according to the Cotton criteria (table 
1). Complications related to fluid infusion were extracted from the included studies. 
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PEP risk factors, defined in the guidelines by both the European and American Society 
for Gastrointestinal Endoscopy12,17, were obtained to identify confounders and assess 
baseline comparability in non-randomized studies. Also, the use of rectal NSAIDs and 
pancreatic duct stents, differences in preprocedural hydration status (measured by blood 
urea nitrogen, hematocrit and creatinine) and comorbid illnesses were collected. 
Table 1: Cotton criteria for PEP39
Mild Moderate Severe
 - Clinical pancreatitis 
 - Amylase >3x upper limit of normal at 
more than 24 hours after the proce-
dure 
 - Admission or prolongation of planned 
admission to 2-3 days
Hospitalization of 
4-10 days
Hospitalization >10 days, or
Hemorrhagic pancreatitis, 
phlegmon, or pseudocyst, or
Intervention (percutaneous 
drainage or surgery) 
Quality assessment
The Cochrane Collaboration’s tool was used to assess the quality of randomized trials18. 
For non-randomized studies, we used the Methodological Index for Non-Randomized 
Studies checklist19,20. Two authors (X.S. and D.d.C.) evaluated each included study 
accordingly. Disagreements were resolved after discussion with a third author (E.v.G.). 
Statistical analysis
Due to the different methodologies used in the included studies, we could not perform a 
data synthesis of the results. 
RESULTS
Search
Using our search terms, we identified a total of 871 studies (figure 1). By scanning 
reference lists, we found two additional studies of interest13,21. After examination of the 
titles and abstracts, we excluded 856 studies. Two articles were excluded because they 
did not address the topic of periprocedural fluid resuscitation13,14 and one paper discussed 
management of PEP instead of fluid resuscitation as prophylactic measure22. Finally, six 
studies21,23–27 were included in the current review: three randomized controlled trials23,24,27 
and three retrospective studies21,25,26. 
4
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Figure 1: Flow diagram of included studies
Prevention of PEP
Study design
We identified three trials and two case-control studies that examined periprocedural fluid 
administration to prevent PEP21,23,24,26,27. In the first trial, performed in Turkey, 40 patients 
received a combination of intramuscular NSAID with isotonic saline infusion for four 
hours following the procedure. The 40 control patients were given a bolus of isotonic fluid 
directly after ERCP24. In the second trial, from Los Angeles, 62 patients were randomized 
in a 2:1 ratio to aggressive or conservative periprocedural fluid resuscitation23. The third 
trial27, performed in Iran, enrolled 150 patients in a 1:1 ratio using the same hydration 
schedule as the Los Angeles trial. All studies had PEP as the primary endpoint. Additional 
information about the included trials can be found in table 2. 
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Table 2: Included randomized controlled trials
Study
(First author, 
year)
Los Angeles trial
(Buxbaum, 2014)
Turkish trial
(Senol, 2009)
Iranian trial 
(Shaygan-nejad, 2015)
Design Randomised controlled 
trial
Randomised controlled 
trial
Randomised controlled 
trial
No. of patients 62 80 150
Objective Impact on PEP preven-
tion 
Impact on PEP pre-
vention
Impact on PEP preven-
tion
Inclusion 
criteria
ERCP for choledocholi-
thiasis, bile duct leak or 
biliary obstruction
ERCP for extrahepatic 
cholestasis and/or 
impaired liver function 
tests
All inpatients and 
outpatients referred for 
ERCP
Exclusion 
criteria
 - Active cholangitis or 
sepsis
 - Chronic pancreatitis
 - Active gallstone pan-
creatitis
 - NYHA class>1
 - Creatinine clearance 
<40mL/min
 - Liver dysfunction
 - Room air oxygen satu-
ration <90%
 - Peripheral or pulmo-
nary edema
 - Electrolyte disturbanc-
es (Na>150mEq/L or 
<130mEq/L)
 - Pregnancy
 - Age >70years
 - Previous sphincter-
otomy
 - Contraindication for 
diclofenac (peptic 
ulcer, renal failure)
 - Use of NSAID in 
preceding week
 - Acute pancreati-
tis within 2 weeks 
before ERCP
 - Chronic pancreatitis
 - Gallstone pancre-
atitis
 - Active cholangitis
 - History of sphincter-
otomy
 - Age >70 years
 - Pregnancy
 - Peripheral edema
 - Pulmonary edema
 - Electrolyte 
disturbances 
(Na>150mEq/L or 
<130mEq/L)
 - NYHA>1
 - Room air oxygen 
saturation <90%
 - Creatinine clearance 
<40mL/min
 - Liver dysfunction
PEP risk cate-
gory of includ-
ed patients
Mixeda Mixeda Mixeda
Other comor-
bid conditions
Similar ‘comorbid condi-
tions’ (not specified)
NR NR
Intervention 
group
RL 3mL/kg/h during 
ERCP, 20mL/kg bolus 
after ERCP, 3mL/kg/h for 
8 hours after the proce-
dure (n=39)
75mg IM diclofenac + 
IV isotonic saline (5-
10mL/kg/h for 4 hours) 
(n=40).
RL 3mL/kg/h during 
ERCP, 20mL/kg bolus 
after ERCP, 3mL/kg/h 
for 8 hours after the 
procedure (n=75)
Control group RL 1.5mL/kg/h during 
and for 8 hours after 
procedure (n=23)
500mL IV isotonic 
saline after ERCP 
(n=40).
RL 1.5mL/kg/h during 
and for 8 hours after 
procedure (n=75)
4
526323-L-bw-Smeets
Processed on: 22-11-2018 PDF page: 70
70
Chapter 4
Table 2: Continued
Study
(First author, 
year)
Los Angeles trial
(Buxbaum, 2014)
Turkish trial
(Senol, 2009)
Iranian trial 
(Shaygan-nejad, 2015)
Outcomes PEP: 
 - Hyperamylasemia (>3x 
ULN) at 2 or 8 hours 
after ERCP
 - Pancreatic pain scored 
by patient as devel-
opment of or increase 
of pain ≥3 on a 0-10 
visual analogue pain 
scale and persisting for 
≥24 hours after ERCP
Individual components 
of PEP
Length of hospitalization
Fluid overload
PEP: 
 - Hyperamylasemia 
(>3x ULN)
 - Epigastric pain, back 
pain and epigastric 
tenderness
PEP:
 - Hyperamylasemia 
(>3x ULN) during the 
24h follow-up
 - Pancreatic pain >3 on 
VAS scale during 24h 
follow-up
Additional 
information
A pilot trial in which 
patients were random-
ized in a 2:1 ratio to 
aggressive or standard 
periprocedural hydration 
with lactated Ringer’s 
solution.
A randomized trial in 
which patients were 
randomized in a 1:1 
ratio to aggressive 
hydration with intra-
muscular NSAID or 
standard hydration
A randomized trial in 
which patients were 
randomized in a 1:1 
ratio to aggressive 
hydration or standard 
hydration
NYHA: New York Heart Association. RL: lactated Ringer’s solution. ULN: institutional upper limit 
of normal. NSAID: non-steroidal anti-inflammatory drugs. IM: intramuscular. IV: intravenous. 
PEP: Post Endoscopic retrograde cholangiopancreatography Pancreatitis. ERCP: Endoscopic Retro-
grade Cholangiopancreatography. aAll studies were judged to have a mixed-case population as not 
all risk factors according to European and American guidelines were taken into account.
The retrospective studies from Michigan26 and Boston21 selected PEP cases from their 
institution’s ERCP database and matched them to control patients without PEP. Data on 
fluid administration before PEP diagnosis were collected retrospectively. The Michigan 
study used crystalloid solutions without further specification. Patients in the Boston 
study received lactated Ringer’s solution. The indications for fluid administration were 
not given. Moreover, the Michigan study group specifically remarked that there was no 
institutional protocol for periprocedural fluid administration during the study period. 
Additional information about the retrospective studies can be found in table 3. 
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Table 3: Included retrospective studies
Study design
(first author, 
year)
Michigan study
(DiMagno, 2014)
Boston study
(Grunwald, 2015)
Indiana study
(Sagi, 2014)
Design Retrospective cohort Case-control study Retrospective cohort
No. of patients 436 312 72
Objective Impact on PEP preven-
tion and PEP severity
Impact on PEP pre-
vention
Impact on PEP severity
Inclusion 
criteria
PEP according to 
Cotton criteria or im-
aging findings of acute 
pancreatitis
PEP:
 - Abdominal pain
 - Elevated amylase/
lipase >3xULN
 - ≥1 night of un-
planned hospital 
admission
PEP according to Cotton 
criteria
Exclusion 
criteria
 - No data on volume 
infusion
 - Age<18years
 - Pregnancy
 - Biliary stent re-
moval or exchange 
without planned 
pancreatogram
 - Active pancreatitis
 - Chronic pancreatitis
 - Pancreatic cancer
 - Prior pancreatic 
surgery
 - History of PEP
No patients excluded.  - No data on volume 
infusion
 - Delayed (>24h) presen-
tation 
 - Admission to different 
facility
 - Concomitant bowel per-
foration or postsphinc-
terotomy bleeding
 - Creatinine ≥1.4
 - NYHA>2
 - Resting air oxygen satu-
ration <90%
Risk category 
of included 
patients
Mixeda Mixeda Mixeda
Other comor-
bid conditions
Similar median Charl-
son score, cardiovas-
cular disease, angina 
and hypertension.
20% of the population 
had history of PSC, 
pancreatic cancer, liver 
transplant, cholangio-
carcinoma, or chronic 
pancreatitis. More 
controls had PSC (6% 
vs 0%, p=0.03).
NR
Study groups  - ERCP control cases 
(n=263)
 - Mild PEP (n=39)
 - Moderate/severe 
PEP (n=134)
 - ERCP control cases 
(n=234)
 - PEP cases (n=78)
 - Mild PEP (n=41)
 - Moderate/severe PEP 
(n=31)
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Table 3: Continued
Study design
(first author, 
year)
Michigan study
(DiMagno, 2014)
Boston study
(Grunwald, 2015)
Indiana study
(Sagi, 2014)
Outcomes Differences in fluid 
volumes (L):
 - Before PEP diagno-
sis: periprocedural, 
ERCP recovery room
 - After PEP diagnosis: 
0-12hrs, 12-24hrs, 
24-48hrs
Difference in peripro-
cedural fluid volumes 
(mL)
Differences in fluid 
volumes (mL): <24hrs, at 
ERCP, after ERCP
Additional 
information
Patients with PEP 
were selected from an 
existing database con-
taining 6505 records. 
Controls were selected 
by random number 
generator by 2-year in-
crements of time. Data 
on administered fluids 
were retrospectively 
collected. PEP cases 
were dichotomized 
in mild or moderate/
severe PEP.
Patients with PEP 
were selected from an 
existing institutional 
database containing all 
ERCPs since 2009. For 
every case, 3 controls 
were selected by using 
a random number 
table. Controls were 
matched by 1-month 
increments of time.
A retrospective study 
aiming to find a correla-
tion between the total 
volume of intravenous 
fluid infusion in the first 
24h after ERCP and length 
of hospitalization.
NYHA: New York Heart Association. ULN: institutional upper limit of normal. NR: not reported. 
PEP: Post Endoscopic retrograde cholangiopancreatography Pancreatitis. ERCP: Endoscopic Retro-
grade Cholangiopancreatography.
aAll studies were judged to have a mixed-case population as not all risk factors according to Europe-
an and American guidelines were taken into account.
Baseline comparability
To assess baseline comparability and identify possible confounders, we collected data on 
European and American guideline risk factors, biochemical parameters of dehydration 
and use of prophylactic measures. The reported baseline and treatment characteristics 
and the reported PEP risk factors were similar in both groups in the randomized trials and 
the Michigan study. No study reported all definite risk factors according to the European 
and American guidelines (Supplementary table 1). Several characteristics in the Boston 
study differed between cases and controls. Notably, 3 patients (4%) in the case group 
and 19 (8%) in the control group had gallstone pancreatitis, possibly confounding the 
diagnosis of PEP. The trials from Los Angeles and Iran reported biochemical parameters 
suggestive of dehydration (hematocrit and creatinine). These were similar between groups 
(Supplementary table 2). Prophylactic pancreatic duct stents to reduce the risk of PEP 
were only used in the Michigan study. There was no significant difference in its use 
526323-L-bw-Smeets
Processed on: 22-11-2018 PDF page: 73
73
Periprocedural hydration to prevent post-ERCP pancreatitis
between PEP cases and controls. Intramuscular NSAIDs were used in the treatment arm 
of the Turkish trial. 
Findings
The Los Angeles trial reported a lower incidence of PEP in the intervention group: 0% 
vs. 17% (P=0.016; table 4). Also, the actual administered volumes in the first 24 hours 
differed between the two groups (P<0.001). The Iranian trial had similar results: 5.3% 
PEP in the intervention group vs. 22.7% in the control group (P=0.002). The Turkish trial 
did not show a significant difference in PEP between the intervention and control group 
(7.5% vs. 17.5%; P=0.176). However, when patients with sphincter of Oddi dysfunction 
were excluded, a significant effect in favour of the intervention group was found: 2.7% vs. 
16.7% (P=0.047). This subgroup analysis was not predefined. In the case-control studies, 
evidence in favour of periprocedural hydration was lacking. The Michigan study found 
no difference in periprocedural volumes between PEP cases and controls. The Boston 
study found that higher volume of periprocedural fluids led to a higher PEP incidence in a 
univariate analysis: 547mL vs. 440mL (P=0.03). However, this correlation lost significance 
in a multivariate analysis (P =0.09). None of the patients in the trials developed clinical 
signs of fluid overload. The non-randomized studies did not report this aspect. 
Table 4: Periprocedural hydration and incidence of PEP
Study PEP incidence, 
n (%)
Mean periproce-
dural fluids (mL)
Total median fluids 
in first 24hrs (mL)
Use of rectal 
NSAIDs
Los Angeles trial
 Control (n=23) 4 (17%)a NR  2200 (IQR: 2100)b 0 (0%)
  Intervention 
(n=39)
0 (0%)a NR 3800 (IQR: 1500)b 0 (0%)
Turkish trial
 Control (n=40) 7 (17.5%) NR NR 0 (0%)
 Intervention  
 (n=40)
3 (7.5%) NR NR 0 (0%)
Iranian trial
 Control (n=75) 17 (22.7%)c NR NR NR
  Intervention 
(n=75)
4 (5.3%)c NR NR NR
4
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Table 4: Continued
Study PEP incidence, 
n (%)
Mean periproce-
dural fluids (mL)
Total median fluids 
in first 24hrs (mL)
Use of rectal 
NSAIDs
Michigan study
 No PEP 
(n=263)
0 (0%) 840 (SD: 400) NR 0 (0%)
 PEP (n=173) 173 (100%) 840 (SD: 300) NR 0 (0%)
Boston study
 No PEP 
(n=234)
0 (0%) 440 (range: 
0-1400)d
NR 0 (0%)
 PEP (n=78) 78 (100%) 547 (range: 
0-2000)d
NR 0 (0%)
a P=0.016. b P<0.001. c P=0.002. d Univariate: P=0.03. Multivariate: P=0.09. NR: not reported. SD: 
standard deviation. IQR: interquartile range.
Impact of fluid volume on PEP severity
Study design
Two retrospective studies investigated the impact of fluid hydration on PEP severity, 
dichotomized in ‘mild’ and ‘moderate to severe’ according to the Cotton criteria25,26 
(table 3). Both studies used crystalloid solutions without further specification. The 
indications for fluid administration were not given (e.g. hospital protocol for pancreatitis, 
hypovolemia). 
Baseline comparability
Baseline comparability in the Michigan study was discussed above. The Indiana study, 
a retrospective cohort, also failed to report all definite risk factors according to the 
European and American guidelines (Supplementary table 1). Except for a higher median 
age of patients with ‘moderate to severe’ PEP in the Indiana study (median 36 years ‘mild’ 
vs median 49 years ‘moderate to severe’; P=0.05), patient and procedure characteristics 
were similar between groups. A majority of patients (~80%) received prophylactic 
pancreatic duct stents. No differences in biochemical parameters of dehydration were 
reported (Supplementary table 2). 
Findings
Both non-randomized studies found an association between higher periprocedural fluids 
and curtailment of PEP severity. The Michigan study found that patients with ‘moderate 
to severe’ PEP received lower volume (130ml; P=0.031) throughout the procedure (table 
5). Multivariate analysis, adjusted for PEP risk factors, revealed a protective effect of 
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periprocedural fluid administration with an odds ratio of 0.13 (95% confidence interval 
0.03-0.62) per liter of fluid. Total fluid administration before PEP diagnosis did not differ 
between groups (P=0.18). The Indiana study found comparable fluid amounts during the 
ERCP procedure. Patients with mild PEP received increased fluid volumes the first 24 
hours after ERCP compared to patients with moderate severe PEP (median fluid difference 
of 800ml; P<0.02). 
Table 5: Periprocedural hydration and PEP severity
Study
Periprocedural fluids 
(mL)
Total fluids first 
24 hours (mL)
Use of 
rectal 
NSAIDs
Use of pan-
creatic duct 
stents
Michigan study
 Mild (n=39) Mean 940a (SD: 270) Mean 1870 (SD: 
690)
n=0 (0%) n =14 (36%)
  Moderate/severe 
(n=134)
Mean 810a (SD: 360) Mean 1660 (SD: 
790)
n =0 (0%) n =41 (31%)
Indiana study
 Mild (n=41)  Median 600 (IQR: 
200-800)
Median 2834b 
(IQR: 2046-3570)
 n =1 (2.%)  n =32 (78%)
  Moderate/severe 
(n=31)
Median 600 (IQR: 
400-800)
Median 2044b 
(IQR: 1227-2875)
n =1 (3%) n =25 (81%)
a P=0.031. b P<0.02. SD: standard deviation. IQR: interquartile range. 
Quality of included studies
Supplementary tables 3 and 4 summarize the quality assessment of included studies. 
Full descriptions and motivations for the scores are given in Supplementary tables 5-10. 
All randomized trials had issues with blinding of participants and personnel. 
Furthermore, in the Turkish and Iranian trial it was not possible to assess the adequacy 
of the randomization method. Finally, the Iranian trial excluded five patients after 
randomization because of an increased PEP risk. A significant effect on the primary 
endpoint cannot be ruled out. The methodological quality of all non-randomized studies 
according to the Methodological Index for Non-Randomized Studies was 14 out of 24. The 
main issues were their retrospective nature, the adequacy of the control group (including 
issues with baseline equivalence), the unbiased assessment of study endpoints and two 
studies25,26 had to deal with a considerable amount of missing data. 
4
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DISCUSSION 
We performed a systematic review that examined the benefit of periprocedural fluid 
resuscitation in the prevention of PEP and in the reduction of its severity. For PEP 
prevention, two trials showed a significant absolute PEP reduction (17% and 18%) whereas 
a third trial found no significant overall reduction. In two case-control studies evidence 
in favour of periprocedural hydration was lacking. 
For the reduction of PEP severity, retrospective studies suggested that PEP severity may 
be positively influenced by greater volumes of periprocedural fluids. One study found an 
odds ratio of 0.13 per liter of fluid that was administered for developing moderate/severe 
PEP while another study showed that patients with mild PEP received a median of 800mL 
more than patients with moderate/severe PEP. The three main issues when considering 
periprocedural hydration with regards to PEP prevention and severity attenuation are 
the type, timing and volume of fluid administration. 
Type of fluid
First, the type of solution needs to be addressed. Three studies used lactated Ringer’s 
solution 21,23,27 and three administered normal saline or crystalloids without any 
specification24–26. It is unknown whether a protective effect of periprocedural fluids 
depend on type of fluid given. Guidelines28,29 on acute pancreatitis advocate the use of 
lactated Ringer’s solution based on one well-designed study that was terminated after an 
interim analysis of 40 patients30. This is at odds with a recent retrospective study that did 
not find a significant difference between lactated Ringer’s solution and normal saline in 
terms of disease severity, pancreatic necrosis and mortality31. The included studies offer 
no clear guidance on this issue. 
Timing of hydration
Second, timing of hydration may be relevant. For PEP prevention it appears that hydration 
during ERCP is important when comparing the schedules used by the Los Angeles and 
Iranian trial (from the start of ERCP) to that of the Turkish trial (postprocedural). This 
seems intuitive as intensive hydration presumably mitigates the course of pancreatitis 
by preserving pancreatic microcirculation during ERCP. Postprocedural hydration may 
simply come too late. The dehydrated state of patients before ERCP could aggravate this 
problem13,14. 
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The studies addressing severity attenuation leave the question of optimal timing of fluid 
administration unanswered: the results of the Michigan study are in favour of hydration 
during ERCP, whereas the Indiana study results seem to favour postprocedural hydration. 
Total administered volume
Last, the total administered volume may matter. Of the PEP prevention studies, two 
trials24,27 did not report actually administered volumes. On the basis of used hydration 
schedules, a 75kg patient undergoing a 1-hour ERCP would receive 3525mL in 9 hours 
(1725mL in the first 2 hours) in the Los Angeles and Iranian trial, compared to 2250mL 
over 4 hours in the Turkish trial. The retrospective studies addressing PEP prevention 
did not find a significant difference between cases and controls.
Both studies addressing severity reduction found a minor effect in favour of higher 
volumes (130mL during ERCP and 33mL/hr for the first 24 hours thereafter, respectively). 
It is unlikely that such small differences can have a significant impact on severity of 
pancreatitis, as patients with pancreatitis lose a median 3,2L of fluids into the third space 
within the first 48 hours32.
It is unclear which hydration schedule should be favoured or whether there is a (re)
hydration threshold that offers protection against PEP. Conclusively, the included studies 
point in the direction of high volume hydration.
Combination with recommended prophylactics
It would be interesting to test whether periprocedural hydration acts in synergy with 
other recommended prophylactic strategies. This hypothesis is reasonable in view of 
the divergent underlying mechanisms: curtailing the pancreatic inflammatory response 
(NSAIDs), preventing pancreatic duct outflow obstruction (pancreatic duct stents) and 
preserving pancreatic microcirculation (periprocedural hydration)4,6,7,33,34. Rectal NSAIDs 
and pancreatic duct stents are both effective, and both strategies are recommended by 
European and American guidelines 12,17. We believe the added value of periprocedural 
hydration lies in its addition to established prophylactics, not in their replacement. 
NSAIDs are (cost-)effective, easy to use and safe in most patients10,35,36. It remains to be 
seen whether periprocedural hydration would be acceptable for most practices as 9-hour 
hydration schedules could limit the practice of ambulatory ERCPs and the intensity of 
hydration may exceed safety limits for some patients. None of the included studies used 
rectal NSAIDs, so an additive effect on PEP prevention or severity reduction could not 
be investigated. The Turkish trial used intramuscular NSAIDs and found no difference 
in PEP incidence. Parenterally administered NSAIDs are probably ineffective37. Only the 
4
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retrospective Indiana study used prophylactic pancreatic duct stents in a majority of 
patients (~80% in both groups). Interestingly, they found that patients with mild PEP 
received increased fluid volumes in the first 24 hours after ERCP compared to patients 
with moderate/severe PEP. This limited evidence points in the direction of a synergistic 
(or additive) effect and warrants further investigation. 
Limitations
This review has several limitations. The included studies had different methodologies 
which precluded a formal data synthesis of our results. We identified a number of 
methodological issues of the included studies such as different endpoint definitions, 
reporting of confounders and small sample sizes. We will expand on these issues below. 
Studies differ in their definition of PEP and not always adhered to the Cotton criteria. 
There are four components to this definition: hyperamylasaemia and pancreatic pain, 
which should be present for 24 hours after the procedure and which lead to prolongation 
of (planned) hospitalization of at least 2 nights. The last two time-related aspects were 
not always used. Since pancreatic pain and hyperamylasemia are both common findings 
early after ERCP8, they could be mistaken for PEP and lead to an overestimation of its 
incidence. As was mentioned in a comment on the Los Angeles trial: the Cotton definition 
is the most validated one and should be used in every prevention study until a more 
accurate tool becomes available38. 
Some parameters which are deemed to be important for baseline comparability were 
not reported. These are risk factors according to European and American guidelines, 
comorbidity, biochemical parameters of dehydration (blood urea nitrogen, hematocrit) 
and use of recommended prophylactic measures (pancreatic duct stents and rectal 
NSAIDs). Therefore, it is possible that groups were not entirely comparable in the non-
randomized studies. Studies probably did not adjust for these possible confounders. The 
observations in the case-control studies (the Michigan and Boston study) could be due 
to insufficient matching of cases and controls. As the indication for fluid administration 
was unknown in these studies, reverse causation bias cannot be ruled out: patients 
with a more difficult ERCP procedure might have received greater fluid volumes as their 
physicians judged their PEP risk to be higher.
All included studies had inadequate statistical power due to their small sample sizes, 
thereby increasing the risk of a type I error (Los Angeles and Iranian trial) or type II 
error (Turkish trial). If periprocedural hydration is as effective as rectal NSAIDs, PEP 
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incidence would be reduced from 13.9% to 8%, a relative reduction of 57%36. A definitive 
study powered to detect this difference would need 878 patients. 
Conclusions
This review provides guidance in the research of periprocedural hydration in the 
prevention of post-ERCP pancreatitis. Because the concept has only recently gained 
attention, the evidence base is still being built. The concept of periprocedural fluid 
resuscitation is an interesting potential strategy to prevent PEP. Adequately powered 
studies are needed that assess the protective effect and cost-effectiveness of intensive 
hydration in patients receiving already established preventive measures, such as rectal 
NSAIDs. The Dutch Pancreatitis Study Group is currently investigating the effect of 
periprocedural fluid resuscitation in the prevention of PEP in a randomized, multicenter 
trial (FLUYT-prevent trial: ISRCTN 13659155). Until large-scale trials have been 
published, most evidence points in the direction of the schedule proposed by Buxbaum 
and colleagues: lactated Ringer’s solution in a rate of 3mL/kg/hr during ERCP, a bolus 
of 20mL/kg directly afterwards, followed by 3mL/kg/hr for eight hours thereafter. 
However, despite encouraging results the evidence for this hydration schedule is still 
limited. Furthermore, periprocedural hydration should always be combined with already 
recommended prophylactics, such as rectal NSAIDs and pancreatic duct stents.
4
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SUPPLEMENTARY MATERIAL
Supplement 1: search strategies
The following search strategy was used in PubMed: (“Cholangiopancreatography, 
Endoscopic Retrograde”[Mesh] OR Endoscopic Retrograde Cholangiopancreatograph*[tiab] 
OR ERCP[tiab]) AND (“Fluid Therapy”[Mesh] OR fluid therap*[tiab] OR hydrat*[tiab] OR 
rehydrat*[tiab] OR fluid administrat*[tiab] OR fluid volume*[tiab] OR intravenous infusion 
OR hemoconcentration).
The following search strategy was used in Embase: (‘endoscopic retrograde 
cholangiopancreatography’/exp OR (“Endoscopic Retrograde” NEXT/1 
Cholangiopancreatograph*):ab,ti OR ERCP:ab,ti) AND (‘fluid therapy’/exp OR 
(fluid NEXT/1 (therap* OR administrat* OR volume*)):ab,ti OR hydrat*:ab,ti OR 
rehydrat*:ab,ti OR ‘intravenous drug administration’/exp OR ‘hemoconcentration’/exp 
OR hemoconcentration*:ab,ti).
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Supplementary table 3: Assessment of study quality by MINORS
Study Score
Michigan study (DiMagno) 14/24
Boston study (Grunwald) 14/24
Indiana study (Sagi) 14/24
The ideal score for non-comparative studies is 16, and for comparative studies 24.
Supplementary table 4: Assessment of RCT study quality by Cochrane
Random 
sequence 
gener-
ation (se-
lection 
bias)
Alloca-
tion con-
cealment 
(selec-
tion bias)
Blinding 
of par-
ticipants 
and per-
sonnel 
(perfor-
mance 
bias)
Blinding 
of out-
come as-
sessment 
(detec-
tion bias)
Incom-
plete 
outcome 
data 
(attrition 
bias)
Selective 
report-
ing (re-
porting 
bias)
Other 
sources 
of bias
Los 
Angeles 
RCT 
(Bux-
baum, 
2014)
+ + - - + + +
Turkish 
RCT 
(Senol, 
2009)
? ? - - + + +
Iranian 
RCT 
(Shay-
gan-ne-
jad, 
2015)
? - - - - - +
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Supplementary table 5: MINORS assessment of Michigan study (DiMagno, 2014)
Items Score Comments
A clearly stated aim 2 Clearly stated in introduction
Inclusion of consecutive patients 2 Clear description of in- and exclusion criteria. 
Also, the reason for excluding patients becomes 
clear from a flow chart.
Prospective collection of data 0 Retrospective study design. 
Endpoints appropriate to the aim 
of the study
2 PEP was defined according to the Cotton criteria. 
Periprocedural fluids were defined as ‘between 
arrival time and procedure completion’. 
Unbiased assessment of study 
endpoint
0 No description of blind assessment.
Follow-up period appropriate to 
the aim of the study
2 Data on administered fluids were collected till 48 
hours after PEP diagnosis. 
Loss to follow-up less than 5% 0 The results section states that ‘all variables had 
a rate of missing data less than 5%’. However, 38 
of 211 eligible patients with PEP (18%) and 85 of 
348 patients without PEP (24%) were excluded 
because data on fluid volumes were missing. 
Prospective calculation of study 
size
0
An adequate control group 1 Patients with PEP were compared to patients 
without PEP. Furthermore, patients with mild PEP 
were compared to patients with moderate/severe 
PEP. We are doubtful as to the comparability of 
mild and moderate/severe PEP. As severe PEP is 
defined as >10 days of hospitalization OR occur-
rence of complications such as necrosis, the mod-
erate/severe group can differ to a great extent.
Contemporary groups 2
Baseline equivalence of groups 1 Not all risk factors according to ESGE can be 
retrieved from the article. Furthermore, the base-
line characteristics between cases and controls 
are not given. It is only stated they were similar. 
Adequate statistical analyses 2
TOTAL 14
4
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Supplementary table 6: MINORS assessment of Boston study (Grunwald, 2015)
Items Score Comments
A clearly stated aim 2 Clearly stated in introduction.
Inclusion of consecutive patients 2 No patients were excluded from the analysis. 
Prospective collection of data 0 Retrospective study design.
Endpoints appropriate to the aim 
of the study
0 No use of Cotton criteria: it is not stated that 
abdominal pain and elevated amylase/lipase had 
to be present for >24 hours after ERCP.
Unbiased assessment of study 
endpoint
0 No description of blind assessment. 
Follow-up period appropriate to 
the aim of the study
2 Patients were followed for 2 weeks after ERCP
Loss to follow-up less than 5% 2 It seems all data on administered fluids could be 
collected without using value imputing. 
Prospective calculation of study 
size
0
An adequate control group 1 Controls were matched by choosing patients that 
had ERCP within 1 month of the case. A random 
number table was used. However, baseline charac-
teristics differed to a great extent. 
Contemporary groups 2 Cases and controls differed a maximum of 1 
month from each other. 
Baseline equivalence of groups 1 Baseline characteristics differed to a great extent. 
Not all risk factors according to ESGE can be 
retrieved from the article. 
Adequate statistical analyses 2
TOTAL 14
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Supplementary table 7: MINORS assessment of Indiana study (Sagi, 2014)
Items Score Comments
A clearly stated aim 2 Clearly stated in introduction
Inclusion of consecutive patients 2 Clear description of in- and exclusion criteria. 
Also, the reason for excluding patients becomes 
clear from a flow chart.
Prospective collection of data 0 Retrospective study design. Although the data-
base is documented in a prospective fashion, data 
on fluid volumes were collected retrospectively. 
Endpoints appropriate to the aim 
of the study
2 PEP was defined according to the Cotton criteria. 
Unbiased assessment of study 
endpoint
0 No description of blind assessment.
Follow-up period appropriate to 
the aim of the study
2 Data on administered fluids were collected till 24 
hours after ERCP. This is within the time frame for 
diagnosing PEP. 
Loss to follow-up less than 5% 0 Of the 83 eligible patients, 11 were excluded due to 
missing data (13%) 
Prospective calculation of study 
size
0
An adequate control group 1 Patients with mild PEP were compared to patients 
with moderate/severe PEP. We are doubtful as to 
the comparability of mild and moderate/severe 
PEP. As severe PEP is defined as >10 days of hospi-
talization OR occurrence of complications such as 
necrosis, the moderate/severe group can differ to a 
great extent.
Contemporary groups 2
Baseline equivalence of groups 1 Not all risk factors according to ESGE can be 
retrieved from the article. Furthermore, patients 
in the mild group were significantly younger (36 
vs. 49 years) than patients in the moderate/severe 
group. Younger age is considered a risk factor for 
PEP.
Adequate statistical analyses 2
TOTAL 14
4
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Supplementary table 8: Cochrane assessment Los Angeles RCT (Buxbaum, 2014)
Domain Support for judgement Review authors’ judgement 
Selec-
tion Bias
Random 
sequence gener-
ation
“Immediately before ERCP, 
subjects were randomly 
assigned in a 2:1 ratio to 
receive aggressive intra-
venous hydration versus 
standard periprocedural 
fluids. A concealed com-
puter-generated block 
randomization schedule 
was used. Randomization 
was stratified by patient 
sex, and the protocol called 
for the randomization of 30 
women and 30 men.”
 A computer-generated 
block randomization 
schedule was used.
+
Allocation con-
cealment
See above.  A concealed computer 
schedule was used.
+
Perfor-
mance 
bias
Blinding of 
participants 
and personnel 
Assessments 
should be made 
for each main 
outcome (or 
class of out-
comes) 
The article did not describe 
blinding procedures. 
Blinding of patients and 
health care providers is 
difficult due to the nature 
of the intervention. There-
fore, we suspect partici-
pants and personnel were 
not blinded.
-
Detec-
tion bias
Blinding of 
outcome assess-
ment Assess-
ments should be 
made for each 
main outcome 
(or class of out-
comes)
The article did not describe 
blinding procedures. 
Blinding of outcome 
assessors is difficult due to 
the nature of the interven-
tion. Therefore, we suspect 
outcome assessors were 
not blinded.
-
Attri-
tion bias
Incomplete 
outcome data 
Assessments 
should be made 
for each main 
outcome (or 
class of out-
comes)
“A total of 62 patients were 
enrolled because 2 patients 
who were enrolled had 
unsuspected prior sphinc-
terotomy, in violation of the 
enrollment criteria. These 
2 patients were included 
in the primary inten-
tion-to-treat analysis but 
not in a secondary per-pro-
tocol analysis.” 
There is no reason to be-
lieve that the unintention-
al inclusion of two patients 
with a previous sphinc-
terotomy had influence on 
the results. Furthermore, 
the supplementary figure 
shows no patients were lost 
to follow-up or discontin-
ued study medication. 
+
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Supplementary table 8: Continued
Domain Support for judgement Review authors’ judgement 
Report-
ing bias
Selective report-
ing
The study protocol is avail-
able and all of the study’s 
pre-specified primary and 
secondary outcomes that 
are of interest have been 
reported in the pre-speci-
fied way.
+
Other 
bias
Other sources 
of bias
There is no reason to 
believe other sources of 
bias confounded the study 
results.
+
Supplementary table 9: Cochrane assessment Turkish RCT (Senol, 2009)
Domain Support for judge-
ment 
Review authors’ judgement
Selection 
Bias
Random sequence 
generation
The article mentions: 
“Between August 2006 
and April 2008, 91 
patients fulfilled the 
inclusion criteria, 80 of 
whom were included in 
the final analysis.” 
The article did not describe 
the randomization proce-
dure. It is not described 
why the 11 patients were 
not included in the study, 
so selection bias cannot be 
ruled out.
?
Allocation con-
cealment
 The article did not describe 
the randomization proce-
dure.
?
Perfor-
mance 
bias
Blinding of partic-
ipants and person-
nel Assessments 
should be made 
for each main 
outcome (or class 
of outcomes) 
The article did not 
describe blinding pro-
cedures. It was stated 
that patients in the 
control group received 
an ‘inert placebo’ 
consisting of 500mL 
isotonic saline.
Blinding of patients and 
health care providers is 
difficult due to the nature of 
the intervention. Therefore, 
we suspect participants and 
personnel were not blinded.
The statement regarding the 
use of an inert placebo impli-
cates no placebo for the IM 
diclofenac was given. Hence, 
blinding will be unlikely.
-
Detec-
tion bias
Blinding of out-
come assessment 
Assessments 
should be made 
for each main 
outcome (or class 
of outcomes)
The article did not 
describe blinding pro-
cedures. It was stated 
that patients in the 
control group received 
an ‘inert placebo’ 
consisting of 500mL 
isotonic saline. 
Blinding of outcome asses-
sors is difficult due to the 
nature of the intervention. 
Therefore, we suspect 
outcome assessors were not 
blinded.
The statement regarding the 
use of an inert placebo impli-
cates no placebo for the IM 
diclofenac was given. Hence, 
blinding will be unlikely.
-
4
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Supplementary table 9: Continued
Domain Support for judgement Review authors’ judgement
Attrition 
bias
Incomplete 
outcome data As-
sessments should 
be made for each 
main outcome (or 
class of outcomes)
 Although it was not explic-
itly stated in the article that 
there were no missing data, 
judging from the results 
section there were none.
+
Report-
ing bias
Selective report-
ing
The article does not state 
that the study protocol was 
available and we did not find 
it online. However, we have 
no reason to believe that the 
primary outcome was not 
pre-specified. In the article, 
emphasis is put on a signifi-
cant difference in a subgroup 
analysis, which was not 
pre-specified. However, the 
primary analysis is clearly 
described as well.
+
Other 
bias
Other sources of 
bias
There is no reason to believe 
other sources of bias con-
founded the study results.
+
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Supplementary table 10: Cochrane assessment Iranian RCT (Shaygan-nejad, 2015)
Domain Support for judgement Review authors’ judgement 
Selection 
Bias
Random 
sequence 
genera-
tion
The article states: ‘After 
giving informed consent, 
a trained staff then gave 
a number to each selected 
patient in a continuous order. 
A schedule was previously 
generated by RandList and 
patients were assigned to the 
target or the control group 
depending on the number 
given to each.’ 
RandList is a known pro-
gramme for generating 
reliable random sequences. 
However, the procedure is 
not described in sufficient 
detail to allow an adequate 
judgement. 
?
Allocation 
conceal-
ment
The article states: ‘After 
giving informed consent, 
a trained staff then gave 
a number to each selected 
patient in a continuous order. 
A schedule was previously 
generated by RandList and 
patients were assigned to the 
target or the control group 
depending on the number 
given to each.’ 
Procedures to conceal the 
previously generated Ran-
dList were not described. 
The description in the article 
suggests treatment allocation 
could have been foreseen in 
advance. 
-
Perfor-
mance 
bias
Blinding 
of partici-
pants and 
personnel 
Assess-
ments 
should be 
made for 
each main 
outcome 
(or class 
of out-
comes) 
‘Both patient and evaluator 
gastroenterologist were blind-
ed to the type of hydration 
of the patient. Because of 
the nature of the investiga-
tion, this was not kept up 
during follow-up…’ ‘However, 
because of the nature of the 
study, the rating investigators 
were not blind at the third 
measurement.’ 
The most validated definition 
of post-ERCP pancreatitis, 
the Cotton criteria, need to 
be assessed 24 hours after 
ERCP. At this crucial point, 
participants and personnel 
were not blinded. Therefore, 
blinding is inadequate and 
performance bias is possible.
-
Detec-
tion bias
Blinding 
of out-
come as-
sessment 
Assess-
ments 
should be 
made for 
each main 
outcome 
(or class 
of out-
comes)
‘Both patient and evaluator 
gastroenterologist were blind-
ed to the type of hydration 
of the patient. Because of 
the nature of the investiga-
tion, this was not kept up 
during follow-up…’ ‘However, 
because of the nature of the 
study, the rating investigators 
were not blind at the third 
measurement.’ 
The most validated definition 
of post-ERCP pancreatitis, 
the Cotton criteria, need to 
be assessed 24 hours after 
ERCP. At this crucial point, 
outcome assessors were not 
blinded. Therefore, blinding 
is inadequate and detection 
bias is possible.
-
4
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Supplementary table 10: Continued
Domain Support for judgement Review authors’ judgement 
Attrition 
bias
Incom-
plete 
outcome 
data As-
sessments 
should be 
made for 
each main 
outcome 
(or class 
of out-
comes)
 ‘The ERCP procedure was 
prolonged because of several 
cannulation attempts in 
of five patients whose data 
were excluded because of the 
increased risk for post-ERCP 
pancreatitis.’
There seem to be no with-
drawals from the study, lim-
iting the chance of attrition 
bias. However, five patients 
were excluded from the 
analysis because of a higher 
risk of post-ERCP pancreati-
tis, although this was not an 
exclusion criterion. Their al-
located groups and outcomes 
are not described. Therefore, 
a significant influence on the 
primary outcome cannot be 
ruled out.
-
Report-
ing bias
Selective 
reporting
‘The ERCP procedure was 
prolonged because of several 
cannulation attempts in 
of five patients whose data 
were excluded because of the 
increased risk for post-ERCP 
pancreatitis.’
As the allocated groups and 
outcomes of the five excluded 
patients were not reported, 
we cannot rule out their 
(significant) influence on 
the primary outcome. This 
should have been reported. 
-
Other 
bias
Other 
sources of 
bias
There is no reason to believe 
other sources of bias con-
founded the study results.
+
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Aggressive hydration for 
the prevention of post-ERCP 
pancreatitis: effective when 
combined with rectal NSAIDs?
Authors
Xavier J.N.M. Smeets, MD, Joost P.H. Drenth MD,  
PhD, Erwin J.M. van Geenen, MD/MSc, PhD. 
Journal of Clinical Gastroenterology 2017, Epub ahead of print.
Response to: ‘Aggressive hydration with lactated Ringer solution in prevention of 
post-ERCP pancreatitis – a meta-analysis of randomized controlled trials’ (Journal 
of Clinical Gastroenterology, 2017)
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Dear editor,
With great interest, we read the meta-analysis by Zhang and colleagues 1 concerning 
aggressive hydration as a prophylactic measure for post-ERCP pancreatitis (PEP). We 
applaud the thorough methodology used in the study. 
The meta-analysis showed a significantly reduced incidence of PEP in patients receiving 
aggressive hydration (P=0.0006; OR 0.47 [0.30-0.72]). Sensitivity analyses did not change 
this outcome. These preliminary results suggest its effectiveness is comparable to rectal 
non-steroidal anti-inflammatory drugs (NSAIDs) (OR 0.44 [0.34-0.57]) and pancreatic 
duct (PD) stents (OR 0.35 [0.25-0.49]) 2,3. Furthermore, the adverse event rate was similar 
between studied groups (P=0.23; OR 0.48 [0.15-1.57]). 
The GRADE assessment in this meta-analysis (low-moderate) can be ascribed in part 
to the small sample sizes of the studies. Six out of seven randomized controlled trials 
in this meta-analysis had a sample size less than 171 patients, which is inadequate for 
investigating a rare complication such as PEP. Assuming a similar effectiveness of rectal 
NSAIDs, 878 patients would have been needed to reach adequate statistical power. 
In addition, five out of seven studies did not use the Cotton criteria for PEP. The studies 
use abdominal pain and hyperamylasemia to score PEP, both of which are common after 
ERCP 4. For a proper PEP diagnosis, both items should still be present 24 hours after ERCP 
and hospitalization should be prolonged for at least 2 nights 5. The use of a less stringent 
PEP definition leads to an overestimation of PEP incidence.
Based on these results, the authors conclude that aggressive hydration is ‘very promising 
in clinical practice’ and add that the low cost and wide availability of lactated Ringer’s 
solution will enhance acceptance.  
We feel that this conclusion is premature, because the authors excluded studies that 
used other prophylactic measures, such as rectal NSAIDs and PD-stents. The evidence 
for their effectiveness in high-risk patients is irrefutable, prompting both the European 
and American Society for Gastrointestinal Endoscopy (ESGE and ASGE) to recommend 
their use 6,7. Furthermore, the evidence base favouring routine use of rectal NSAIDs in all 
patients is accumulating 8, especially following a large clinical trial in 2600 patients 9. In 
the era of prophylactic rectal NSAIDs, an important debate is concerned with combining 
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rectal NSAIDs and other prophylactics: ‘Do PD-stents (or other prophylactic treatment 
modalities such as periprocedural hydration) give additional PEP prevention on top of 
rectal NSAIDs/standard of care?’ To that end, Elmunzer and colleagues 10 are currently 
investigating the combination of rectal NSAIDs and PD-stents. Periprocedural hydration 
should be approached similarly. Due to the burden of 9-hour hydration schedules, it 
is unlikely that periprocedural hydration will replace rectal NSAIDs as (cost-effective) 
measure to prevent PEP, but it could serve as an adjunctive therapy, or as an alternative 
for those with contra-indications against NSAIDs.  
To our knowledge, only two RCTs have investigated prophylactic lactated Ringer’s solution 
on top of rectal NSAIDs 11,12. The first trial 11, in 192 patients, found a significant lower PEP 
rate in patients receiving both lactated Ringer’s solution (1L/30min before ERCP) and 
100mg indomethacin compared to controls (1L/30min normal saline with placebo). The 
second study 12 in 406 patients found that the combination of hydration and indomethacin 
significantly reduced the incidence of PEP compared to either treatment alone or placebo. 
These results suggest a role for periprocedural hydration in PEP prevention, but the small 
sample sizes and design of intervention groups (whether 1L/30min before ERCP qualifies 
as aggressive hydration is debatable) preclude firm conclusions. 
  
The three issues above (an adequate sample size, use of the Cotton criteria and 
combination with rectal NSAIDs) are addressed in a nationwide randomized controlled 
trial currently recruiting patients in the Netherlands (ISRCTN 13659155). A sample of 
826 patients receiving rectal NSAIDs is randomized to either aggressive hydration with 
Ringer’s (20mL/kg within 60 minutes at the start of ERCP, followed by 3mL/kg/hr for 
eight hours) or no hydration. We believe this trial will answer the question whether 
periprocedural hydration can prevent post-ERCP pancreatitis in patients already receiving 
rectal NSAIDs.   
Xavier J.N.M. Smeets, MD, Joost P.H. Drenth, MD, PhD, Erwin J.M. van Geenen, MD/
Msc, PhD
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ABSTRACT
Background
Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the 
most common complication of ERCP and may run a severe course. Evidence suggests that 
vigorous periprocedural hydration can prevent PEP, but studies to date have important 
methodological drawbacks. Importantly, evidence for its added value in patients already 
receiving prophylactic rectal NSAIDs is lacking and the cost-effectiveness of the approach 
has not been investigated. We hypothesize that combination therapy of rectal NSAIDs 
and periprocedural hydration significantly lowers the incidence of post-ERCP pancreatitis 
compared to rectal NSAIDs alone in moderate-high risk patients undergoing ERCP. 
Methods
The FLUYT trial is a multicenter, parallel group, open label, superiority randomized 
controlled trial. A total of 826 moderate-high risk patients undergoing ERCP that receive 
prophylactic rectal NSAIDs will be randomized to a control group (no fluids or normal 
saline with maximum of 1.5mL/kg/hr and 3L /24hrs) or intervention group (lactated 
Ringer’s solution with 20mL/kg in 60min at start of ERCP, followed by 3mL/kg/hr for 
8 hours thereafter). The primary endpoint is the incidence of post-ERCP pancreatitis. 
Secondary endpoints include PEP severity, hydration related complications and cost-
effectiveness. 
Discussion
The FLUYT trial design, including hydration schedule, fluid type and sample size, 
maximize its power of identifying a potential difference in post-ERCP pancreatitis 
incidence in patients receiving prophylactic rectal NSAIDs.
Trial registration
 - EudraCT: 2015-000829-37. Registered 18-02-2015.
 - ISRCTN: 13659155. Registered on 18-05-2015. URL
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BACKGROUND
Endoscopic retrograde cholangiopancreatography (ERCP) is widely used to treat diseases 
of the pancreaticobiliary tree. The most frequent complication is post-ERCP pancreatitis 
(PEP) 1. The reported overall incidence varies from 7 to 10% and approaches 15% in high 
risk patients 2. In the United States, costs related to PEP are estimated to be over $200 
million annually 3.
Numerous prophylactic measures for PEP have been investigated 4. However, for only 
two measures the evidence is indisputable: rectal nonsteroidal anti-inflammatory drugs 
(NSAIDs) and prophylactic pancreatic duct (PD) stents. Recent meta-analyses calculated 
an odds ratio of 0.44 for rectal NSAIDs 5 and 0.35 for PD-stents 6. Therefore, the American 
Society for Gastrointestinal Endoscopy (ASGE) recommends the use of rectal NSAIDs 
and PD-stents in high risk patients and suggests the use of rectal NSAIDs in average risk 
patients 7. The European Society for Gastrointestinal Endoscopy (ESGE) recommends 
routine use of rectal NSAIDs in all patients undergoing ERCP, while reserving PD-stents 
for high risk patients 4. 
A new promising prophylactic strategy for PEP is periprocedural hydration. It is intended to 
preserve adequate pancreatic perfusion and tissue oxygenation during ERCP. The strategy 
finds its justification in the theory that early pancreatic microcirculatory perfusion 
derangements are correlated with severity of acute pancreatitis 8. Circumstantial evidence 
supporting this theory is that an increased level of pre-procedural blood urea nitrogen, 
a marker of haemoconcentration, has been associated with PEP development and 
severity 9,10. Many patients subjected to ERCP are fasting and may therefore be relatively 
dehydrated. Furthermore, a retrospective cohort study found an inverse relationship 
between peri-ERCP hydration and PEP severity 11. 
A recent meta-analysis on periprocedural hydration 12 included seven RCTs with 
1047 patients and showed an odds ratio of 0.47 (0.30-0.72; p=0.0006) in favour of 
protection against PEP. There was no significant difference in adverse events between 
the intervention and control groups (p=0.23). However, the included RCTs had several 
shortcomings, the most important of which is that patients did not receive rectal 
NSAIDs. These cannot be withheld from patients due to the clear evidence in favour of 
their use 13. Furthermore, a synergistic effect of hydration and rectal NSAIDs is plausible 
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because both act at a different stage of PEP development: hydration preserves pancreatic 
microcirculation and NSAIDs suppress the inflammatory response.  
The FLUYT trial is designed to investigate whether periprocedural hydration with lactated 
Ringer’s solution can prevent post-ERCP pancreatitis in moderate-high risk patients 
undergoing ERCP who already receive prophylactic rectal NSAIDs. 
METHODS
The trial protocol is written in accordance with the SPIRIT guidelines (figure 1; Additional 
file 2)  14.
STUDY PERIOD
Pre-randomization Primary study period Follow-up
Enrolment Allocation ERCP +1h +9h +24h +30d +90d +180d
TIMEPOINT -t2 -t1 t0 t1 t2 t3 t4 t5 t6
ENROLMENT
Eligibility screen X
Informed consent X
Allocation X
INTERVENTION
Control 
Intervention 
ASSESSMENTS
Baseline vari-
ables*
X
Primary out-
come^
X
Secondary out-
comes#
X X X X X X X
Figure 1: SPIRIT schedule of enrolment, interventions and assessments. *Baseline 
variables: age, gender, comorbidity, American Society of Anesthesiologists (ASA) score, ERCP 
indication, PEP risk factors, use of pancreatic duct stents. ^Primary outcome: post-ERCP 
pancreatitis. #Secondary outcomes: incidence of delayed PEP (>24 hours after ERCP), severity 
of PEP, other ERCP complications, hydration related complications, length of hospital and in-
tensive care unit stay, health-related quality of life, cost-effectiveness, exocrine and endocrine 
pancreatic insufficiency.
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Study setting
The FLUYT trial is a multicenter, parallel group, open label, superiority randomized 
controlled trial that will include 826 patients from 20 hospitals of the Dutch Pancreatitis 
Study Group, including 3 university medical centres and 17 large teaching hospitals (see 
‘Participating Centres’ at the end of the protocol for more details). 
Eligibility criteria
The inclusion criteria are as follows:
 - Patients aged 18-85 years undergoing ERCP
 - Written informed consent
The exclusion criteria are as follows:
 - Low risk of post-ERCP pancreatitis: 1) definite chronic pancreatitis according to 
MANNHEIM criteria 15, 2) previous sphincterotomy, 3) pancreatic head mass, 4) 
routine biliary stent exchange. In case of a pancreatic duct intervention, chronic 
pancreatitis and previous sphincterotomy are not exclusion criteria.  
 - Acute pancreatitis
 - Altered anatomy, defined as anatomical variations in which bile and/or pancreatic 
secretions (in case of pancreatic duct interventions) do not enter the duodenum 
by way of the ampulla of Vater (e.g. Roux-Y reconstruction, surgery for chronic 
pancreatitis)
 - Pregnancy
 - Signs of congestive heart failure, such as pitting oedema or >NYHA class 1 heart 
failure
 - Respiratory insufficiency (pO2<60mmHg or saturation <90% despite FiO2 of 30% or 
requiring mechanical ventilation)
 - Severe liver disease (cirrhosis and ascites)
 - Patients receiving more than 1.5mL/kg/hr or 3L/24hrs of intravenous fluids in the 
24 hours before ERCP
 - Hypotension (systolic blood pressure <90mmHg or mean arterial pressure 
<70mmHg)
 - Hypo- or hypernatremia (serum Na+-levels <130 or >150mmol/L) 
 - Contraindications for rectal NSAIDs, including allergy, active gastrointestinal 
bleeding, ulcer disease, renal insufficiency (GFR <30mL/min) and NSAID use for 
other indications (other than cardioprotective aspirin)
6
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 - Treatment arms and co-interventions 
 - Eligibility of all potential participants will be discussed with the central study coor-
dinator. After written informed consent, patients are randomized to either:
Control group: 
 - 100mg indomethacin or diclofenac within <30 min before or after ERCP
 - No hydration or mild hydration with normal saline, with a maximum of 1.5mL/kg/
hr and a maximum of 3L/24hrs. After 24 hours, the volume and nature of intrave-
nous infusion is at the discretion of the treating physician.
Intervention group:
 - 100mg indomethacin or diclofenac within <30 min before or after ERCP
 - Periprocedural hydration with lactated Ringer’s solution: 20mL/kg within 60 min-
utes from the start of ERCP (endoscope-mouth contact), directly followed by 3mL/
kg/hr for 8 hours. Thereafter, the volume and nature of intravenous infusion is at 
the discretion of the treating physician.
The type, dosing and timing of rectal NSAID application follow the recommendations 
of the ESGE 4. Current ERCP guidelines give no guidance for hydration in the control 
group. Therefore, the hydration schedules in both the intervention and control group 
are based on the favorable results seen in Buxbaum’s pilot study 16. 
To ensure timely delivery of the 60min bolus, pressure bags or double infusion pumps 
will be used. The hydration is maximized in patients with morbid obesity (body mass 
index [BMI]>40), because their altered physiology is characterized by a decrease of lean 
body in tissue water content 17. Therefore, in these patients a maximum amount of fluid 
is calculated by using a fictive maximum weight (FMW) associated with a BMI of 40 kg/
m2. The FMW is calculated as follows: 
FMW = 40 (patient length in meters)2
The FMW is inserted in the fluid equations of the intervention group. 
If the clinical condition of patients in the control group does not allow the infusion 
restrictions (e.g. in case of hypovolemic shock), higher volume infusion is allowed at the 
discretion of the treating physician. Furthermore, if patients in the intervention group 
develop signs of fluid overload, the intensive hydration will be stopped and, if needed, 
diuretics will be started. 
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General treatment measures include a fasting state before ERCP. Antibiotic prophylaxis, 
measures to correct coagulation disorders and diet reintroduction after endoscopic 
sphincterotomy will be managed according to local protocol. We did not encourage 
the use of pancreatic duct stents to prevent confounding with the intensive hydration 
regimen. After ERCP, all patients will be hospitalized for a minimum stay of 24 hours for 
timely diagnosis of adverse events and monitoring of intravenous fluid volumes. Longer 
monitoring, hospitalization and treatment of adverse events is at the discretion of the 
treating physician. Post-ERCP pancreatitis will be treated in accordance with the IAP/
APA guidelines for treatment of acute pancreatitis 18. 
To improve adherence to the trial protocol, involved staff members (gastroenterologists, 
residents, physician assistants, endoscopy nurses, ward nurses and sedationists) in all 
participating centres will receive specific training in the trial’s standard operating 
procedures (SOPs). In coordination with the local principal investigator, these SOPs are 
adapted to the local hospital setting, while ensuring adherence to the trial protocol. 
Furthermore, these SOPs will be readily available on all wards and on the dedicated 
FLUYT trial website. The trial coordinator is on call 24/7 to assist in case of any questions. 
Protocol adherence is evaluated regularly in participating centres. 
Outcomes
The primary outcome is the incidence of post-ERCP pancreatitis according to the Cotton 
criteria 19. All criteria below must be present: 
 - New onset upper abdominal pain 
 - Elevation of pancreatic enzymes (amylase and/or lipase) more than 3 times the 
institutional upper limit of normal
 - Criteria 1 and 2 are present at least 24 hours after ERCP
 - Hospitalization (or extension of planned admission) for at least 2 nights
The secondary endpoints (see Additional file 1) are:
 - Incidence of delayed PEP (PEP occurring >24 hours after the procedure)
 - Severity of PEP: this will be reported according to the Cotton criteria 19 and the 
revised Atlanta criteria 20. This is because the severity grading differs between the 
two classifications 21,22 and both are reported in studies. 
 - ERCP-related complications according to the Cotton criteria 19: bleeding, perfora-
tion, infection 
 - Hydration related complications, such as pulmonary oedema and congestive heart 
failure
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 - Length of hospital and intensive care unit stay
 - Generic health related quality of life, measured by the EQ5D and SF-36 23,24 
 - Cost-effectiveness
 - Exocrine (faecal elastase-1 <200µg/L) and endocrine (HbA1c >42mmol/L) pancreat-
ic insufficiency 
Sample size calculation
A recent meta-analysis 25 reported an 8% PEP incidence in patients receiving prophylactic 
rectal NSAIDs. We believe periprocedural hydration is a useful addition to rectal NSAIDs 
if it has a similar relative risk reduction of 60% 25,26. This minimal clinically important 
difference will cause the incidence of PEP to decrease from 8% in the control group to 
3.2% in the intervention group, a 4.8% absolute risk reduction. With a 2-sided significance 
level of 5% and a power of 80%, a total of 718 patients (359 per treatment arm) is required 
to demonstrate this effect. To account for drop-out and missing data, we increased the 
sample size by 15%. This amounts to a final number of 826 patients (413 per treatment 
arm). 
Randomization
Patients are randomized centrally by the study coordinator in a 1:1 ratio by using a web-
based randomization module. Participants were stratified by centre. Within each stratum, 
random block sizes of 2, 4 and 6 were used. Due to the large sample size, age and gender 
are expected to be distributed equally between the groups. Therefore, no additional strata 
are used. 
Blinding
Patients and treating physicians are not blinded for treatment allocation (see Discussion). 
However, a blinded adjudication committee will assess and weigh all events (severe 
complications and mortality) and decide whether the pre-specified definitions of the 
primary and secondary endpoints are met. The adjudication committee consists of six 
gastroenterologists with extensive ERCP experience, a radiologist and a nephrologist. 
On the basis of primary source data, each member will individually evaluate a patient’s 
disease course. Disagreements are resolved in a plenary consensus meeting. A final 
analysis will only be performed after consensus has been reached on each individual 
endpoint for each individual patient.
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Data collection methods and follow-up
Clinical data are collected locally on standardized digital case record forms (CRFs) 
before ERCP, directly afterwards and in the 24 hours thereafter. CRFs were created for 
the endoscopist, nursing staff and treating physician on which the occurrence of the 
primary and secondary endpoints are scored. Endoscopy and ward nurses will monitor 
all intravenous fluid infusion during the first 24 hours after ERCP. After 24 hours, the 
treating physician will assess the primary endpoint (abdominal pain suggestive of PEP) 
and blood is drawn for measurement of serum amylase and lipase. To ensure data quality, 
the central study coordinator will check all CRFs and contact responsible staff members 
in case of inconsistencies.  
All patients are followed up for 180 days after randomization. Patients are contacted 
by telephone after 30, 90 and 180 days by a trial nurse. The validated EQ-5D, SF-36 and 
iMTA PCQ questionnaires for measuring quality of life and indirect nonmedical costs 
will be sent simultaneously by (e-)mail, with a telephone reminder after a week if there 
is no response 23,24,27. After one month of non-response, another telephone reminder will 
follow and a new questionnaire will be sent. In case of hospitalization, patients will be 
interviewed by a ward nurse. If patients experienced post-ERCP pancreatitis, pancreatic 
function will be assessed at 180 days post-randomization by faecal elastase and serum 
HbA1c measurements. 
Unblinded, independent monitors will visit participating sites yearly for source document 
verification of 10% of the CRFs, including all components of the primary endpoint. If 
inconsistencies are encountered, all CRFs will be inspected.   
Statistical methods
Descriptive statistics
The following baseline characteristics will be reported: age, gender, comorbidity, 
American Society of Anesthesiologists (ASA) score, ERCP indication, PEP risk factors 
according to ESGE 4 and the use of other prophylactics (mainly pancreatic duct stents). 
Data will be presented in percentages for categorical variables. Continuous variables 
will be presented as mean with standard deviation (normal distribution) or median with 
interquartile range (skewed distribution).  
6
526323-L-bw-Smeets
Processed on: 22-11-2018 PDF page: 112
112
Chapter 6
Primary analysis
The primary endpoint will be analysed according to the intention-to-treat principle with 
the use of Fisher’s exact test. That is, all randomized patients will be analysed according 
to their original treatment allocation, regardless of study protocol violations. The only 
patients excluded from the analysis are those in which the duodenum was not reached and 
the papilla was not manipulated (e.g. in case of upper gastrointestinal stenosis, aspiration 
risk, restless patients). Because these patients did not have an ERCP, there is no risk of 
PEP. Comparison of the primary endpoint will be expressed in terms of a relative risk 
and 95% confidence intervals. An exploratory per-protocol analysis will be performed 
as well. Reasons for protocol violations will be described. In these analyses we will not 
adjust for stratification by site. A two-tailed P-value <0.05 is considered to be statistically 
significant.
Additional analyses
The secondary endpoints will be compared between treatment groups by the Student’s 
T test, Wilcoxon rank sum test, Pearson’s χ2 test or Fischer exact test as appropriate. We 
cannot rule out the possibility that pancreatic duct stents are placed. If that scenario 
plays out, we will perform a sensitivity analysis of the primary endpoint in two subgroups: 
patients that only received rectal NSAIDs and patients that received combination therapy 
with pancreatic duct stents. Furthermore, we will conduct a sensitivity logbinomial 
regression analysis of our primary endpoint in which we adjust for stratification by site. 
Finally, the costs and effects of both treatment strategies within the 6 months of follow-
up will be compared. Cost-effectiveness will be expressed as costs per patient with poor 
outcome (severe morbidity and/or death) and costs per quality adjusted life year (QALY) up 
to 180 days after randomization. Health care costs are registered on structured case record 
forms. Unit prices according to the handbook of the Dutch Health Council are used 28,29. 
Productivity costs are measured by iMTA PCQ and QALY’s by the EQ-5D questionnaire 
24,27. The cost-effectiveness analysis will be reported separately from the primary study 
manuscript. 
Safety
All adverse events, regardless of a supposed connection to the trial, will be reported to the 
study coordinator. In turn, the coordinator reports adverse events to the CCMO according 
to the CCMO directive (death within 24 hours, other serious adverse events within 15 
days after the sponsor has first knowledge of the event). All serious adverse events will 
be followed until they have abated, or until a stable situation has been reached.
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To monitor patient recruitment and safety, an independent data safety monitoring board 
(DSMB) will be appointed (see Acknowledgments for details). Plenary DSMB meetings 
will be held after inclusion of 50, 150, 413 (interim analysis) and 650 patients. The DSMB 
has access to the unblinded patient data and discusses all serious adverse events. These 
events will be tabulated and a narrative of the complete case will be provided. All deceased 
patients will be evaluated by the DSMB for cause of death and whether this is related 
to a study intervention. After every meeting, the DSMB reports to the trial steering 
committee. A copy is sent to the ethical committee. 
A one-sided interim-analysis of the primary endpoint will be performed when 50% of 
patients (n=413) have been randomized and discharged. Based on raw data of every 
patient, a blinded adjudication committee will determine if the criteria for the primary 
endpoint are met. The interim-analysis will be performed by a blinded, independent 
statistician who will report to the DSMB, that has access to unblinded data. The advice 
of the DSMB will be sent to both the ethics boards and the steering committee. Finally, 
the steering committee decides whether the FLUYT trial should be continued. The Peto 
approach is used for beneficial effect. For harm (higher incidence of the primary endpoint 
in the intervention group) no stopping rule is chosen.  The trial will be terminated using 
an upper stopping boundary at P-value <0.001. 
DISCUSSION
The FLUYT trial will answer the question whether combination therapy with 
periprocedural hydration and rectal NSAIDs significantly lowers PEP incidence 
compared to NSAID monotherapy. Although several RCTs 12,30,31 investigated the value 
of periprocedural hydration, they have several shortcomings. 
First, only two trials 30,31 combined periprocedural hydration with standard-of-care PEP 
prophylactics such as rectal NSAIDs. Because of the solid evidence favoring rectal NSAID 
use in average-high risk patients 4,7 and an accumulating evidence base for routine use in 
all patients 32,33, patients must not be withheld rectal NSAIDs. 
Second, the trials had small sample sizes ranging from 26 to 510 patients. This increases 
the chances of type I and II errors and results in a power that is too low for reliably 
investigating an infrequent complication like PEP. This could explain some unexpected 
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findings that are not in line with the current literature. For instance, two RCTs found 
no significant difference between placebo and rectal NSAID groups 30,31. The FLUYT 
trial includes 826 patients in two parallel groups, which gives us adequate power to 
detect a potential difference. Furthermore, our multicenter setting allows for a higher 
generalisability of results.
Third, many trials deviated from the Cotton criteria to classify PEP 19. Instead, they defined 
PEP as abdominal pain and hyperamylasemia, but these symptoms are common after 
ERCP 34. For a proper diagnosis according to Cotton, both items should still be present 24 
hours after ERCP and hospitalization should be prolonged for at least 2 nights. The use of 
a less stringent PEP definition might result in an overestimation of PEP incidence. In the 
FLUYT trial, we strictly adhere to the Cotton criteria and all patients are hospitalized for 
24 hours. Not only does this ensure timely recognition and treatment of adverse events, 
it also allows for a precise assessment of the primary endpoint by physical examination 
and measurement of amylase and/or lipase 24 hours after ERCP. 
The design of the two trials that did use combination therapy do probably not allow 
conclusions regarding periprocedural hydration. One trial 30 used a four-arm parallel 
group design in which all trial arms received 1L/30min before ERCP. There was no control 
group without hydration and therefore, the additive value of hydration cannot be assessed. 
The other trial 31 used a conservative hydration schedule of 1L in 2 hours before ERCP 
and 2L in 16 hours thereafter. This could explain the absence of a significant difference 
in PEP incidence between the hydration and control groups. The study group design in 
the FLUYT trial does allow a proper evaluation of periprocedural hydration. With respect 
to fluid type, there is evidence suggesting that lactated Ringer’s solution is preferable in 
the treatment of acute pancreatitis 18. Therefore, we chose to compare lactated Ringer’s 
to a control of normal saline. With respect to fluid volume, the vigorous hydration in our 
intervention group is expected to result in a significant fluid difference of 1.4L directly 
after ERCP and 2.3L after 9 hours (for a 75kg patient undergoing a 1 hour ERCP). 
A potential drawback of the FLUYT trial design is the lack of blinding. However, we 
presume that the large difference in fluid administration will lead to a notable difference 
in a patient’s urine output. Furthermore, we performed a pilot in which treating staff was 
blinded for treatment allocation. It was concluded that the blinding procedure would be 
both unfeasible (with respect to the multicenter setting) and undesirable (with respect 
to breaking the blinding in case of hydration-related complications). Therefore, a blinded 
adjudication committee will assess the occurrence of all primary and secondary endpoints.
526323-L-bw-Smeets
Processed on: 22-11-2018 PDF page: 115
115
FLUYT trial protocol
The 9-hour hydration schedule used in most trials raised concerns about its cost-
effectiveness. For many hospitals, the schedule could prove difficult to adopt in an 
outpatient ERCP practice 35. To address this issue, we will perform a separate cost-
effectiveness analysis if our trial finds a significant reduction in PEP incidence in the 
hydration group. 
Several choices in the FLUYT trial design, including hydration schedule, fluid type and 
sample size, maximize the power of finding a difference in post-ERCP pancreatitis if 
such a difference really exists. Therefore, we can answer the question if periprocedural 
hydration provides additional protection against PEP on top of rectal NSAIDs and whether 
this approach is cost-effective. 
Trial status
The first patient was randomized on the 5th of June, 2015. To date, 515 patients have been 
randomized and inclusion rate is on schedule. Protocol version 3 is being used and patient 
recruitment is expected to last until the end of 2019. 
DECLARATIONS 
Ethical Approval and Consent to participate
The FLUYT trial will be performed in accordance with the declaration of Helsinki and 
the Dutch Medical Research Involving Human Subjects Act (WMO). Informed consent 
will be obtained from each patient before inclusion in the trial. The medical ethics 
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SUPPLEMENTARY MATERIAL
Additional file 1: Definitions of secondary endpoints
Additional table 1: Severity of PEP according to Cotton and revised Atlanta criteria
Mild Moderate Severe
Cotton criteria Hospitalization to 
2-3 days
Hospitalization to 4-10 
days
Hospitalization > 10 days, or 
hemorrhagic pancreatitis, 
phlegmon or pseudocyst or 
intervention (percutaneous 
drainage or surgery) 
Revised Atlanta 
criteria
 - No organ failure
 - No local* or sys-
temic* complica-
tions
 - Transient organ fail-
ure (resolves <48h) 
and/or
 - Local or systemic 
complications with-
out persistent (>48h) 
organ failure
Persistent (>48h) organ 
failure
Single organ failure
Multiple organ failure
*See Additional table 2 for elaborate definitions
Additional table 2: Local and systemic complications according to (revised) Atlanta criteria
Local complications 
Acute peripancre-
atic fluid collec-
tion
Peripancreatic fluid associated with interstitial oedematous pancreatitis 
with no associated peripancreatic necrosis. This term applies only to areas 
of peripancreatic fluid seen within the first 4 weeks after onset of intersti-
tial oedematous pancreatitis and without the features of a pseudocyst.
Pancreatic 
pseudocyst
An encapsulated collection of fluid with a well-defined inflammatory wall 
usually outside the pancreas with minimal or no necrosis. This entity 
usually occurs more than 4 weeks after onset of interstitial oedematous 
pancreatitis to mature.
Acute necrotic 
collection
A collection containing variable amounts of both fluid and necrosis 
associated with necrotising pancreatitis; the necrosis can involve the 
pancreatic parenchyma and/or the peripancreatic tissues.
Walled-off  
necrosis
A mature, encapsulated collection of pancreatic and/or peripancreatic ne-
crosis that has developed a well-defined inflammatory wall. WON usually 
occurs >4 weeks after onset of necrotising pancreatitis.
Infected necrosis The diagnosis of infected necrosis can be suspected by the patient’s 
clinical course or by the presence of gas within the collection seen on 
CECT. This extraluminal gas is present in areas of necrosis and may or 
may not form a gas/fluid level depending on the amount of liquid content 
present at that stage of the disease. Infected necrosis is also diagnosed by 
positive culture of necrosis obtained by fine needle aspiration, drainage 
or necrosectomy.
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Additional table 2: Continued
Systemic complications 
Circulatory organ 
failure
Systolic blood pressure <90 mmHg, despite adequate fluid resuscitation, 
or need for inotropic catecholamine support
Pulmonary organ 
failure
PaO2 <60 mmHg, despite FiO2 of 0.30, or need for mechanical ventilation
Renal failure Creatinine ≥ 177 µmol/l after rehydration or new need for hemofiltration 
or hemodialysis
Gastrointestinal 
bleeding
>500 ml of blood/24 hours
Disseminated 
intravascular 
coagulation
Platelet count <100x109/l  
Severe metabolic 
disturbance
Calcium < 1.87 mmol/l 
Additional table 3: ERCP related complications (adopted from Cotton)
Mild Moderate Severe
Bleeding Clinical evidence of bleeding (ie not 
just endoscopic). Hb-level drop < 
1.86mM; no need for transfusion
Transfusion: ≤4 units; 
no angiographic in-
tervention or surgery
Transfusion: ≥5 
units or interven-
tion (angiograph-
ic or surgical)
Perforation Possible, or only very slight leak of 
fluid or contrast dye; treatable by 
fluids and suction for ≤ 3 days
Any definite perfora-
tion treated medically 
for 4-10 days
Medical treat-
ment for more 
than 10 days, 
or intervention 
(percutaneous or 
surgical) 
Infection  - ≥ 38.5°C with chills, without 
an obvious other cause like a 
cystitis, pneumonia, thrombo-
phlebitis, etc.), or 39°C without 
chills, without an obvious cause 
for fever 
 - And either:
 - Cholecystodocholithiasis on 
US, CT, EUS or MRI, 
 - OR, in the absence of gall-
stones and/or sludge, a dilated 
common bile duct on imaging 
(US, CT or MR) defined as 
>8mm in patients ≤ 75 years or 
> 10mm in patients >75 years 
 - OR progressive cholestasis for 
at least two consecutive days 
AND a bilirubin > 2.3 mg/dL 
(40 µmol/L). 
>48h febrile or septic 
illness requiring > 3 
days of hospital treat-
ment or endoscopic 
or percutaneous 
intervention
Septic shock or 
Surgery
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Additional file 2: SPIRIT checklist
Section/item Item No Description Addressed on page number
Administrative information
Title 1 Descriptive title identifying the 
study design, population, inter-
ventions, and, if applicable, trial 
acronym
1
Trial registra-
tion
2a Trial identifier and registry name. 
If not yet registered, name of in-
tended registry
3, Abstract
2b All items from the World Health 
Organization Trial Registration 
Data Set
Throughout entire protocol
Protocol 
version
3 Date and version identifier 15, ‘Trial status’
Funding 4 Sources and types of financial, 
material, and other support
17, ‘Funding’
Roles and re-
sponsibilities
5a Names, affiliations, and roles of 
protocol contributors
17-23
5b Name and contact information for 
the trial sponsor
18 ‘Coordinating centre, pri-
mary sponsor and principal 
investigators’
5c Role of study sponsor and funders, 
if any, in study design; collec-
tion, management, analysis, and 
interpretation of data; writing of 
the report; and the decision to 
submit the report for publication, 
including whether they will have 
ultimate authority over any of these 
activities
p. 17 ‘Funding’
5d Composition, roles, and responsi-
bilities of the coordinating centre, 
steering committee, endpoint adju-
dication committee, data manage-
ment team, and other individuals 
or groups overseeing the trial, if 
applicable (see Item 21a for data 
monitoring committee)
17-23
Introduction
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Section/item Item No Description Addressed on page number
Background 
and rationale
6a Description of research question 
and justification for undertaking 
the trial, including summary of 
relevant studies (published and un-
published) examining benefits and 
harms for each intervention
4-5 ‘Background’
6b Explanation for choice of compar-
ators
7-8 ‘Treatment arms and 
co-interventions’
Objectives 7 Specific objectives or hypotheses 4-5 ‘Background’, 8-9 ‘Out-
comes’
Trial design 8 Description of trial design includ-
ing type of trial (eg, parallel group, 
crossover, factorial, single group), 
allocation ratio, and framework (eg, 
superiority, equivalence, noninferi-
ority, exploratory)
6 ‘Study setting’, 9 ‘Random-
ization’
Methods: Participants, interventions, and outcomes
Study setting 9 Description of study settings (eg, 
community clinic, academic hos-
pital) and list of countries where 
data will be collected. Reference 
to where list of study sites can be 
obtained
6 ‘Study setting’, 20-21 ‘Par-
ticipating centers’
Eligibility 
criteria
10 Inclusion and exclusion criteria 
for participants. If applicable, 
eligibility criteria for study centres 
and individuals who will perform 
the interventions (eg, surgeons, 
psychotherapists)
6-7 ‘Eligibility criteria’
Interventions 11a Interventions for each group with 
sufficient detail to allow replica-
tion, including how and when they 
will be administered
7-8 ‘Treatment arms and 
co-interventions’
11b Criteria for discontinuing or mod-
ifying allocated interventions for 
a given trial participant (eg, drug 
dose change in response to harms, 
participant request, or improving/
worsening disease)
7-8 ‘Treatment arms and 
co-interventions’
11c Strategies to improve adherence 
to intervention protocols, and 
any procedures for monitoring 
adherence (eg, drug tablet return, 
laboratory tests)
7-8 ‘Treatment arms and 
co-interventions’, 10 ‘Data 
collection methods and 
follow-up’
11d Relevant concomitant care and 
interventions that are permitted or 
prohibited during the trial
7-8 ‘Treatment arms and 
co-interventions’
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Section/item Item No Description Addressed on page number
Outcomes 12 Primary, secondary, and other 
outcomes, including the specific 
measurement variable (eg, systolic 
blood pressure), analysis metric (eg, 
change from baseline, final value, 
time to event), method of aggrega-
tion (eg, median, proportion), and 
time point for each outcome. Expla-
nation of the clinical relevance of 
chosen efficacy and harm outcomes 
is strongly recommended
8-9 ‘Outcomes’, 11 ‘Primary 
analysis’, ‘Supplement 1’ 
Participant 
timeline
13 Time schedule of enrolment, in-
terventions (including any run-ins 
and washouts), assessments, and 
visits for participants. A schematic 
diagram is highly recommended 
(see Figure)
Figure 1
Sample size 14 Estimated number of participants 
needed to achieve study objectives 
and how it was determined, includ-
ing clinical and statistical assump-
tions supporting any sample size 
calculations
9 ‘Sample size calculation’
Recruitment 15 Strategies for achieving adequate 
participant enrolment to reach 
target sample size
8
Methods: Assignment of interventions (for controlled trials)
Allocation:
Sequence 
generation
16a Method of generating the alloca-
tion sequence (eg, computer-gen-
erated random numbers), and list 
of any factors for stratification. To 
reduce predictability of a random 
sequence, details of any planned 
restriction (eg, blocking) should be 
provided in a separate document 
that is unavailable to those who 
enrol participants or assign inter-
ventions
11 ‘Randomization’
Allocation 
concealment 
mechanism
16b Mechanism of implementing the 
allocation sequence (eg, central 
telephone; sequentially num-
bered, opaque, sealed envelopes), 
describing any steps to conceal the 
sequence until interventions are 
assigned
9 ‘Randomization’
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Section/item Item No Description Addressed on page number
Implementa-
tion
16c Who will generate the allocation 
sequence, who will enrol partici-
pants, and who will assign partici-
pants to interventions
9 ‘Randomization’
Blinding 
(masking)
17a Who will be blinded after assign-
ment to interventions (eg, trial par-
ticipants, care providers, outcome 
assessors, data analysts), and how
10 ‘Blinding’, 13 ‘Discussion’
17b If blinded, circumstances under 
which unblinding is permissible, 
and procedure for revealing a 
participant’s allocated intervention 
during the trial
Not applicable: unblinded
Methods: Data collection, management, and analysis
Data collec-
tion methods
18a Plans for assessment and collection 
of outcome, baseline, and other 
trial data, including any related 
processes to promote data quality 
(eg, duplicate measurements, train-
ing of assessors) and a description 
of study instruments (eg, ques-
tionnaires, laboratory tests) along 
with their reliability and validity, 
if known. Reference to where data 
collection forms can be found, if 
not in the protocol
9 ‘Data collection methods’
18b Plans to promote participant 
retention and complete follow-up, 
including list of any outcome data 
to be collected for participants who 
discontinue or deviate from inter-
vention protocols
9 ‘Data collection methods’
Data manage-
ment
19 Plans for data entry, coding, 
security, and storage, including 
any related processes to promote 
data quality (eg, double data entry; 
range checks for data values). 
Reference to where details of data 
management procedures can be 
found, if not in the protocol
10 ‘Data collection methods’
Statistical 
methods
20a Statistical methods for analysing 
primary and secondary outcomes. 
Reference to where other details of 
the statistical analysis plan can be 
found, if not in the protocol
11-12 ‘Statistical methods’
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Section/item Item No Description Addressed on page number
20b Methods for any additional anal-
yses (eg, subgroup and adjusted 
analyses)
11-12 ‘Statistical methods’
20c Definition of analysis population 
relating to protocol non-adherence 
(eg, as randomised analysis), and 
any statistical methods to handle 
missing data (eg, multiple imputa-
tion)
11-12 ‘Statistical methods’
Methods: Monitoring
Data moni-
toring
21a Composition of data monitoring 
committee (DMC); summary of its 
role and reporting structure; state-
ment of whether it is independent 
from the sponsor and competing 
interests; and reference to where 
further details about its charter can 
be found, if not in the protocol. Al-
ternatively, an explanation of why a 
DMC is not needed
12 ‘Safety’, 20 ‘DSMB’
21b Description of any interim analyses 
and stopping guidelines, includ-
ing who will have access to these 
interim results and make the final 
decision to terminate the trial
12 ‘Safety’
Harms 22 Plans for collecting, assessing, 
reporting, and managing solicited 
and spontaneously reported ad-
verse events and other unintended 
effects of trial interventions or trial 
conduct
12 ‘Safety’
Auditing 23 Frequency and procedures for 
auditing trial conduct, if any, and 
whether the process will be inde-
pendent from investigators and the 
sponsor
Not applicable
Ethics and dissemination
Research 
ethics ap-
proval
24 Plans for seeking research ethics 
committee/institutional review 
board (REC/IRB) approval
17 ‘Ethical Approval…’
Protocol 
amendments
25 Plans for communicating important 
protocol modifications (eg, changes 
to eligibility criteria, outcomes, 
analyses) to relevant parties (eg, 
investigators, REC/IRBs, trial par-
ticipants, trial registries, journals, 
regulators)
17 ‘Ethical Approval…’: 
standard according to Dutch 
Medical Research Involving 
Human Subjects Act (WMO)
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Section/item Item No Description Addressed on page number
Consent or 
assent
26a Who will obtain informed consent 
or assent from potential trial par-
ticipants or authorised surrogates, 
and how (see Item 32)
17 ‘Ethical Approval…’: 
standard according to Dutch 
Medical Research Involving 
Human Subjects Act (WMO)
26b Additional consent provisions for 
collection and use of participant 
data and biological specimens in 
ancillary studies, if applicable
Not applicable
Confidenti-
ality
27 How personal information about 
potential and enrolled partici-
pants will be collected, shared, 
and maintained in order to protect 
confidentiality before, during, and 
after the trial
17 ‘Ethical Approval…’: 
standard according to Dutch 
Medical Research Involving 
Human Subjects Act (WMO)
Declaration of 
interests
28 Financial and other competing 
interests for principal investigators 
for the overall trial and each study 
site
17 ‘Competing interests’
Access to data 29 Statement of who will have access 
to the final trial dataset, and disclo-
sure of contractual agreements that 
limit such access for investigators
17 ‘Availability of data…’
Ancillary and 
post-trial care
30 Provisions, if any, for ancillary and 
post-trial care, and for compensa-
tion to those who suffer harm from 
trial participation
17 ‘Ethical Approval…’: 
standard according to Dutch 
Medical Research Involving 
Human Subjects Act (WMO)
Dissemination 
policy
31a Plans for investigators and sponsor 
to communicate trial results to 
participants, healthcare profes-
sionals, the public, and other 
relevant groups (eg, via publication, 
reporting in results databases, or 
other data sharing arrangements), 
including any publication restric-
tions
No publication restrictions
31b Authorship eligibility guidelines 
and any intended use of profession-
al writers
31c Plans, if any, for granting public 
access to the full protocol, partic-
ipant-level dataset, and statistical 
code
17 ‘Availability of data…’
Appendices
Informed con-
sent materials
32 Model consent form and other re-
lated documentation given to par-
ticipants and authorised surrogates
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Section/item Item No Description Addressed on page number
Biological 
specimens
33 Plans for collection, laboratory 
evaluation, and storage of bio-
logical specimens for genetic or 
molecular analysis in the current 
trial and for future use in ancillary 
studies, if applicable
Not applicable
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ABSTRACT
Background/objectives
Acute pancreatitis (AP) progresses to necrotizing pancreatitis in 15% of cases. An 
important pathophysiological mechanism in AP is third spacing of fluids, which leads 
to intravascular volume depletion. This results in a reduced splanchnic circulation 
and reduced venous return. Non-visualisation of the portal and splenic vein on early 
computed tomography (CT) scan, which might be the result of smaller vein diameter due 
to decreased venous flow, is associated with infected necrosis and mortality in AP. This 
observation led us to hypothesize that smaller diameters of portal system veins (portal, 
splenic and superior mesenteric) are associated with increased severity of AP. 
Methods
We conducted a post-hoc analysis of data from two randomized controlled trials that 
included patients with predicted severe and mild AP. The primary endpoint was AP-
related mortality. The secondary endpoints were (infected) necrotizing pancreatitis and 
(persistent) organ failure. We performed additional CT measurements of portal system 
vein diameters and calculated their prognostic value through univariate and multivariate 
Poisson regression. 
Results
Multivariate regression showed a significant inverse association between splenic vein 
diameter and mortality (RR 0.75 (0.59-0.97)). Furthermore, there was a significant 
inverse association between splenic and superior mesenteric vein diameter and (infected) 
necrosis. Diameters of all veins were inversely associated with organ failure and persistent 
organ failure. 
Conclusions
We observed an inverse relationship between portal system vein diameter and morbidity 
and an inverse relationship between splenic vein diameter and mortality in AP. Further 
research is needed to test whether these results can be implemented in predictive scoring 
systems.  
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INTRODUCTION
Acute pancreatitis (AP) has an annual incidence of 13 to 45/100,000 1. In 85% of cases 
the disease course is limited to interstitial pancreatitis without organ failure. However, 
in about 15% of cases the disease progresses to necrotizing pancreatitis with a mortality 
rate up to 20% 2. One of the pathophysiological hallmarks of AP disease progression is 
third spacing of fluids, which leads to reduced intravascular volume that may progress 
to hypovolemic shock 3,4. The physiologic response is to preserve circulation to vital 
organs at the expense of the gastrointestinal tract with vasoconstriction of the splanchnic 
circulation (blood flow of the gut, spleen, pancreas and liver) resulting in hypoperfusion 
of the mesenteric organs 5–8. Reduced perfusion leads to reduced venous return and lower 
cardiac preload in severe AP 9.
Contrast-enhanced computed tomography (CE-CT) permits evaluation of patency of veins 
that drain into the portal venous circulation such as the portal, splenic and superior 
mesenteric (SMV) veins. In a multicenter prospective cohort of 228 patients with severe 
AP, non-visualisation of the portal and splenic vein on early CT scan was associated with 
infected necrosis and mortality 10. The authors postulated that non-visualisation might be 
the result of smaller vessel diameter and partial volume effects due to decreased venous 
flow. This observation led us to hypothesize that smaller diameters of portal system veins 
(portal, splenic and SMV) are associated with increased severity of AP.
We conducted a post-hoc analysis of prospective trial data with the primary aim to 
investigate the association between diameters of portal system veins and mortality in 
AP. Our secondary aim was to investigate the association between diameters of portal 
system veins and AP-related morbidity.
METHODS
In this study we adhered to the Strengthening The Reporting of Observational studies 
in Epidemiology (STROBE) guidelines 11. Both original trials were approved by a Medical 
Ethics Committee. All participants of the original trials provided written informed 
consent. This study follows the declaration of Helsinki. 
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Study design and participants
We conducted a post-hoc analysis of data from two multicenter randomized controlled 
trials carried out in the Netherlands between 2004 and 2013 (see Supplementary table 1 
for trial details) 12,13. One trial included AP patients with a predicted severe disease course 
at admission 12. According to the study protocol, all patients had a CE-CT scan at 7-10 days 
after admission regardless of disease course. The other trial included patients with mild 
biliary pancreatitis 13. A mild disease course was defined as absence of local complications 
(e.g. necrosis, fluid collections), absence of persistent organ failure, CRP<100mg/L, no 
need for opioids and tolerance of normal diet. In this trial, patients received a CE-CT scan 
at the discretion of the treating physician. From the second trial we included patients who 
received a CE-CT scan within 7 days of admission. In all patients we performed additional 
CE-CT measurements. We excluded scans that did not include the pelvic region, were not 
digitally available or demonstrated evidence of alternative diagnoses (chronic pancreatitis 
or pancreatic malignancy). 
CE-CT measurements
Diameters of the portal, splenic and superior mesenteric veins proximal to the confluence 
were measured retrospectively in the axial plane by two radiologists (TB and DdC), 
blinded for the study endpoints. Furthermore, the presence of arteriosclerosis in the 
aorta, celiac trunk, inferior or superior mesenteric artery was evaluated as a measure of 
cardiovascular disease. 
Endpoints and variables
The primary endpoint was AP-related mortality. The secondary endpoints were the 
occurrence of necrotizing pancreatitis, infected necrosis, organ failure or persistent organ 
failure. We defined necrotizing pancreatitis according to the revised Atlanta criteria 14. 
Infected necrosis was defined as a positive culture of peripancreatic fluid or pancreatic 
necrosis obtained by either fine needle aspiration, during the first percutaneous drainage 
or during the first surgical intervention. Organ failure was defined as 15: 
Pulmonary: PaO2 <60 mmHg despite FiO2 of 30%, or the need for mechanical ventilation 
Renal: serum creatinine >177umol/L after rehydration, or need for hemofiltration/
hemodialysis 
Circulatory: systolic blood pressure <90 mmHg (despite adequate fluid resuscitation), or 
need for vasopressor support 
Persistent organ failure was defined as organ failure lasting >48 hours. 
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We collected data on the following potentially confounding variables: age, gender, body 
mass index (BMI), diabetes mellitus (DM), aetiology (biliary, alcoholic, idiopathic or 
other), comorbidity (according to American Society of Anesthesiologists (ASA) score) 
and presence of arteriosclerosis on CT scan 16–21. Finally, the predicted severity of AP was 
confirmed and recorded as defined by Acute Physiology and Chronic Health Evaluation 
(APACHE II) score above 7, Imrie score above 2 or C-reactive protein (CRP) above 150 
mg/L. 
Statistical analyses
Continuous variables are presented as mean with standard deviation or as median 
with range, categorical variables as frequencies with percentages. First, we performed 
univariate Poisson regression analyses to assess the uncorrected prognostic value of 
vein diameters. If a univariate analysis showed a significant association, we performed 
a multivariate Poisson regression analysis with confounder correction. We included all 
confounders with P-values below 0.1 on univariate analysis (by Student’s t-test or χ2 test, 
as appropriate). Finally, in an exploratory subgroup analysis we compared mean vein 
diameters in patients with predicted mild and predicted severe acute pancreatitis by 
Student’s t-test. The primary and secondary analyses were performed in the patients from 
one trial 12. The subgroup analysis was performed by comparing patients from both trials. 
All results are expressed as a relative risk (RR) with 95% confidence interval (CI). A two-
tailed P-value below 0.05 is regarded as significant. All analyses were performed by using 
IBM SPSS version 25.
RESULTS
Patient flow
The original trial data used for our primary and secondary analyses came from 298 patients 
12. We excluded 87 patients due to missing BMI data, 64 patients due to unavailability of 
CT scan and 3 patients because of an alternative diagnosis (pancreatic malignancy in two 
patients, chronic pancreatitis in one patient) [figure 1]. Finally, 144 patients were included 
for the primary and secondary analyses. There were no significant differences in baseline 
characteristics between in- and excluded patients. From the second trial 13, 33 patients 
with predicted mild AP met the in- and exclusion criteria. Ultimately, we included 177 
patients in the subgroup analysis. 
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Figure 1: Flow chart. AP: acute pancreatitis. BMI: body mass index. CT: computed tomography.
Baseline characteristics
The baseline characteristics of patients with predicted severe AP are summarized in table 
1. Their mean age was 58 years (SD: 15) and 58 were female (40%). Twelve patients had 
diabetes (8%) and over a third had arteriosclerosis (n=52; 36%). Gallstones were the most 
prevalent AP aetiology in 84 patients (58%). A total of 54 patients (38%) progressed to 
necrotizing pancreatitis and 34 (24%) developed organ failure. Ultimately, 15 patients 
(11%) died. The mean diameters of the portal, splenic and SMV were 14, 8 and 11mm, 
respectively. 
Table 1: Baseline characteristics of patients with predicted severe AP (n=144)
Age, mean (SD) 58 (15)
Female gender, n (%) 58 (40%)
BMI, mean (SD) 28 (6)
Diabetes, n (%) 12 (8%)
ASA
 I
 II
 III
64 (44%)
70 (49%)
10 (7%)
Arteriosclerosis, n (%) 52 (36%)
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Table 1: Continued
Vein diameters
 Portal vein in mm, mean (SD)
 Splenic vein in mm, mean (SD)
 SMV in mm, mean (SD)
13.7 (2.4)
7.9 (2.0)
10.6 (2.4)
Aetiology
 Biliary
 Alcoholic
 Idiopathic
 Other
84 (58%)
26 (18%)
22 (15%)
12 (8%)
Necrosis, n (%) 54 (38%)
Infected necrosis, n (%) 24 (17%)
Organ failure, n (%) 34 (24%)
Persistent organ failure, n (%) 30 (21%)
Intervention, n (%) 26 (18%)
ICU admission, n (%) 43 (30%)
Mortality, n (%) 15 (11%)
ASA: American Society of Anesthesiologists. BMI: body mass index. ICU: intensive care unit. SD: 
standard deviation. SMV: superior mesenteric vein. 
Primary endpoint
Univariate analyses showed a significant inverse relationship between splenic vein 
diameter and mortality: larger vein diameter was associated with lower RR for mortality 
(figure 2). There was no such relation for portal vein and SMV. In a multivariate analysis, 
the association between smaller splenic vein diameter and mortality remained significant. 
Figure 2: Univariate and multivariate analyses of association between vein diameter and 
mortality. Values on the right of the graph depict relative risk (95% confidence interval). SMV: 
superior mesenteric vein. 
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Secondary endpoints
In our secondary analysis we investigated the association between vein diameter and 
AP-related morbidity (figure 3). A larger diameter of the splenic vein and SMV was 
significantly associated with a lower RR for the development of necrosis, infected necrosis, 
organ failure and persistent organ failure. For the portal vein, no significant association 
was found between vein diameter and development of necrosis or infected necrosis. There 
was a significant inverse association between portal vein diameter and development of 
organ failure or persistent organ failure. 
Figure 3: Univariate and multivariate analyses of association between vein diameter and 
AP-related morbidity. Values on the right of the graph depict relative risk (95% confidence 
interval). SMV: superior mesenteric vein.
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Subgroup analysis
For the comparison between predicted severe and predicted mild pancreatitis, data of 33 
patients were available from the second trial who underwent CT scanning within 7 days 
of disease onset 13. Baseline characteristics are summarized in supplementary table 2. 
Patients with predicted mild AP had significantly larger diameters of the portal, splenic 
and SMV compared to patients with predicted severe pancreatitis (table 2). 
Table 2: Comparison of mean vein diameters between patients with predicted mild and 
predicted severe AP
Predicted mild Predicted severe P-value
Portal vein in mm, mean (SD) 15.3 (2.1) 13.7 (2.4) P=0.001
Splenic vein in mm, mean (SD) 9.6 (1.7) 7.9 (2.0) P<0.001
SMV in mm, mean (SD) 12.2 (2.3) 10.6 (2.4) P<0.001
SMV: superior mesenteric vein. 
DISCUSSION
We observed an inverse relationship between splenic vein diameter and mortality in AP. 
We also found that splenic, portal and SMV diameters were inversely related to organ 
failure and persistent organ failure. Similarly, we observed that splenic vein and SMV 
(but not portal vein) diameter are inversely related to necrosis and infected necrosis. 
Finally, patients with predicted mild AP had significantly larger vein diameters compared 
to patients with predicted severe AP.
It is intuitive to explain our results through the distinct and well-known hemodynamic 
changes described in mild and severe AP 22. Mild AP is associated with increased tissue 
blood flow, oxygen tension and oxygen saturation of haemoglobin. The opposite is true 
for severe AP with reduced tissue perfusion and reduced pancreatic oxygen consumption. 
Third spacing of fluids causes the splanchnic perfusion to fall and the resulting 
hypoperfusion can turn mild interstitial AP into necrotizing AP 23. It can also lead to 
gut barrier dysfunction, increased translocation of bacteria and ultimately, secondary 
infection of necrosis 24. Evidence for the role of hypoperfusion in the development of 
necrosis comes from experimental as well as clinical studies 8. Animal studies repeatedly 
showed that temporary ischemia results in parenchymal necrosis 25,26. An autopsy study 
of patients who died from hypovolemic shock reported an association between severity 
of shock and a higher incidence of necrosis 27.
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The reduced splanchnic perfusion results in decreased venous return. Because blood 
volume and vessel radius are tightly linked, this results in a subsequent decrease in vein 
diameter 28,29. This might explain the association between vein diameter and development 
of necrotizing pancreatitis and organ failure. Of the three investigated veins, the 
splenic vein had the strongest association with AP morbidity and mortality. A possible 
explanation is that only the spleen and pancreas drain into the splenic vein, whereas the 
SMV and portal vein also receive blood from the intestines. Therefore, the pancreatic 
flow represents a smaller percentage of the total blood flow in these vessels and hence the 
diameter of these two vessels. Also, in experimental severe AP splanchnic hypoperfusion 
exerts its effects first in the pancreas before it progresses to the intestines 30.
A strength of our study is that the endpoints of our analysis (necrosis, organ failure and 
mortality) were those used in the clinical trials. As such, they were uniformly defined 
and collected prospectively, limiting bias. However, we measured vessel diameters 
retrospectively and the studies were not designed with our research question in mind. 
Thus, we cannot entirely rule out the presence of bias that is inherent to retrospective 
analyses. We could address this partially by blinding the radiologists for patient outcomes. 
Also, the measurements of vessel diameter, as well as the original CE-CT evaluations 
in the respective trials, were performed by radiologists with extensive experience in 
abdominal radiology, limiting possible measurement errors.
A caveat of our study is that we could not establish a temporal relationship between vein 
diameter and necrosis or organ failure. That is because vein diameter and necrosis were 
measured on the same CT scan. Also, we lacked data on the timing of CT scan and onset 
of organ failure, but we were able to establish a temporal relationship with mortality. 
Furthermore, vein diameter is possibly affected by complex regulatory mechanisms for 
preservation of adequate circulation. We assume that vein diameter can be used as a proxy 
for blood flow, but our study does not allow statements on the cause of vein diameter. 
Therefore, our results should be interpreted with caution. However, vein diameter as a 
proxy for blood flow has been used successfully in the prediction of rectal adenocarcinoma 
invasiveness and prediction of oesophageal varices in patients with liver cirrhosis 31–34. 
Also, causation is not a prerequisite for prognostication of outcomes 35. Finally, although 
some patients were excluded from the analyses due to missing data, we demonstrated 
that there were no significant baseline differences between in- and excluded patients. 
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Our findings could be used in the optimization of radiological scoring systems for severity 
of pancreatitis, such as the CT severity index (CTSI). Its predictive value for severe AP and 
mortality is generally lower compared to clinical scoring systems such as the Ranson and 
APACHE II score 36. Prospective studies using imaging at regular intervals are needed to 
validate the (temporal) relationship between portal system veins and patient outcomes, to 
identify potential cut off values and to investigate its use in scoring systems. Nevertheless, 
our results add to the body of evidence on the relationship between (splanchnic) perfusion 
and outcomes in AP, such as prognostication through CT perfusion, blood urea nitrogen 
(BUN) and serum markers of intestinal perfusion such as intestinal fatty acid binding 
protein (I-FABP) 37–40. 
In conclusion, we observed an inverse relationship between portal system vein diameter 
and morbidity and an inverse relationship between splenic vein diameter and mortality 
in AP. Further research is needed to test whether these results can be implemented in 
predictive scoring systems.  
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SUPPLEMENTARY MATERIAL
Supplementary table 1: Characteristics of included studies
Besselink (2008) Da Costa (2015)
Inclusion criteria Predicted severe acute pancreatitis at 
admission^
Mild biliary pancreatitis*
Exclusion criteria  - Post-ERCP pancreatitis
 - Suspected malignancy of pancreas or 
biliary tree
 - Non-pancreatic infection or sepsis
 - AP diagnosed at operation
 - Medical history of immune deficiency
 - ASA III and >75 years
 - ASA IV
 - Chronic pancreatitis
 - Ongoing alcohol abuse
 - Pregnancy
No. of patients 298 266
Recruitment 
period
2004-2007 2010-2013
CT scan Standard CT-scan at 7-10 days after ad-
mission
CT-scan at discretion of 
treating physician
Duration follow-up 90 days 180 days
^APACHE II>7, IMRIE>2 or CRP>150mg/L. *Defined as absence of local complications (e.g. necrosis, 
fluid collections), absence of persistent organ failure, CRP<100mg/L, no need for opioids and toler-
ance of normal diet. Biliary aetiology defined as gallstones, biliary sludge or a dilated common bile 
duct on imaging. ASA: American Society of Anesthesiologists. CT: computed tomography. ERCP: 
endoscopic retrograde cholangiopancreatography. 
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Supplementary table 2: Baseline characteristics of patients with predicted mild AP (n=33)
Age, mean (SD) 55 (13)
Female gender, n (%) 19 (58%)
BMI, mean (SD) 32 (8)
Diabetes, n (%) 5 (15%)
ASA
 I
 II
 III
6 (18%)
17 (52%)
10 (30%)
Vein diameters
 Portal vein in mm, mean (SD)
 Splenic vein in mm, mean (SD)
 SMV in mm, mean (SD)
15 (2)
10 (2)
12 (2)
Biliary etiology 33 (100%)
Necrosis, n (%) 0 (0%)
Infected necrosis, n (%) 0 (0%)
Organ failure, n (%) 0 (0%)
Persistent organ failure, n (%) 0 (0%)
Intervention, n (%) 0 (0%)
ICU admission, n (%) 0 (0%)
Mortality, n (%) 0 (0%)
ASA: American Society of Anesthesiologists. BMI: body mass index. ICU: intensive care unit. SD: 
standard deviation. SMV: superior mesenteric vein.
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ABSTRACT
Objectives
Early prediction of necrotizing pancreatitis is important for tailoring treatment, but 
current scoring systems have moderate accuracy and can be calculated only 24-48 
hours after disease onset. Evaluation of (micro)circulatory changes in acute pancreatitis 
at admission by perfusion computed tomography (PCT) or angiography could predict 
necrosis earlier. Our aim was to systematically review the evidence for angiographic and 
PCT prediction of necrotizing pancreatitis. 
Methods 
We performed a systematic review and searched Medline and Embase. We included 
cohort studies addressing pancreatic perfusion for prognostication of severity of acute 
pancreatitis and assessed study quality with a tool specific for diagnostic accuracy studies.
Results 
Six prospective cohorts with 334 patients were included. Sensitivity of PCT for predicting 
necrosis ranged from 71% to 100% and specificity from 74% to 100%. The only study 
directly comparing PCT and angiography found a similar sensitivity (100%) but higher 
specificity for PCT (90% vs 72%). The included studies had moderate quality.
Conclusions 
Current studies consistently demonstrate excellent sensitivity and specificity of PCT for 
early prediction of necrosis. The performance found in our review should be confirmed 
in larger prospective cohorts as published studies have moderate quality. Furthermore, 
it should be investigated whether early PCT improves disease course. 
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INTRODUCTION
Acute pancreatitis (AP) is accountable for 275,000 admissions annually in the United 
States and it is the most common gastroenterological discharge diagnosis.1 Its incidence 
ranges from 13-45/100.000 and is increasing.1,2 The natural course of AP represents a 
continuum and ranges from mild oedematous pancreatitis to fulminant necrotizing 
pancreatitis with persistent multiple organ failure. Necrotizing pancreatitis has a 
mortality rate up to 30%.3 
Early prediction of pancreatic necrosis is important to allow management decisions that 
may include aggressive hydration or referral to a tertiary care center. Although a large 
number of predictive scoring systems is available for AP4, their sensitivity and specificity 
leave much to be desired with areas under the curve between 0.72 and 0.85.5 Furthermore, 
clinical application of most scoring systems is hampered because scores can only be 
calculated 24-48 hours after disease onset.
Predicting necrotizing pancreatitis by early radiological assessment of the (micro)
circulatory changes in acute pancreatitis could be a meaningful addition to the clinician’s 
repertoire. Pancreatic microvascular derangements probably initiate the development of 
pancreatic necrosis. These changes may be present within 30 minutes of disease onset.6 
The extent of microvascular derangements correlates with disease severity and with the 
necrotic areas on follow-up computed tomography (CT) scanning.7,8 
In acute pancreatitis, the pancreatic microcirculation is affected in several ways. Early 
vasoconstriction of end arteries causes ischemia, leading to hypoperfusion and stasis of 
blood in capillaries. Pathological shunting exacerbates hypoperfusion, while changes 
in coagulation and blood viscosity induce stasis. Perfusion pressure rises due to post-
capillary venous occlusion and impaired lymph drainage. Coupled with increased capillary 
permeability and loss of endothelial barrier function, proteases enter the pancreatic tissue. 
Ultimately, these processes may cause necrotizing pancreatitis.9 
Imaging techniques to study these (micro)vasculature changes are perfusion computed 
tomography (PCT) and angiography. PCT analyses tissue microcirculation through 
the kinetics of intravenous contrast.10,11 Depending on the organ under study and the 
underlying pathophysiology, a mathematical model is chosen for calculating parameters 
such as blood flow, blood volume, transit time of blood through tissue and permeability 
8
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surface area. Angiography through arterial catheters detects macrovascular changes 
that underlie pancreatic necrosis, such as arterial vasospasms. In that way, necrotizing 
pancreatitis could be predicted.12 
The evidence for angiography and PCT as predictors of necrotizing pancreatitis and severe 
pancreatitis has not been critically evaluated to date. Therefore, the primary aim of this 
study is to systematically review the evidence for angiographic and PCT prediction of 
necrotizing pancreatitis. As a secondary aim, we summarize the evidence of angiography 
and PCT for predicting morbidity and mortality of acute pancreatitis.  
MATERIALS AND METHODS
This study adhered to the Meta-analysis of Observational Studies in Epidemiology 
guidelines.13
Literature search
In the electronic databases Medline and Embase a search was conducted with the aid of an 
expert librarian. We searched for studies addressing pancreatic perfusion to prognosticate 
severity of pancreatitis by using the term ‘pancreatitis’, combined with ‘perfusion’, ‘blood 
flow’ or ‘ischemia’, and ‘mortality’, ‘complication’ or ‘prognosis’ (see Supplemental 
Digital Content 1 for full electronic search strategy). We restricted the search to articles 
published after 1990. The last search was conducted on 24-03-2017. Two authors (K.G. 
and G.L.) independently excluded papers based on title and abstract. The eligibility of 
the remaining articles was assessed by the same authors by reading the full text papers. 
Included articles were cross-referenced for other eligible studies. Disagreements were 
resolved after discussion with a third and fourth author (X.S. and E.v.G.). 
Inclusion and exclusion criteria
We included English cohort studies addressing the accuracy of perfusion CT or angiography 
in predicting necrotizing pancreatitis. Conference abstracts, studies without original data 
and animal studies were excluded, as well as studies evaluating other pancreatic diseases 
and studies discussing perfusion not in relation to prognosis of pancreatitis. 
Data extraction
Data from the included studies were independently collected by two authors (G.L. 
and X.S.). Disagreements were resolved after discussion with a third author (E.V.G.). 
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Retrieved general study characteristics are author and year of publication. For assessment 
of external validity, we extracted study design, number of included patients, in- and 
exclusion criteria, timing of initial and follow-up imaging, scanning techniques and used 
mathematical PCT models. All comparisons of radiological endpoints were extracted and, 
were possible, we extracted or calculated diagnostic accuracy for predicting necrotizing 
pancreatitis (measured by area under the curve, sensitivity and specificity). Secondarily, 
we extracted or calculated diagnostic accuracy for predicting morbidity or mortality. 
Quality assessment
The Quality Assessment of Diagnostic Accuracy Studies tool was used for study quality 
evaluation.14 Two authors (G.L. and X.S.) evaluated each included study independently. 
Disagreements were resolved after discussion with a third author (E.V.G.). If conditions 
are met, a funnel plot will be constructed to assess the presence of publication bias. 
Statistical analysis
Considering the differences in methodology (scanning protocols, measurement units and 
used mathematical PCT models) and endpoints of the included studies, we decided not 
to perform a data synthesis of the results. 
RESULTS
Search
Using our search terms, we identified a total of 909 studies (figure 1). After removal of 
duplicates, 796 records were assessed for eligibility. 790 articles were excluded based 
on title, abstract or full text. Most of those studies were not concerned with AP or PCT/
angiography or were animal studies. 
8
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Figure 1: Flow chart of included studies. PCT: perfusion computed tomography.
Included studies
Six studies15–20 with a total of 334 patients with acute pancreatitis were included in the 
final analysis (see table 1). Four studies15,17–19 investigated perfusion CT, one study20 
angiography and one study16 compared both techniques. In two studies18,19, all patients 
with acute pancreatitis were eligible, while three studies15–17 focused on patients with 
severe acute pancreatitis. One study20 investigated patients with a high suspicion of 
necrotizing pancreatitis. All initial scans were made at admission, but the interval 
between disease onset and scan ranged from 1 to 7 days. The timing of follow-up contrast-
enhanced CT (CE-CT) to diagnose necrotizing pancreatitis was also highly variable (4 to 
21 days), as were the scanning techniques and models used.
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Prediction of pancreatic necrosis by perfusion CT
Four perfusion CT studies15,17–19 compared pancreatitis cases with and without necrosis. 
The findings are summarized in table 2. Apart from Yadav18, who found non-significant 
results in mean transit time, permeability surface and time to peak, all measured perfusion 
parameters were significantly different between patients with and without necrosis. 
Table 2: Differences in Perfusion Parameters Between Patients With and Without Necrosis
No necrosis (n = 132) Necrosis (n = 79) P value
Yadav et al, 201518* N = 37 N = 16
BF, mL/100mL/min 89.6 (46.1) 11.5 (5.6) 0.0001
BV, mL/100mL 33.8 (14.4) 3.8 (2.4) 0.0001
PEI, HU 118.0 (18.9) 64.8 (9.8) 0.0001
Tsuji et al,200715 N = 21 N = 9
BF, mg/100g/min 57.3 (55.9) 10.9 (2.0) <0.01
BV, mg/100g 14.5 (11.1) 3.5 (0.9) <0.01
Pienkowska et al, 201619 N = 38 N = 41
BF, mL/100g/min
 Head 126.4 (34.9) 79.1 (21.1) 0.0001
 Body 125.0 (30.6) 81.9 (21.1) 0.0001
 Tail 131.7 (34.4) 87.1 (30.6) 0.0001
BV, mL/100g
 Head 19.7 (6.0) 10.1 (3.5) 0.0001
 Body 19.3 (6.1) 9.5 (3.6) 0.0001
 Tail 20.1 (6.1) 10.3 (4.5) 0.0001
MTT, sec
 Head 10.9 (2.3) 8.7 (2.2) 0.0001
 Body 10.8 (2.6) 7.9 (1.9) 0.0001
 Tail 10.5 (2.6) 8.3 (1.7) 0.0001
PS, mL/100g/min
 Head 28.3 (11.2) 58.0 (10.8) 0.0001
 Body 27.1 (13.4) 58.7 (10.2) 0.0001
 Tail 25.9 (14.0) 57.9 (9.3) 0.0001
Watanabe et al, 201317† N = 36 N = 13
BF, min-1 1.7 (0.8) 0.2 (1.0) <0.01
F, % 7.4 (6.2) 1.5 (1.5) <0.01
Τ, sec -1.5 (4.7) -8 (5.3) <0.01
All parameters are displayed as mean (standard deviation). BF: blood flow, BV: blood volume, PEI: 
peak enhancement intensity, HU: Hounsfield unit, MTT: mean transit time, PS: permeability sur-
face, f: vascular density; τ: delay time during which contrast travels from aorta to pancreas.
*The article states that PS, TTP and MTT did not show ‘any specific pattern of difference between 
the groups and within the groups’
†No significant differences in the perfusion parameters were found between patients with and with-
out multiple organ failure
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The included studies used two methods to calculate the sensitivity and specificity of 
perfusion CT and angiography for predicting necrosis. The first method is a dichotomous 
method that relates pancreatic to hepatic perfusion. Pancreatic ischemia is present when 
either hepatic blood flow or volume surpasses that of the pancreas. The studies used 
controls to assess normal pancreatic perfusion. The second method compares continuous 
perfusion parameters between patients with and without necrosis. Receiver operating 
curves were constructed for ideal cut-off values with calculation of diagnostic properties. 
The results are summarized in table 3. 
Table 3: Accuracy of Perfusion CT and Angiography in Predicting Pancreatic Necrosis
Cut-off 
values
AUC Sensitivity Specificity
Yadav et al, 201518
Dichotomous - - 88% 100%
BF, mL/100mL/min 27.3 1.00 100% 100%
BV, mL/100mL 9.0 0.99 97% 100%
PEI, HU 86.9 0.96 87% 100%
Tsuji et al, 200715
Dichotomous - - 100% 95.3%
Pienkowska et al, 201619
BF, mL/100g/min
 Head 96.9 0.87 88% 82%
 Body 93.3 0.88 76% 92%
 Tail 95.1 0.83 71% 90%
BV, mL/100g
 Head 12.8 0.93 83% 92%
 Body 12.7 0.92 90% 90%
 Tail 13.5 0.92 90% 92%
MTT, sec
 Head 9.7 0.77 7% 74%
 Body 8.7 0.82 73% 82%
 Tail 9.3 0.76 76% 74%
PS, mL/100g/min
 Head 40.1 0.97 100% 84%
 Body 42.2 0.95 100% 92%
 Tail 43.1 0.96 100% 90%
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Table 3: Continued
Cut-off 
values
AUC Sensitivity Specificity
Watanabe et al, 201317*
- - - -
Takeda et al, 200520
- - - -
Tsuji et al,201016
Perfusion CT - - 100% 90%
Angiography - - 100% 71%
All parameters are displayed as mean ± standard deviation. BF: blood flow, BV: blood volume, PEI: 
peak enhancement intensity, HU: Hounsfield units, MTT: mean transit time, PS: permeability sur-
face. *Watanabe found significant differences between patients with and without necrosis, but did 
not calculate sensitivity and specificity.
The sensitivity of the various perfusion CT parameters for predicting necrosis ranges from 
71% to 100% and specificity from 74% to 100%. Substantial performance differences were 
seen between different parameters within a study and between the same parameters across 
studies. Using only the best parameter in each study consistently yielded a sensitivity of 
100% at a specificity of 84% to 100%. Excellent areas under the curve (AUC) above 0.90 
were seen for permeability surface area, blood volume and peak enhancement intensity. 
Blood flow had an AUC of 1.00 in Yadav’s study18, but performed less in Pienkowska19 
with AUCs below 0.90. Only one16 study reported performance measures for angiography: 
sensitivity was 100% and specificity 71%. 
Prediction of pancreatic necrosis by angiography
In the study by Takeda and colleagues20, 102 patients with acute pancreatitis underwent 
CE-CT and directly thereafter angiography on admission. A poorly perfused area (PPA) 
on CE-CT was regarded as necrotizing pancreatitis. The angiographic abnormalities 
(impaired filling of capillaries with calibre irregularities of intrapancreatic or 
extrapancreatic arteries) were correlated to CE-CT findings with respect to their location 
in the pancreas (head, body, tail) and their magnitude. Two weeks after admission a 
follow-up CE-CT was performed to confirm the diagnosis of necrotizing pancreatitis. 
The accuracy of early CE-CT and angiography for predicting necrosis on follow-up CE-CT 
and pancreatitis-related mortality were then calculated. The study found that in all 
patients with a PPA on CE-CT, angiographic abnormalities of intrapancreatic arteries 
were seen in the same region. Angiographic abnormalities of extrapancreatic arteries 
showed less consistency. In general, as the extent of PPA increased, the involvement of 
8
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extrapancreatic abnormalities increased as well. If the PPA was located in the pancreatic 
head, the gastroduodenal artery was involved most often. For a PPA in the body and tail, 
most abnormalities were seen in the splenic artery. 
Table 4 displays the percentage of patients with intra-pancreatic vasospasms on 
angiography that had confirmed presence of necrotizing pancreatitis on CE-CT after 
two weeks. As the suspicion of necrotizing pancreatitis rises at admission (with more 
extensive PPA), a larger percentage of patients is correctly identified on angiography. 
Unfortunately, performance measures for angiography cannot be calculated based on 
Takeda’s article. 
Table 4: Percentage of Patients With Intrapancreatic Vasospasms in Which Necrosis was Confirmed
Head Head and body Body and tail
PPA <30% 13.3% 16.7%
PPA 30-50% 41.2% 33.3%
PPA >50% 50% 47.1%
PPA: poorly perfused area on admission CE-CT.
Comparison of perfusion CT and angiography in predicting pancreatic necrosis
Tsuji and colleagues16 were the only ones to directly compare perfusion CT and 
angiography. In a prospective cohort of 21 patients with predicted severe acute 
pancreatitis, a perfusion CT and angiography were performed at admission. Necrotizing 
pancreatitis was confirmed at a follow-up CE-CT after 3 weeks. The parameters of both 
perfusion-CT and angiography were dichotomized: presence/absence of perfusion defects 
and presence/absence of vasospastic arteries. In that way, among others the sensitivity 
and specificity were calculated. A comparable sensitivity of 100% was found, but the 
specificity of perfusion-CT was higher than angiography: 90% vs. 71%. Therefore, the 
accuracy of perfusion-CT in predicting necrotizing pancreatitis was significantly higher: 
94% vs. 81% (p<0.05). 
Prediction of morbidity and mortality
Patients with necrotizing pancreatitis generally have a more severe disease course than 
patients with interstitial pancreatitis. Therefore, accurate prediction of necrosis could 
possibly predict morbidity and mortality. Only one study17 related perfusion parameters to 
morbidity by comparing patients with and without multiple organ failure. These authors 
found a significant reduction in τ (delay time for contrast material to travel from the aorta 
526323-L-bw-Smeets
Processed on: 22-11-2018 PDF page: 169
169
PCT and Angiography to Predict Pancreatic Necrosis
to the pancreas) in patients with multiple organ failure: -7.3 (±6.7) vs. -2.3 (±5.0) seconds 
(p<0.05). Other perfusion parameters did not differ significantly. 
Two studies15,16 provided data for sensitivity and specificity of perfusion CT and 
angiography for predicting mortality. In the study by Tsuji from 200715, PCT sensitivity 
was 100% and specificity 69%. One patient died of multiple organ failure with systemic 
infection. The patient also had radiologically confirmed necrosis. 
In the study by Tsuji in 201016, sensitivity and specificity of PCT for mortality were 25% 
and 12%, respectively. For angiography, this was 25% and 6%, respectively. Three out 
of four deceased patients did not have confirmed necrosis. The causes of death were 
infected endocarditis, multiple organ failure due to systemic infection and non-occlusive 
mesenteric ischemia. Only one patient died because of multiple organ failure in the 
presence of infected necrotizing pancreatitis. The necrosis in this patient was correctly 
identified by both perfusion CT and angiography.
Takeda and colleagues20 categorized ischemic change on angiography as mild (n = 31), 
moderate (n = 61) or severe (n = 10), with mortality rates of respectively 0%, 12% and 50% 
(p<0.05). Of the 10 patients with severe ischemic changes, five died of multiple organ 
failure and four developed infected necrosis. 
Quality of included studies
A summary of the study quality is given in table 5. Full evaluations can be found in 
supplementary tables 1-6 in Supplemental Digital Content 2. 
Table 5: Quality of Included Studies
Study Risk of bias Applicability concerns
Patient 
selection
Index 
test
Reference 
standard
Flow and 
timing
Patient 
selection
Index 
test
Reference 
standard
Tsuji et 
al,200715
- + ? + - + +
Watanabe 
et al,  201317
- - ? ? - + +
Yadav et al, 
201518
+ - ? - + + +
Pienkowska 
et al, 201519
+ - ? - + + +
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Table 5: Continued
Study Risk of bias Applicability concerns
Takeda et 
al, 200520
- + ? + - + +
Tsuji et al, 
201016
- + ? + - + +
+: low risk of bias. -: high risk of bias. ?: unclear risk of bias. 
The risk of bias was increased because of issues with patient selection (four studies only 
included a subgroup of patients with severe acute pancreatitis), the index test (absence of 
pre-specified thresholds), the reference standard (unclear blinding) and flow and timing 
(inappropriate time interval between index and reference test or patients did not receive 
the reference test). There were concerns with generalizability if studies only included a 
subgroup of patients with severe acute pancreatitis. 
As only six studies were included in the final analysis, we did not make funnel plots. It is 
an unreliable method if the number of included studies is below 10.21
DISCUSSION
The six studies included in this review found promising results for angiography and PCT 
in predicting the occurrence of necrotizing pancreatitis at admission. The sensitivity of 
both techniques is comparable (both 100%), but specificity of PCT is higher (74-100% 
vs. 71%).
The different specificity can be explained by the fact that angiography does not examine 
the pancreatic microcirculation. The defects found in large arteries do not necessarily 
reflect microvascular changes. Experimental studies support this by showing that total 
pancreatic blood flow does not necessarily reflect pancreatic capillary perfusion due to 
pathological shunting.9 Therefore, PCT is probably a more reliable tool to predict necrosis.
The diagnostic performance of angiography and PCT should be compared to other scoring 
systems for acute pancreatitis. For predicting necrosis, the AUC of the various PCT 
parameters ranged from 0.76 to 1.00 (60% were above 0.90). The best parameters for each 
of the three studies that calculated AUC, however, predicted necrosis with AUC values 
between 0.95 and 1.00. Clinical scoring systems have a general lower AUC between 0.61 
and 0.90 (88% were below 0.90).22 The included studies did not investigate the predictive 
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accuracy for morbidity, but it is likely that clinical scoring systems prevail therein: the 
clinical scoring systems capture morbidity better by incorporating parameters of organ 
function, such as creatinine, heart rate and PaO2. For predicting mortality, PCT has lower 
performance compared to clinical scoring systems. This can be explained by the fact that 
necrosis does not directly cause mortality. Rather, it predisposes for infected necrosis and 
organ failure, both of which are the main determinants for mortality.3,23
The question is which prediction method would change clinical practice. Although it is 
said that severity prediction guides treatment tailoring, its effect has never been formally 
investigated.24 Furthermore, most clinical scoring systems are calculated 24-48 hours 
after disease onset. Taking into account the early microcirculatory changes in acute 
pancreatitis, it could well be that fluid resuscitation measures guided by clinical severity 
prediction are too late.9 PCT may be applied at an earlier stage, but even then the question 
remains whether microvascular changes are irreversible at that time. 
Knol25 shows that aggressive fluid resuscitation, albeit improving cardiac function and 
splanchnic blood flow, does nothing to improve pancreatic perfusion. However, a reduced 
blood flow and blood volume in patients with necrotizing pancreatitis was consistent 
across studies. On the other hand, patients with necrotizing pancreatitis had an increased 
permeability surface as well, which could counteract the effects of hydration. Studies 
investigating (early) aggressive resuscitation report similar conflicting results.26  Apart 
from hydration, a second finding with implications for therapeutic research is that 
vasospasms are correlated with necrosis. In theory, vasodilators could be beneficial in 
acute pancreatitis. Animal studies demonstrate a protective effect of vasodilators27, but 
the precise role of vasodilators and vasoconstrictors is unknown. 
Before clinical implementation of PCT, its diagnostic accuracy should be confirmed 
in large prospective cohorts and compared to other severity prediction methods. Our 
review shows that the results of the current studies should be interpreted with caution 
due to several limitations. First, scanning protocols, parameter definitions and applied 
mathematical models differed greatly. As increased permeability is a hallmark of (severe) 
acute pancreatitis, this should be taken into account in the tracer kinetic model for 
PCT. Therefore, models that assume no exchange between the capillary bed and the 
interstitium are less suitable. Furthermore, to predict the occurrence of necrotizing 
pancreatitis, PCT should be able to detect early microcirculatory hypoperfusion and 
stasis. Models that assume a high perfusion are therefore less suitable. 
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Second, the timing of index imaging was highly variable from one to seven days after 
disease onset, which influences reported accuracy. The same holds true for the follow-up 
CT for confirming necrotizing pancreatitis, which was done after 4 to 21 days. The widely 
used 2012 Atlanta classification states that the diagnosis of pancreatic necrosis should 
be made after the first week of the disease.3 Therefore, it is possible that early follow-up 
CTs underestimate the presence of necrosis. Third, disease severity of included patients 
differed and this affects diagnostic accuracy as well. Whereas Yadav and Pienkowska 
included all patients with acute pancreatitis, the other studies only included patients with 
a predicted severe disease course. Definitions for predicted severity differed. To compare 
PCT and angiography with other scoring systems, all patients with acute pancreatitis 
should be included. A final important issue is the reproducibility of perfusion CT. A 
small (n = 30) Belgian study28 showed there is remarkable intraindividual variation in 
contrast enhancement for perfusion CT. In contrast, Kaufmann29 assessed variation in 
perfusion parameters in normal pancreatic tissue in 41 patients. The intraclass correlation 
coefficient, a measure of reproducibility, ranged from 0.41 to 0.72. This indicates a fair-
to-good reproducibility.   
In conclusion, perfusion CT is an interesting method for the early prediction of 
necrotizing pancreatitis. The high accuracy found in our review should be confirmed in 
larger, prospective cohorts. Furthermore, it should be investigated whether early PCT 
will influence treatment decisions and disease course. 
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SUPPLEMENTARY MATERIAL
Supplemental digital content 1: Full electronic search
Search used in Medline and Embase:
“(pancreatitis) AND (perfusion OR blood flow OR ischemia) AND (mortality OR 
complication OR prognosis)”  
Limits: 1990 - recent.
Supplemental digital content 2: Full quality assessment of included studies
Table 1: Tusji et al, 200715
Domain Risk of bias Applicability Remarks
Signalling question Answer Concern
Patient 
selection
Consecutive or random 
sample?
Yes In a monocenter setting, 
consecutive patients with 
acute pancreatitis were 
assessed. Only patients 
with a predicted severe 
course (APACHE II>6) 
were included, which 
could exaggerate diag-
nostic accuracy. Based on 
the finding in 5 healthy 
controls that pancreatic 
blood flow is always faster 
than liver blood flow, 
the researchers defined 
pancreatic ischemia as 
pancreatic blood flow that 
was lower than hepatic 
blood flow. 
Case-control design 
avoided?
Yes
Avoidance of inappropri-
ate exclusions?
No
Inclusion of all pancreati-
tis severity categories?
No
High High
Index test Interpreted without 
knowledge of reference 
standard?
Yes Perfusion CT was per-
formed within 3 days of 
disease onset (average 1.7 
days). The threshold for 
pancreatic ischemia was 
pre-defined (see remarks 
on patient selection). 
Perfusion CT was always 
made before reference 
follow-up CT.
Pre-specified threshold 
used?
Yes
Low Low
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Table 1: Continued
Domain Risk of bias Applicability Remarks
Reference 
standard
Reference standard likely 
to classify correctly?
Yes A CE-CT is not 100% 
accurate in diagnosing 
necrotizing pancreatitis. 
This is also dependent on 
the radiologist. However, 
no alternative standard is 
available and therefore, 
the study uses the best 
possible test. No informa-
tion on blinding is given.
Interpreted without 
knowledge of index test?
Unclear
Unclear Low
Flow and 
timing
Appropriate interval 
between index and ref-
erence?
Yes Follow-up CT was per-
formed after 3 weeks of 
disease onset. Necrosis is 
visible at that time. No pa-
tients were excluded from 
reference test and every-
one received the same. All 
patients were included in 
the analysis.
Did all patients receive 
the reference?
Yes
Did patients receive the 
same reference?
Yes
All patients included in 
the analysis?
Yes
Low
Table 2: Watanabe et al, 201317
Domain Risk of bias Applicability Remarks
Signalling ques-
tion
Answer Concern
Patient 
selection
Consecutive or 
random sample?
Unclear In a monocenter setting, patients 
with acute pancreatitis were 
assessed. Only patients with a pre-
dicted severe course (APACHE II>6, 
Atlanta) were included, which could 
exaggerate diagnostic accuracy. No 
information on exclusions is given. 
No control patients were used. PCT 
was performed on admission. 
Case-control 
design avoided?
Yes
Avoidance of 
inappropriate 
exclusions?
No
Inclusion of all 
pancreatitis 
severity catego-
ries?
No
High High
8
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Table 2: Continued
Domain Risk of bias Applicability Remarks
Index test Interpreted 
without knowl-
edge of reference 
standard?
Yes Perfusion CT was performed at 
admission and always before the 
reference standard. No pre-defined 
cut-offs were used.
Pre-specified 
threshold used?
No
High Low
Reference 
standard
Reference 
standard likely 
to classify cor-
rectly?
Yes A CE-CT is not 100% accurate in 
diagnosing necrotizing pancreati-
tis. This is also dependent on the 
radiologist. However, no alternative 
standard is available and therefore, 
the study uses the best possible 
test. No information on blinding is 
given.
Interpreted 
without knowl-
edge of index 
test?
Unclear
Unclear Low
Flow and 
timing
Appropriate 
interval between 
index and refer-
ence?
Yes Follow-up CT was performed after 
3 weeks of disease onset. Necrosis 
is visible at that time. No patients 
were excluded from reference test. 
Not reported if all patients received 
the same reference or whether 
all patients were included in the 
analysis.
Did all patients 
receive the 
reference?
Yes
Did patients 
receive the same 
reference?
Yes
All patients 
included in the 
analysis?
Unclear
Unclear
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Table 3: Yadav et al, 201518
Domain Risk of bias Applicability Remarks
Signalling ques-
tion
Answer Concern
Patient 
selec-
tion
Consecutive or 
random sample?
Yes In a monocenter setting, consecutive 
patients with acute pancreatitis were 
included within 72h of disease onset. 
Perfusion CT was made at admission. 
Control patients with pancreas-un-
related pathology, patients with 
interstitial pancreatitis and patients 
with necrotizing pancreatitis were 
compared. Reasons for excluding 
patients are given. Although control 
patients were used, analyses were 
also between interstitial and nec-
rotizing pancreatitis patients, thus 
avoiding a case-control design. 
Case-control 
design avoided?
Yes
Avoidance of 
inappropriate 
exclusions?
Yes
Inclusion of all 
pancreatitis 
severity catego-
ries?
Yes
Low Low
Index 
test
Interpreted 
without knowl-
edge of reference 
standard?
Yes Perfusion CT was performed at 
admission and always before the 
reference standard. The research-
ers defined pancreatic ischemia as 
pancreatic blood flow that was lower 
than hepatic blood flow. In those 
areas, quantitative measurements 
were performed and ROC-curves 
were made.
Pre-specified 
threshold used?
No
High Low
Refer-
ence 
standard
Reference 
standard likely 
to classify cor-
rectly?
Yes A CE-CT is not 100% accurate in 
diagnosing necrotizing pancreati-
tis. This is also dependent on the 
radiologist. However, no alternative 
standard is available and therefore, 
the study uses the best possible test. 
No information on blinding is given.
Interpreted 
without knowl-
edge of index 
test?
Unclear
Unclear Low
8
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Table 3: Continued
Domain Risk of bias Applicability Remarks
Flow and 
timing
Appropriate 
interval between 
index and refer-
ence?
Yes Three weeks between perfusion and 
follow-up CT. Three patients exclud-
ed because follow-up CT was not 
available. Whether this was missing 
at random is not reported. Applica-
bility concern is unclear because the 
details of the excluded patients are 
not stated
Did all patients 
receive the refer-
ence?
No
Did patients 
receive the same 
reference?
Yes
All patients 
included in the 
analysis?
No 
High
Table 4: Pienkowska et al, 201519
Domain Risk of bias Applicability Remarks
Signalling ques-
tion
Answer Concern
Patient 
selec-
tion
Consecutive or 
random sample?
Yes In a monocenter setting, consecutive 
patients with acute pancreatitis were 
included. No control patients were 
used. PCT was performed on the first 
day of hospitalization. 
Case-control 
design avoided?
Yes
Avoidance of 
inappropriate 
exclusions?
Yes
Inclusion of all 
pancreatitis sever-
ity categories?
Yes
Low Low
Index 
test
Interpreted 
without knowl-
edge of reference 
standard?
Yes Perfusion CT was performed within 
24 hours of disease onset. Cut-off 
points were set for each perfusion 
parameter based on ROC curve. Per-
fusion CT was always made before 
reference follow-up CT.
Pre-specified 
threshold used?
No
High Low
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Table 4: Continued
Domain Risk of bias Applicability Remarks
Refer-
ence 
stan-
dard
Reference stan-
dard likely to 
classify correctly?
Yes A CE-CT is not 100% accurate in 
diagnosing necrotizing pancreati-
tis. This is also dependent on the 
radiologist. However, no alternative 
standard is available and therefore, 
the study uses the best possible test. 
No information on blinding is given.
Interpreted with-
out knowledge of 
index test?
Unclear
Unclear Low
Flow 
and 
timing
Appropriate inter-
val between index 
and reference?
No Follow-up CT as reference standard 
was performed between 4-6 days. 
It could be necrosis was not yet 
visible at that time. No patients were 
excluded from reference test and 
everyone received the same. All pa-
tients were included in the analysis.
Did all patients 
receive the refer-
ence?
Yes
Did patients 
receive the same 
reference?
Yes
All patients 
included in the 
analysis?
Yes
High
Table 5: Takeda et al, 200520
Domain Risk of bias Applicability Remarks
Signalling 
question
Answer Concern
Patient 
selec-
tion
Consecutive 
or random 
sample?
Unclear Study of patients with acute necrotiz-
ing pancreatitis (ANP) that received 
continuous regional arterial perfusion 
with nafamostat mesylate within 7 days 
of disease onset. ANP was defined as a 
poorly perfused area in the pancreas on 
admission CE-CT, but necrosis cannot 
be diagnosed adequately at that time. 
CE-CT and angiography were per-
formed simultaneously at admission. Of 
the 147 patients with ANP, 122 received 
regional perfusion. Characteristics of 
the 25 excluded patients are not given. 
Case-control 
design avoid-
ed?
Yes
Avoidance of 
inappropriate 
exclusions?
No
Inclusion of all 
pancreatitis 
severity cate-
gories?
No
High High
8
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Table 5: Continued
Domain Risk of bias Applicability Remarks
Index 
test
Interpret-
ed without 
knowledge 
of reference 
standard?
Yes Two radiologists without knowledge of 
the clinical outcome and CE-CT find-
ings analysed the angiographic find-
ings. Although definitions seem to be 
predefined, these are highly subjective. 
Pre-specified 
threshold 
used?
Yes
Low Low
Refer-
ence 
stan-
dard
Reference 
standard likely 
to classify 
correctly?
Yes A CE-CT is not 100% accurate in diag-
nosing necrotizing pancreatitis. This 
is also dependent on the radiologist. 
However, no alternative standard is 
available and therefore, the study uses 
the best possible test. No information 
on blinding is given.
Interpreted 
without knowl-
edge of index 
test?
Unclear
Unclear Low
Flow 
and 
timing
Appropriate in-
terval between 
index and 
reference?
Yes Follow-up CT was two weeks after 
admission. Necrosis is visible at that 
time. No patients were excluded from 
reference test. 
Did all patients 
receive the 
reference?
Yes
Did patients re-
ceive the same 
reference?
Yes
All patients 
included in the 
analysis?
Yes
Low
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Table 6: Tusji et al, 201016
Domain Risk of bias Applicability Remarks
Signalling 
question
Answer Concern
Patient 
selec-
tion
Consecutive 
or random 
sample?
Yes From two centres, 21 consecutive 
patients with acute pancreatitis were 
included at admission. Only patients 
with severe acute pancreatitis (Atlanta) 
were included, which could exaggerate 
diagnostic accuracy. The researchers 
defined pancreatic ischemia as pan-
creatic blood flow that was lower than 
hepatic blood flow.
Case-control 
design avoid-
ed?
Yes
Avoidance of 
inappropriate 
exclusions?
No
Inclusion of all 
pancreatitis 
severity cate-
gories?
No
High High
Index 
test
Interpret-
ed without 
knowledge 
of reference 
standard?
Yes Perfusion CT was performed at ad-
mission. The threshold for pancreatic 
ischemia was pre-defined (see remarks 
on patient selection). Perfusion CT was 
always made before reference follow-up 
CT.Pre-specified 
threshold 
used?
Yes 
Low Low
Refer-
ence 
standard
Reference 
standard likely 
to classify 
correctly?
Yes A CE-CT is not 100% accurate in diag-
nosing necrotizing pancreatitis. This 
is also dependent on the radiologist. 
However, no alternative standard is 
available and therefore, the study uses 
the best possible test. No information 
on blinding is given.
Interpreted 
without knowl-
edge of index 
test?
Unclear
Unclear Low
8
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Table 6: Continued
Domain Risk of bias Applicability Remarks
Flow and 
timing
Appropriate in-
terval between 
index and 
reference?
Yes Presence of necrosis was confirmed at 
CE-CT after 3 weeks. Al patients re-
ceived the reference standard and were 
included in the analysis. 
Did all patients 
receive the 
reference?
Yes
Did patients re-
ceive the same 
reference?
Yes
All patients 
included in the 
analysis?
Yes
Low
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ABSTRACT
Introduction
There are data to suggest that obesity is associated with local and systemic complications 
as well as mortality in acute pancreatitis. Cohort studies to date, however, have shown 
conflicting results from mostly unadjusted analyses. Therefore, we performed an 
individual patient data meta-analysis with the primary aim to investigate the association 
between obesity and mortality in acute pancreatitis. Our secondary aim was to investigate 
the association between obesity and necrosis, organ failure, multiple organ failure and 
invasive intervention.  
Methods
We systematically searched four electronic databases for prospective studies on obesity 
and outcomes in acute pancreatitis. Researchers of eligible studies were invited to share 
individual patient data using a standardized data collection form. All endpoints were 
investigated with a one-stage mixed effects Poisson model with random intercepts and 
forced entry of relevant confounders. 
Results
We included 5 databases with 1302 patients of whom 418 (32%) were obese. In total, 466 
(36%) patients had necrosis, 328 (25%) had organ failure, 188 (14%) had multiple organ 
failure, 210 (16%) had an intervention and 84 patients (7%) died. We found no significant 
association between obesity and mortality (RR 1.40 (95% CI: 0.89-2.20)), necrosis (RR 
1.08 (0.90-1.31)) or invasive intervention (RR 1.10 (0.83-1.47)) after adjustment for 
confounders. However, obesity was independently associated with the development of 
organ failure (RR 1.38 (1.11-1.73)) and multiple organ failure (RR 1.81 (1.35-2.42)). 
Conclusions
Obesity is independently associated with the development of organ failure and multiple 
organ failure in acute pancreatitis. However, there is no association between obesity and 
mortality, necrosis and an intervention. 
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INTRODUCTION
Acute pancreatitis (AP) has an annual incidence of 13 to 45/100,000 and it is the third 
most common gastrointestinal discharge diagnosis in the United States1,2. Approximately 
80% of AP cases is mild and self-limiting, but in 20% of cases the disease progresses to 
necrotizing pancreatitis with a high risk of organ failure and a mortality rate up to 20%3. 
AP is one of the leading causes of death from gastrointestinal and liver diseases2. 
The incidence of AP is increasing and this is in part due to the rising prevalence of obesity: 
a high body mass index (BMI) stimulates gallstone formation, the leading cause of AP1,4,5. 
The prevalence of obesity, defined by the World Health Organization (WHO) as a BMI of 
at least 30 kg/m2, has doubled between 1980 and 2014. In 2014, 11% of adult males and 
15% of adult women were obese, predominantly in high-income countries6. 
There are data to suggest that obesity is also associated with local and systemic 
complications as well as mortality in acute pancreatitis. Pancreatic enzymes released in 
AP digest adipocytes, causing an outflux of unsaturated fatty acids that can contribute 
to local and systemic complications7–9. Furthermore, obesity is thought to promote the 
excessive inflammatory response in AP10. Alternatively, it is possible that the association 
between obesity and mortality in severe AP is explained by the so-called ‘obesity paradox’: 
the finding that critically ill patients with overweight or moderate obesity have a lower 
mortality compared to patients with a normal weight or morbid obesity11.
It is therefore not surprising that a systematic review on the association between obesity 
and outcomes in AP reported conflicting results12. However, these conflicts could also 
arise due to heterogeneity in the study populations (e.g. only biliary aetiology), adopted 
definitions (continuous BMI vs. WHO cut-off values) and the reporting of unadjusted 
analyses in 12 of 19 included studies. As a result, the question whether obesity is an 
independent prognostic factor in AP remains unanswered. Furthermore, traditional 
meta-analyses can only synthesize aggregate data obtained from study publications. 
In contrast, an individual patient data meta-analysis (IPDMA) combines raw patient 
data derived from published and unpublished cohorts13. An IPDMA has the advantage 
that effect estimates can be adjusted for confounders, data for subgroup analyses can be 
extracted (e.g. patients with overweight or obesity subclasses) and it allows for the use 
of uniform definitions.
9
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We performed an IPDMA of prospective cohort studies on acute pancreatitis from 
international expert centers. Our primary aim was to examine the association between 
obesity and mortality in AP. Our secondary aim was to investigate the association between 
obesity and four other widely studied outcomes in acute pancreatitis: the development 
of necrosis, organ failure, multiple organ failure and invasive intervention (i.e. catheter 
drainage or necrosectomy).
METHODS
Our methodology consisted of two steps. First, we systematically searched the literature 
for prospective cohort studies on the subject. Second, we performed an IPDMA by 
combining the identified cohorts. In this study we adhered to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses – Individual Patient Data (PRISMA-IPD) 
guidelines13 (see supplement 1). All original patient data were collected in accordance 
with the declaration of Helsinki. 
Systematic review
Literature search and study selection
We conducted a literature search in the electronic databases MEDLINE, EMBASE, Web 
of Science and Cochrane by combining the following search terms with synonyms: obese, 
pancreatitis and prognosis (see supplement 2 for full search strategy). Thereafter, we 
screened all articles on title and abstract to ensure they reported on acute pancreatitis 
and obesity. The eligibility of the remaining articles was assessed by examining the full 
text papers for adherence to predefined in- and exclusion criteria (table 1). Finally, we 
screened all eligible studies for cross-references in Web of Science. Two investigators 
(I.K. and K.G.) independently executed all screenings. Disagreements were resolved after 
discussion with a third author (E.v.G.). 
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Table 1: Inclusion and exclusion criteria systematic search
Inclusion Exclusion
 - Patients (> 18 years) with admission to the hospi-
tal for acute pancreatitis
 - BMI as primary or secondary determinant
 - Clinical outcome: mortality
 - Original, human in vivo studies 
 - Full-text articles or abstracts of presenta-
tions
 - Publication date > 1980
 - English language
 - Prospective study design
 - The risk of obesity on the development of 
acute pancreatitis as the purpose of the 
study
 - Chronic pancreatitis (or acute-on-chronic 
pancreatitis), pancreatic cancer or auto-im-
mune pancreatitis as aetiology of acute 
pancreatitis
 - Animal studies
 - Case reports, letters, editorials, comments, 
reviews 
 - No full text available. 
BMI: body mass index. 
Data collection and individual patient data integrity
We invited the primary researchers of all eligible studies to share their individual patient 
data. When contact with the primary author failed, other co-authors or the author’s 
department were contacted. After agreement, the authors received a standardised list 
of all variables and definitions of interest (see supplement 3 for study definitions). We 
collected the following variables: age, gender, comorbidity, BMI, aetiology, predicted 
severity, (infected) necrosis, organ failure (circulatory, pulmonary, renal), invasive 
interventions for AP (percutaneous/endoscopic drainage, surgical/endoscopic 
necrosectomy) and mortality. The received databases were checked for completeness 
and internal consistency. All queries were discussed with the original investigators. 
Quality assessment
The quality of all eligible articles, regardless of data sharing, was critically appraised 
using the Quality In Prognosis Studies (QUIPS) tool14. As advocated by the designers 
of QUIPS, we optimized the tool for the specific research questions of the current study 
(see supplement 4, table 3). For each domain, we designated whether the study had a low, 
moderate or high risk of bias. The critical appraisal was performed independently by two 
investigators (I.K. and X.S.). Disagreements were resolved after discussion with a third 
author (E.v.G.). We made funnel plots to assess possible publication bias.
Individual patient data meta-analysis
Outcomes 
The primary endpoint was AP-related mortality. In our first analysis, we investigated the 
influence of obesity on mortality in the entire cohort and in subgroups of patients with 
9
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organ failure and multiple organ failure. In our second analysis we investigated whether 
the relationship between body mass index and mortality follows that of the obesity 
paradox. To that end, we categorized patients according to the World Health Organization 
(WHO) BMI categories (supplement 3). For each category, we calculated the relative risk 
(RR) for mortality with normal weight as a reference. Because the obesity paradox is 
specifically for critically ill patients, we performed our analyses in three subgroups with 
severe disease: 1) patients with predicted severe AP, 2) patients with organ failure and 
3) patients with multiple organ failure.  We did not analyse the subgroup of ICU patients 
because indications for ICU admission are variable and subjective. 
The secondary endpoints were presence of pancreatic necrosis, organ failure, multiple 
organ failure and invasive intervention. All results are expressed as RR with 95% 
confidence interval (CI).
Synthesis methods
After integrating all contributed databases to one final database, missing values were 
managed by multiple (20x) imputation by chained equations and predictive mean 
matching. For all analyses we used a one-stage mixed effects Poisson model with random 
intercepts and forced entry of the potential confounders age, gender, comorbidity, 
aetiology, necrosis, organ failure and intervention. 
A two-tailed P-value below 0.05 is regarded as statistically significant. The statistical 
analyses were performed with R. Funnel plots were made with Review Manager (RevMan) 
version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen). 
RESULTS
Systematic review and individual patient data collection
The systematic review yielded 1303 results, after removal of duplicates (figure 1). We 
excluded 1176 studies on the basis of title and abstract. Of the 127 remaining studies, 
109 were excluded based on full text evaluation. Finally, our dataset consisted of 18 
studies15–32. We were not able to retrieve individual data of 13 studies, mostly because 
the databases were no longer available. Characteristics of all eligible studies are found 
in supplement 5.
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Figure 1: Flow chart.
Five authors provided individual patient data28–32. Three cohorts29–31 included unpublished 
data. All authors confirmed that the additional data were collected in accordance with the 
methodology of the original manuscript. We found no inconsistencies in data integrity. 
The sample sizes ranged from 120 to 400 patients, with 1302 patients in total. The studies 
were conducted in a mostly Western population between 1997 and 2008. Two studies28,32 
collected data from multiple centres. The prevalence of obesity ranged from 26 to 40%. 
Baseline characteristics
The baseline characteristics of the 1302 patients are given in table 2. The mean age of 
the patients was 53 years, 602 (46%) were female and 651 (50%) had comorbidity. The 
median BMI was 27.2 (range 13.6-77.9). A total of 418 (32%) patients in the cohort were 
9
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obese. Biliary aetiology was the most prevalent, in 515 patients (40%). 684 patients (53%) 
had a predicted severe disease course, 466 (36%) developed necrotizing pancreatitis and 
328 (25%) developed organ failure. In total, 84 patients (7%) died. Data were missing in 4 
of the 11 baseline variables. Necrosis was missing in 278 (21%) patients, mainly because 
the decision to perform a CT scan (to assess necrosis) in four cohorts29–32 was left to the 
discretion of the treating physician, as is common practice in these countries. Univariate 
analyses showed there were significant differences between non-obese and obese patients 
with respect to aetiology, organ failure, multiple organ failure, intervention and mortality. 
Table 2: Baseline characteristics and differences between non-obese and obese patients
Total (n=1302)
Non-obese 
(n=871) Obese (n=418) P-value Missing
Age, mean (SD) 53 (17) 54 (18) 52 (16) 0.194 0 (0%)
Gender (female) 602 (46%) 393 (45%) 203 (49%) 0.246 0 (0%)
Comorbidity 651 (50%) 442 (51%) 203 (49%) 0.463 0 (0%)
BMI, median (range) 27.2 (13.6-77.9) 25.0 (13.6-29.9) 35.7 (30.0-77.9) <0.001 13 (1%)
Aetiology
 Biliary
 Alcohol
 Idiopathic
 Other
515 (40%)
239 (18%)
210 (16%)
333 (26%)
307 (35%)
177 (20%)
142 (16%)
241 (28%)
205 (49%)
58 (14%)
67 (16%)
87 (21%)
<0.001 5 (0.4%)
Predicted severe 684 (53%) 472 (54%) 209 (50%) 0.158 0 (0%)
Necrosis 466 (36%) 306 (44%) 159 (49%) 0.166 278 (21%)
Organ failure 328 (25%) 196 (23%) 131 (31%) 0.001 0 (0%)
Multiple organ failure 188 (14%) 102 (12%) 85 (20%) <0.001 0 (0%)
Invasive intervention 210 (16%) 128 (16%) 82 (21%) 0.045 120 (9%)
Mortality 84 (7%) 47 (5%) 36 (9%) 0.028 0 (0%)
Values represent no. of patients (percentage of total in column), mean (SD) or median (range). 
Numbers of non-obese and obese patients don’t always add up to the total number of patients due to 
missing BMI data in 13 patients. SD: standard deviation. BMI: body mass index. 
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Association between obesity and mortality
For our primary analysis we investigated the association between obesity and AP-related 
mortality. The results are shown in figure 2. After adjustment for confounders, there 
was no statistically significant association between obesity and mortality in any of the 
subgroups.
Figure 2: Forest plot depicting relative risk of obesity for mortality in subgroups. Values repre-
sent relative risk (95% confidence interval). In all subgroup analyses, we adjusted for age, gender, 
comorbidity, aetiology, necrosis and intervention. In the analysis of the entire cohort, we also 
adjusted for organ failure. OF: organ failure. MOF: multiple organ failure.
We then went on to investigate the presence of an obesity paradox in subgroups with 
(predicted) severe disease. The results are shown in figure 3. We found that BMI did not 
have a statistically significant effect on mortality, with the exception of an increased risk 
for mortality in underweight patients with predicted severe acute pancreatitis (RR 3.03; 
95% CI: 1.00-9.18; p=0.048). Therefore, we found no evidence for an obesity paradox, i.e. 
the concept that patients with overweight or mild obesity have a lower risk of mortality 
as compared to patients with normal weight or severe obesity. This result was maintained 
regardless of subgroup. 
9
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Figure 3: Forest plot depicting relative risk for mortality per WHO BMI category in subgroups 
with predicted and severe AP. Values represent relative risk (95% confidence interval), relative to 
a reference of normal weight. In all subgroup analyses we adjusted for age, gender, comorbidity, 
aetiology, necrosis and intervention. In the analysis of pSAP, we also adjusted for organ fail-
ure. pSAP: predicted severe acute pancreatitis. OF: organ failure. MOF: multiple organ failure. 
*P=0.048.
Association between obesity and morbidity or invasive intervention
In our secondary analysis, we investigated the association between obesity and AP-
related morbidity or invasive intervention (figure 4). There was no statistically significant 
association between obesity and necrotizing pancreatitis or intervention after adjustment 
for confounders. However, obesity was independently associated with the development of 
organ failure (RR 1.38; 95% CI: 1.11-1.73; p=0.005) and multiple organ failure (RR 1.81; 
95% CI: 1.35-2.42; p<0.001). 
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Figure 4: Forest plot depicting relative risk of obesity for different outcomes in AP. Values repre-
sent relative risk (95% confidence interval). In all analyses we adjusted for age, gender, comorbid-
ity and aetiology. In the analysis of intervention, we also adjusted for organ failure. *P<0.05.
Risk of bias assessment
We assessed the risk of bias in all eligible studies (supplement 4, table 4). The 
most important reasons for assigning a high risk of bias were as follows. First, six 
studies15,17,21,22,28,32 targeted only a subgroup of AP patients, which limits generalisability to 
the entire AP population. Second, five studies17,21,22,25,26 incorporated BMI as a continuous 
parameter instead of using WHO cut-off values for obesity. Third, all studies did not 
measure, report or take into account relevant confounders, which increases the chances 
of biased results. 
To assess risk of publication bias, funnel plots were made for all meta-analyses 
(supplement 4, figures 1-3). For the analyses of organ failure and mortality, there 
is a suggestion of missing studies on the lowest end of the plot. Because this region 
contains studies with high as well as low significance, publication bias seems unlikely. 
Furthermore, the asymmetry could be explained by the relatively low number of studies 
and the considerable heterogeneity encountered.
DISCUSSION
This IPDMA from five prospective cohorts with 1302 patients found that obesity is 
independently associated with the development of organ failure and multiple organ 
failure. We found no significant relationship between obesity and necrosis, an intervention 
9
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or mortality after correction for confounders. Our findings did not confirm the so-called 
‘obesity paradox’.
Our results differ from conventional meta-analyses that only utilized published data33–
36. These studies found that obesity was a prognostic factor for local and systemic 
complications as well as mortality in AP. However, reported outcomes included in 
these studies were derived from both adjusted and unadjusted analyses. This could 
lead to confounding. Indeed, results from multivariable analyses are consistent with 
our findings17,37,38. The fact that obesity was first proposed as a risk factor, but was later 
discarded in multivariate analyses, is seen in other disease populations as well39–42. 
An explanation that obesity is associated with a higher risk for organ failure can be 
found in the pathophysiology underlying the disease. Regardless of the initiating 
event, pancreatic acinar cells produce mediators that elicit an inflammatory response. 
The ensuing cytokine storm can either resolve or progress to a systemic inflammatory 
response syndrome with accompanying organ failure. Obesity is thought to promote this 
excessive inflammatory response in several ways. Proposed mechanisms include a chronic 
inflammatory state, increased inflammatory M1 macrophages, downregulation of anti-
inflammatory cytokines and inhibition of autophagy10. Furthermore, obesity is associated 
with pancreatic steatosis43. Pancreatic enzymes released in AP digest adipocytes, 
causing an outflux of unsaturated fatty acids. In turn, these can act as pro-inflammatory 
mediators and they are implicated in development of systemic inflammation and multiple 
organ failure7–9. 
We found that obese patients are more likely to develop organ failure. Organ failure is 
the main determinant for mortality in AP3,44, which suggests that obesity would be an 
important risk factor for mortality as well. However, in the subgroup analyses we did not 
find an additional risk of mortality in obese patients with organ failure, nor was higher 
BMI a protective factor for mortality. There is an ongoing debate whether critically ill 
patients (e.g. those with organ failure) with moderate obesity have a lower mortality 
risk11,45 or whether this obesity paradox is the result of methodological limitations46. Our 
results suggest the latter.
The main strength of this study is our access to individual patient data. This gave us the 
opportunity to correct for important confounders and to adopt uniform definitions (e.g. 
WHO cut-off values for BMI, necrotizing pancreatitis instead of local complications in 
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general). Indeed, our quality assessment showed that these were the main drawbacks of 
individual cohort studies, which cannot be corrected in conventional meta-analyses. The 
extensive literature search in four databases ensured comprehensive literature coverage 
and by focusing on prospective studies we ensured a high data quality. Finally, our large 
sample size allowed us to perform subgroup analyses in patients with a (predicted) severe 
disease course.
Several limitations must be acknowledged. First, 13 of the 18 identified cohorts could 
not be retrieved because they were no longer available. However, for the same reason it 
is unlikely that other IPDMAs will include more patients. Our sample size is comparable 
to conventional meta-analysis on this subject that did not depend on individual patient 
data33,34. Second, despite our large sample size some of our subgroups were very small, 
as is evident from the broad confidence intervals in our analysis of the obesity paradox. 
It results in a higher chance of type I and II errors, and thus in a higher chance of false 
positive and false negative findings. This could explain the significantly higher RR 
for mortality in underweight patients with predicted severe AP. Third, three included 
cohorts29–31 were from single tertiary referral centers and the remaining two cohorts 
included only patients with predicted severe AP28 or necrosis32. Therefore, the study 
population of our cohort may be biased towards more severe disease. Although this does 
not influence our internal validity, it could limit external validity. Fourth, we were unable 
to investigate the influence of obesity on persistent organ failure due to unavailability 
of data. It is mainly the persistent nature of organ failure that is linked to mortality47. 
However, patients with multiple organ failure usually have persistent organ failure48. It is 
therefore likely that obesity is associated with higher rates of persistent organ failure as 
well. Fifth, BMI is a suboptimal surrogate marker for visceral fat and body composition, 
while android fat distribution has been implicated as a strong risk factor for severe AP49. It 
is likely that a more direct measurement, for instance by CT scan, would result in a more 
accurate prediction of disease severity46,50,51. Finally, despite our adjustment for important 
confounders, observational studies have an inherent risk of residual confounding that 
cannot be fully corrected. 
Regardless of these limitations, our study shows that BMI has significant predictive 
properties in AP. It can be regarded as a useful surrogate marker of pancreatic fat that can 
be easily incorporated in clinical practice. The question is how BMI can be used in clinical 
practice to predict severity of pancreatitis. Johnson and colleagues addressed this question 
by adding a score depending on BMI class to the APACHE II: the APACHE-O18. Although a 
9
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higher predictive accuracy was found (82% vs. 77%), the results failed replication30. This 
was mainly due to the small proportion of patients who were reclassified from predicted 
mild to predicted severe acute pancreatitis by adding BMI. With this in mind, it could be 
useful to recalibrate the APACHE-O score. 
In conclusion, this individual patient data meta-analysis demonstrated that obesity is 
independently associated with development of organ failure and multi-organ failure 
in acute pancreatitis. However, we found no association with development of necrosis, 
intervention or AP-related mortality. There was no evidence to support the obesity 
paradox in AP.
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SUPPLEMENTARY MATERIAL
Supplement 1: PRISMA-IPD checklist
Supplementary table 1: PRISMA-IPD checklist
PRISMA-IPD
Section/topic
Item No Checklist item Reported 
on page
Title
Title 1 Identify the report as a systematic review 
and meta-analysis of individual partici-
pant data.
1
Abstract
Structured summary 2 Provide a structured summary including as 
applicable:
3
Background: state research question and 
main objectives, with information on 
participants, interventions, comparators 
and outcomes.
Methods: report eligibility criteria; data 
sources including dates of last bibliograph-
ic search or elicitation, noting that IPD 
were sought; methods of assessing risk of 
bias.
Results: provide number and type of stud-
ies and participants identified and number 
(%) obtained; summary effect estimates 
for main outcomes (benefits and harms) 
with confidence intervals and measures 
of statistical heterogeneity. Describe the 
direction and size of summary effects in 
terms meaningful to those who would put 
findings into practice.
Discussion: state main strengths and 
limitations of the evidence, general inter-
pretation of the results and any important 
implications.
Other: report primary funding source, reg-
istration number and registry name for the 
systematic review and IPD meta-analysis.
Introduction
Rationale 3 Describe the rationale for the review in the 
context of what is already known.
6, 7
9
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Supplementary table 1: Continued
PRISMA-IPD
Section/topic Item No Checklist item
Reported 
on page
Objectives 4 Provide an explicit statement of the 
questions being addressed with reference, 
as applicable, to participants, interven-
tions, comparisons, outcomes and study 
design (PICOS). Include any hypotheses 
that relate to particular types of partici-
pant-level subgroups. 
7
Methods
Protocol and registra-
tion
5 Indicate if a protocol exists and where 
it can be accessed.  If available, provide 
registration information including regis-
tration number and registry name. Provide 
publication details, if applicable.
n.a.
Eligibility criteria 6 Specify inclusion and exclusion criteria 
including those relating to participants, 
interventions, comparisons, outcomes, 
study design and characteristics (e.g. years 
when conducted, required minimum fol-
low-up). Note whether these were applied 
at the study or individual level i.e. whether 
eligible participants were included (and 
ineligible participants excluded) from a 
study that included a wider population 
than specified by the review inclusion 
criteria. The rationale for criteria should 
be stated.
Table 1
Identifying studies - 
information sources 
7 Describe all methods of identifying pub-
lished and unpublished studies including, 
as applicable: which bibliographic databas-
es were searched with dates of coverage; 
details of any hand searching including 
of conference proceedings; use of study 
registers and agency or company databas-
es; contact with the original research team 
and experts in the field; open adverts and 
surveys. Give the date of last search or 
elicitation. 
8
Identifying studies - 
search
8 Present the full electronic search strategy 
for at least one database, including any 
limits used, such that it could be repeated. 
8, Supple-
ment 2
Study selection pro-
cesses
9 State the process for determining which 
studies were eligible for inclusion. 
8
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Supplementary table 1: Continued
PRISMA-IPD
Section/topic Item No Checklist item
Reported 
on page
Data collection pro-
cesses
10 Describe how IPD were requested, collect-
ed and managed, including any processes 
for querying and confirming data with 
investigators.  If IPD were not sought 
from any eligible study, the reason for this 
should be stated (for each such study).
8
If applicable, describe how any studies for 
which IPD were not available were dealt 
with. This should include whether, how 
and what aggregate data were sought or 
extracted from study reports and pub-
lications (such as extracting data inde-
pendently in duplicate) and any processes 
for obtaining and confirming these data 
with investigators.
Data items 11 Describe how the information and vari-
ables to be collected were chosen. List and 
define all study level and participant level 
data that were sought, including baseline 
and follow-up information. If applicable, 
describe methods of standardising or 
translating variables within the IPD data-
sets to ensure common scales or measure-
ments across studies.
8, supple-
ment 3
IPD integrity A1 Describe what aspects of IPD were subject 
to data checking (such as sequence gener-
ation, data consistency and completeness, 
baseline imbalance) and how this was 
done.
8
Risk of bias assessment 
in individual studies.
12 Describe methods used to assess risk of 
bias in the individual studies and whether 
this was applied separately for each out-
come.  If applicable, describe how findings 
of IPD checking were used to inform the 
assessment. Report if and how risk of bias 
assessment was used in any data synthesis. 
9, supple-
ment 4
Specification of 
outcomes and effect 
measures
13 State all treatment comparisons of inter-
ests. State all outcomes addressed and 
define them in detail. State whether they 
were pre-specified for the review and, if 
applicable, whether they were primary/
main or secondary/additional outcomes. 
Give the principal measures of effect (such 
as risk ratio, hazard ratio, difference in 
means) used for each outcome.
8-9,  sup-
plement 3
9
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Supplementary table 1: Continued
PRISMA-IPD
Section/topic Item No Checklist item
Reported 
on page
Synthesis methods 14 Describe the meta-analysis methods used 
to synthesise IPD. Specify any statistical 
methods and models used. Issues should 
include (but are not restricted to):
Use of a one-stage or two-stage approach.
How effect estimates were generated 
separately within each study and combined 
across studies (where applicable).
Specification of one-stage models (where 
applicable) including how clustering of 
patients within studies was accounted for.
Use of fixed or random effects models and 
any other model assumptions, such as 
proportional hazards.
How (summary) survival curves were gen-
erated (where applicable).
Methods for quantifying statistical hetero-
geneity (such as I2 and τ2). 
How studies providing IPD and not pro-
viding IPD were analysed together (where 
applicable).
How missing data within the IPD were 
dealt with (where applicable).
9-10
Exploration of variation 
in effects
A2 If applicable, describe any methods used 
to explore variation in effects by study or 
participant level characteristics (such as 
estimation of interactions between effect 
and covariates). State all participant-level 
characteristics that were analysed as po-
tential effect modifiers, and whether these 
were pre-specified.
9-10
Risk of bias across 
studies
15 Specify any assessment of risk of bias relat-
ing to the accumulated body of evidence, 
including any pertaining to not obtaining 
IPD for particular studies, outcomes or 
other variables.
9
Additional analyses 16 Describe methods of any additional anal-
yses, including sensitivity analyses. State 
which of these were pre-specified.
9
Results
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Supplementary table 1: Continued
PRISMA-IPD
Section/topic Item No Checklist item
Reported 
on page
Study selection and IPD 
obtained
17 Give numbers of studies screened, assessed 
for eligibility, and included in the system-
atic review with reasons for exclusions at 
each stage. Indicate the number of studies 
and participants for which IPD were sought 
and for which IPD were obtained. For those 
studies where IPD were not available, give 
the numbers of studies and participants 
for which aggregate data were available. 
Report reasons for non-availability of IPD. 
Include a flow diagram.
11, figure 
1
Study characteristics 18 For each study, present information on key 
study and participant characteristics (such 
as description of interventions, numbers of 
participants, demographic data, unavail-
ability of outcomes, funding source, and if 
applicable duration of follow-up). Provide 
(main) citations for each study. Where ap-
plicable, also report similar study charac-
teristics for any studies not providing IPD.
Supple-
ment 5
IPD integrity A3 Report any important issues identified in 
checking IPD or state that there were none.
11
Risk of bias within 
studies
19 Present data on risk of bias assessments. If 
applicable, describe whether data checking 
led to the up-weighting or down-weighting 
of these assessments. Consider how any 
potential bias impacts on the robustness of 
meta-analysis conclusions. 
12-13, 
supple-
ment 4
Results of individual 
studies
20 For each comparison and for each main 
outcome (benefit or harm), for each indi-
vidual study report the number of eligible 
participants for which data were obtained 
and show simple summary data for each 
intervention group (including, where 
applicable, the number of events), effect 
estimates and confidence intervals. These 
may be tabulated or included on a forest 
plot.  
Supple-
ment 5
9
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Supplementary table 1: Continued
PRISMA-IPD
Section/topic Item No Checklist item
Reported 
on page
Results of syntheses 21 Present summary effects for each me-
ta-analysis undertaken, including confi-
dence intervals and measures of statistical 
heterogeneity. State whether the analysis 
was pre-specified, and report the numbers 
of studies and participants and, where 
applicable, the number of events on which 
it is based. 
11-12, 
figure 2-4
When exploring variation in effects due to 
patient or study characteristics, present 
summary interaction estimates for each 
characteristic examined, including confi-
dence intervals and measures of statistical 
heterogeneity. State whether the analysis 
was pre-specified. State whether any inter-
action is consistent across trials. 
Provide a description of the direction and 
size of effect in terms meaningful to those 
who would put findings into practice.
Risk of bias across 
studies
22 Present results of any assessment of risk 
of bias relating to the accumulated body 
of evidence, including any pertaining to 
the availability and representativeness 
of available studies, outcomes or other 
variables.
Supple-
ment 4
Additional analyses 23 Give results of any additional analyses 
(e.g. sensitivity analyses). If applicable, 
this should also include any analyses that 
incorporate aggregate data for studies that 
do not have IPD. If applicable, summarise 
the main meta-analysis results following 
the inclusion or exclusion of studies for 
which IPD were not available.
n.a.
Discussion
Summary of evidence 24 Summarise the main findings, including 
the strength of evidence for each main 
outcome.
14, 15
Strengths and limita-
tions
25 Discuss any important strengths and lim-
itations of the evidence including the ben-
efits of access to IPD and any limitations 
arising from IPD that were not available.
15, 16
Conclusions 26 Provide a general interpretation of the 
findings in the context of other evidence.
14
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Supplementary table 1: Continued
PRISMA-IPD
Section/topic Item No Checklist item
Reported 
on page
Implications A4 Consider relevance to key groups (such 
as policy makers, service providers and 
service users). Consider implications for 
future research.
14-16
Funding
Funding 27 Describe sources of funding and other sup-
port (such as supply of IPD), and the role in 
the systematic review of those providing 
such support.
21
Supplement 2: Full search strategy 
 Embase
1 obesity/ (275987)
2 overnutrition/ (3632)
3 “Waist-Hip-Ratio”/ (7940)
4     ((bmi adj3 2?) or (bmi adj3 3?)).tw. (41285)
5 ((body mass index adj3 2?) or (body mass index adj3 3?)).tw. (17514)
6 (obese or obesi* or overweight).tw. (280176)
7 or/1-6 (378587) component obesity
8 pancreatitis/ (45250)
9 pancreatiti*.tw. (61878)
10 8 or 9 (78647) component pancreatitis
11 disease course/ (314351)
12 prognosis/ (449861)
13 exp disease severity/ (1193369)
14 mortality/ (560598)
15 exp death/ (503288)
16 (prognosis or outcome or mortality).tw. (1697229)
17  ((risk adj assessement?) or (predict* adj risk?) or (risk adj factor?) or (validat* or 
predict* or rule*)).tw. (2118704)
18 or/11-17 (4712713) component prognosis
19 7 and 10 (1610) combination obesity and pancreatitis
20 18 and 19 (878) combination obesity and pancreatitis and prognosis
9
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 Medline 
TOPIC: (obesity OR obesi* OR overnutrition OR “Waist-hip-Ratio” OR BMI OR “body 
mass index” OR obese OR overweight) AND TOPIC: (pancreatiti* OR pancreatitis) AND 
TOPIC: (“disease course” OR prognosis OR “disease severity” OR mortality OR death OR 
outcome OR “risk factor”) 
Timespan: All years. Indexes: SCI-EXPANDED, SSCI, A&HCI.
 Web of Science 
1 exp Obesity/ (146839)
2 Overnutrition/ (292)
3 “Waist-Hip-Ratio”/ (2986)
4 ((bmi adj3 2?) or (bmi adj3 3?)).tw. (20380)
5 ((body mass index adj3 2?) or (body mass index adj3 3?)).tw. (12981)
6 (obese or obesi* or overweight).tw. (199997)
7 or/1-6 (247557) component obesity
8 Pancreatitis/ (38810)
9 pancreatiti*.tw. (46488)
10 8 or 9 (55351) component pancreatitis 
11 disease course.mp. (8186)
12 prognosis/ or disease-free survival/ or exp treatment outcome/ (1037859)
13 exp Mortality/ (289826)
14 Death/ (12086)
15 (prognosis or outcome or mortality).tw. (1255950)
16 Hospital Mortality/ (24748)
17  ((risk adj assessement?) or (predict* adj risk?) or (risk adj factor?) or (validat* or 
predict* or rule*)).tw. (1634037)
18 (hospital adj3 mortality).tw. (25912)
19 or/11-18 (3328618) component prognosis
20 7 and 10 (652) combination obesity and pancreatitis
21 19 and 20 (300) combination obesity and pancreatitis and prognosis
 Cochrane 
1  obesity or “overnutrition” or Waist-Hip-Ratio or “BMI” or “body mass index” 
(Word variations have been searched) 
2 overweight
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3 #1 or #2
4 pancreatitis
5  “disease course” or prognosis or “disease severity” or mortality or death or “risk 
factor”
6 #3 and #4 and #5
Supplement 3: Study definitions
Supplementary table 2: Study definitions 
Acute 
pancreatitis
According to revised Atlanta criteria(1). Presence of two of the following three 
features:
• Abdominal pain
• Serum amylase/lipase >3x upper limit of normal
• Characteristic findings of acute pancreatitis on CE-CT, MRI or transabdomi-
nal US
BMI 
categories
According to World Health Organization(2), measured by body mass index (kg/
m2):
• Underweight: <18.5
• Normal: 18.5-24.9
• Overweight: 25.0-29.9
• Obesity: ≥30.0
• Class I: 30.0-34.9
• Class II: 35.0-39.9
• Class III: ≥40.0
Comorbidity Comorbidity is defined as:
• Presence of comorbidity in any of the following categories: cardiovascular, 
respiratory, renal, hepatic, pancreatic, gall bladder, diabetes mellitus, malig-
nancy <5 years, dyslipidemia or immunological disease, or
• ASA score >1
Aetiology Biliary, alcohol, idiopathic, other
Severity 
prediction 
A predicted severe disease course is present when one of the following criteria is 
met within 72 hours of admission:
• APACHE II score >7
• Imrie >2
• CRP >150mg/L
• Ranson >2
• BISAP >3
Necrosis According to revised Atlanta criteria(1): a collection containing both fluid and 
necrosis associated with necrotising pancreatitis, no definable wall encapsulat-
ing the collecting. Can involve the pancreatic parenchyma and/or the peripan-
creatic tissues.
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Supplementary table 2: Continued 
Organ 
failure
According to Atlanta criteria(3):
• Circulatory organ failure: systolic blood pressure <90 mm Hg, despite ade-
quate fluid resuscitation or need for inotropic catecholamine support
• Pulmonary organ failure: PaO2 <60 mm Hg, despite FiO2 of 0.30 or need for 
mechanical ventilation
• Renal organ failure: creatinine level >177 µmol/liter after rehydration, or new 
need for hemofiltration or haemodialysis
Multiple organ failure: failure of ≥ 2 organs simultaneously 
Intervention Any drainage (percutaneous or endoscopic) or necrosectomy (surgical or endo-
scopic) for necrotizing pancreatitis
Mortality Death during hospitalization for acute pancreatitis or within 30 days of hospital 
discharge.
ASA: American Society of Anesthesiologists score. CE-CT: contrast-enhanced computed 
tomography. MRI: magnetic resonance imaging. US: ultrasound. ERCP: endoscopic retrograde 
cholangiopancreatography. APACHE: Acute Physiology and Chronic Health Evaluation. CRP: 
C-reactive protein. BISAP: Bedside Index of Severity in Acute Pancreatitis. PaO2: partial pressure of 
arterial oxygen. FiO2: fraction of inspired oxygen.
Supplement 4: Study quality assessment
QUIPS tool
Supplementary table 3: QUIPS assessment for study quality
Domain Specific interpretation IPDMA Remarks Rating 
study
Study participation: whether the study’s reported association is a valid estimate of the true rela-
tionship between the prognostic factor and the outcome of interest in the source population.
Adequate participa-
tion in the study by 
eligible persons
Proportion of available patients with acute 
pancreatitis who participate in the study. 
Inclusion of consecutive patients is preferable. 
Description of the 
source population or 
population of interest
All patients >18 years with acute pancreatitis. 
It is considered suboptimal if a study targets 
only a subgroup of AP patients (e.g. those 
admitted to ICU or with necrotizing pancre-
atitis).
Description of the 
baseline study sample
Sex distribution of AP is approximately 1:1. 
Incidence of AP tends to increase with age. 
Gall stones and alcohol are the most prevalent 
aetiologies. About 20% of patients develop 
necrosis, 30% of which becomes infected. The 
mortality rate is <2% in mild pancreatitis, but 
can increase to 30% in case of infected necro-
tizing pancreatitis(4,5). 
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Supplementary table 3: Continued
Domain Specific interpretation IPDMA Remarks Rating 
study
Adequate description 
of the sampling frame 
and recruitment
The sampling frame (e.g. hospital records, ICD 
codes) identifies all patients that are hospital-
ized with acute pancreatitis. 
Adequate description 
of the period and 
place of recruitment
Multicentre studies are preferable, as are more 
recent recruitment periods that better reflect 
the current standard of care. 
Adequate descrip-
tion of inclusion and 
exclusion criteria
Preferably, acute pancreatitis is defined 
according to the revised Atlanta criteria(1). 
In case of exclusion criteria, these should 
be described in detail to allow for adequate 
judgement. All criteria definitions should 
be in line with current standards for acute 
pancreatitis.   
Study Attrition: whether the reported association between the prognostic factor and outcome 
is biased by the assessment of outcomes in a selected group of participants who completed the 
study.
Adequate response 
rate for study partic-
ipants
The follow-up should be until in-hospital 
mortality or until discharge.  
Description of 
attempts to collect 
information on par-
ticipants who dropped 
out
Reasons for loss to 
follow-up are pro-
vided
There should be no systematic reason for 
loss to follow-up. Loss to follow-up should be 
completely random. 
Adequate description 
of participants lost to 
follow-up
Baseline characteristics should be described 
as under ‘Study participation’ part C.
There are no im-
portant differences 
between participants 
who completed the 
study and those who 
did not
The baseline characteristics as described 
under ‘Study participation’ part C, should be 
similar between patients retained in the study 
and those that were lost to follow-up. 
Prognostic factor (PF) measurement: whether the study measured the prognostic factor (PF) in a 
similar, valid, and reliable way for all participants.
A clear definition or 
description of the PF 
is provided
The prognostic factor under study is obesity. 
For the purpose of this IPD, it should be mea-
sured by body mass index (BMI). 
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Supplementary table 3: Continued
Domain Specific interpretation IPDMA Remarks Rating 
study
Method of PF mea-
surement is adequate-
ly valid and reliable
BMI is measured by weighing the patient and 
measuring the persons length. It is considered 
suboptimal if BMI is extrapolated from im-
aging such as CT-scan. There is a protocolled 
BMI measurement and/or uniform assessment 
(e.i. weighing in underwear). BMI should ide-
ally be measured within 24 hours of admission 
as AP patients receive large amounts of intra-
venous fluids, which affects weight.
Continuous vari-
ables are reported or 
appropriate cut points 
are used
BMI is interpreted according to the World 
Health Organization definition(2): under-
weight (BMI<18.5), normal weight (18.5-24.9), 
overweight (25.0-29.9), obesity I (30.0-34.9), 
obesity II (35.0-39.9), extreme obesity (>40). 
BMI≥30 represents obesity. For an Asian pop-
ulation, a BMI≥25 represents obesity. Report-
ing of continuous BMI values is suboptimal. 
The method and set-
ting of measurement 
of PF is the same for 
all study participants
BMI is measured the same in all patients.
Adequate proportion 
of the study sample 
has complete data for 
the PF
BMI is measured in all study patients. Propor-
tion of missing data is reported to assess its 
influence.
Appropriate methods 
of imputation are 
used for missing PF 
data
Ideally, multiple imputation techniques are 
used. 
Outcome measurement: whether the study measured the outcome in a similar, reliable, and valid 
way for all participants.
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Supplementary table 3: Continued
Domain Specific interpretation IPDMA Remarks Rating 
study
A clear definition 
of the outcome is 
provided
 - For this IPDMA, outcomes were defined as:
 - Necrotizing pancreatitis: according to 
revised Atlanta criteria(1)
 - Organ failure(3): 
 - Circulatory: systolic blood pressure <90 
mm Hg, despite adequate fluid resuscita-
tion, or need for inotropic catecholamine 
support
 - Pulmonary: PaO2<60 mm Hg, despite FiO2 
of 0.30, or need for mechanical ventila-
tion
 - Renal: creatinine >177 umol/liter after 
rehydration or new need for hemofiltra-
tion or haemodialysis
 - Multiple organ failure: failure of 2 or more 
organ systems at the same time
 - Mortality: death within the same hospital 
admission for acute pancreatitis.
Method of outcome 
measurement used is 
adequately valid and 
reliable
Necrosis is assessed on CE-CT scan at least 
1 week after disease onset(1). Preferably, CT 
assessment of necrosis was standard in all 
patients. Preferably, outcomes were defined as 
specified under a). 
The method and 
setting of outcome 
measurement is the 
same for all study 
participants
Study confounding: whether another factor may explain the study’s reported association.
All important 
confounders are 
measured
Possible confounders in this study are age, 
gender, predicted severity, comorbidity, ne-
crosis and organ failure. 
Clear definitions of 
the important con-
founders measured 
are provided
 - Predicted severity: in accordance with the 
literature APACHE>7, BISAP>2, IMRIE>2, 
Ranson>2 and/or CRP>150mg/L within 72 
hours of admission. 
 - Comorbidity is given per organ system or 
by validated scores such as ASA or Charlson 
comorbidity index
 - Necrosis: see outcome definitions.
 - Organ failure: see outcome definitions. 
Measurement of all 
important confound-
ers is adequately valid 
and reliable
Prediction of severity is within 72 hours of 
admission. Necrosis is assessed on CE-CT scan 
at least 1 week after disease onset. Preferably, 
outcomes were defined as specified under b). 
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Supplementary table 3: Continued
Domain Specific interpretation IPDMA Remarks Rating 
study
The method and 
setting of confound-
ing measurement are 
the same for all study 
participants
Appropriate methods 
are used if imputation 
is used for missing 
confounder data
Ideally, multiple imputation techniques are 
used.
Important potential 
confounders are 
accounted for in the 
study design and 
analysis
In the analyses of the impact of BMI on dis-
ease course of AP, correction took place for all 
relevant confounders. 
 
Statistical analysis and reporting: whether results are likely to be spurious or biased because of 
analysis or reporting.
Sufficient presenta-
tion of data to assess 
the adequacy of the 
analytic strategy
Strategy for model 
building is appropri-
ate and is based on a 
conceptual framework 
or model
The selected statisti-
cal model is adequate 
for the design of the 
study
There is no selective 
reporting of results
All primary outcomes are reported.
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In our quality assessment, we adhered to the following predefined rules:
 - Study participation: it is judged whether the study population adequately reflects 
the source population (adults with acute pancreatitis). A high risk of bias was 
designated if there was no inclusion of consecutive patients, if only subgroups of 
patients were targeted, if the baseline study sample deviated in important ways 
from the current general AP epidemiology.
 - Study attrition: A high risk of bias was designated if a large proportion of patients 
were excluded because of missing data. If the baseline characteristics of these 
patients did not differ from the rest of the study population, a low risk of bias was 
appointed.
 - Prognostic factor measurement: the main reason for a moderate risk of bias was 
that BMI was not measured within 24 hours of admission. Importantly, many stud-
ies did not report the exact moment of BMI measurement and therefore, we gave 
these studies a moderate risk of bias. Also, some studies incorporated BMI as a 
continuous variable in their analyses, instead of adopting the WHO cut-off values. 
In those cases, a moderate risk of bias was appointed as well. 
 - Outcome measurement: A high risk of bias was designated if outcome measures 
were not clearly defined (e.g. multi-interpretable) or if they were clearly defined but 
unvalid (e.g. incorporation of predictive scoring systems in final disease severity 
assessment). A moderate risk of bias was given to almost all studies as CT-scans to 
assess necrotizing pancreatitis were not standard and time frames for CT-scanning 
(ideally 1 week after disease onset) were not reported. 
 - Study confounding: A high risk of bias was designated if important confounders 
were not measured or were not accounted for in analyses (e.g. only univariate anal-
yses or multivariate analyses without taking all confounders into account). 
 - Statistical analyses and reporting: A high risk of bias was designated if only uni-
variate analyses were performed that did not take into account important con-
founders. 
 - Finally, in all domains a high risk of bias was appointed if information could not be 
retrieved from the article.
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Funnell plots for assessment of publication bias 
Supplementary figure 1: Funnell plot for meta-analysis of necrosis. RR: risk ratio. SE: standard 
error.
Supplementary figure 2: Funnell plot for meta-analysis of organ failure. RR: risk ratio. SE: 
standard error.
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Supplementary figure 3: Funnell plot for meta-analysis of mortality. RR: risk ratio. SE: standard 
error.
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In this part of the thesis I will enter into a general discussion of our main findings. I 
will give my view on the implications of the studies in this thesis and describe in what 
direction future research should be headed in my opinion. I will discuss this separately for 
prevention of post-ERCP pancreatitis (Part I) and prognostication of AP disease severity 
(Part II). To guide the discussion, table 1 provides an overview of the thesis’ aims, main 
findings and implications. 
Table 1: Main findings and conclusions of this thesis
Chapter Aims Main findings Implications
Part I: Prevention of post-ERCP pancreatitis
2. Primary: To determine 
which classification 
system (consensus or 
revised Atlanta) is the 
strongest predictor of 
PEP-related mortality
Secondary: To determine 
the correlation between 
consensus and revised 
Atlanta for PEP severity
Tertiary: To investigate 
which factors influence 
length of stay in PEP
 - Revised Atlanta more 
accurately predicts 
PEP-related mortality
 - Significant discrepancy 
between both classifi-
cations
 - Length of stay in PEP 
is influenced by other 
factors in 32% of cases
 - Revised Atlanta clas-
sification is the prefer-
able scoring system to 
define PEP severity
 - This influences design 
and feasibility of 
future PEP studies
 - This affects previously 
reported efficacy of 
PEP prophylactics
 - Consensus criteria 
have value from 
patient and societal 
perspective
3. Primary: To create a pre-
diction model for severe 
PEP (PEPSI score)
 - The model performed 
with AUC of 0.63 (0.57-
0.69)
 - Significant correlation 
between PEPSI and ne-
crosis, organ failure, ICU 
stay and length of stay, 
but not mortality
 - Traditional PEP risk fac-
tors were not statistical-
ly significant predictors 
of severe PEP
 - The PEPSI score is 
able to risk stratify 
patients immediately 
after ERCP
 - PEPSI can be used in 
choices regarding 1) 
discharge and refer-
ral, 2) prophylactic 
measures, 3) fluid 
resuscitation
 - Risk factors for severe 
PEP (according to re-
vised Atlanta) should 
be identified
 - PEPSI should be val-
idated and optimized 
in external cohorts
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Table 1: Continued
Chapter Aims Main findings Implications
4. Primary: To systematical-
ly review the evidence 
for periprocedural 
hydration in the preven-
tion of PEP 
 - Higher fluid volumes are 
associated with a lower 
incidence of PEP and 
severe PEP
 - Included studies offer 
no guidance on type and 
timing of hydration
 - Limited evidence in 
favour of synergistic 
effect with established 
prophylactics
 - Included studies of lim-
ited quality
 - Adequately powered 
RCTs are needed to 
confirm the pro-
phylactic effect 
of periprocedural 
hydration in patients 
receiving established 
prophylactics
5./6. Primary: To investigate 
whether periprocedural 
hydration with lactated 
Ringer’s solution can 
prevent post-ERCP 
pancreatitis in moder-
ate-high risk patients 
undergoing ERCP who 
already receive prophy-
lactic rectal NSAIDs
Secondary: To investigate 
the effect of periproce-
dural hydration on PEP 
severity, ERCP com-
plications and hydra-
tion-related complica-
tions
Tertiary: To investigate 
the cost-effectiveness 
of periprocedural hy-
dration
 - The FLUYT trial is still 
recruiting patients.  
 - Results of the FLUYT 
trial are still needed 
as trials published in 
the meantime were 
not able to fill the 
knowledge gaps in 
periprocedural hydra-
tion effectiveness
Part II: Prediction of AP disease course
7. Primary: To investigate 
association between 
portal system vein 
diameter and mortality 
in AP
Secondary: To investigate 
association between 
portal system vein 
diameter and morbidity 
in AP
Exploratory: To compare 
mean vein diameters 
between patients with 
predicted mild and 
predicted severe AP
 - Portal system vein diam-
eters are associated with 
morbidity and mortality 
in AP
 - Patients with predicted 
mild AP had significant-
ly larger portal system 
vein diameters 
 - Results can be used to 
optimize radiological 
scoring systems for 
severity of AP, for 
instance by recalibrat-
ing CTSI
 - Results add to body 
of evidence between 
(splanchnic) perfusion 
and outcomes in AP
10
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Table 1: Continued
Chapter Aims Main findings Implications
8. Primary: To systematical-
ly review evidence for 
angiography and PCT 
for predicting necrosis 
Secondary: To systemati-
cally review evidence for 
angiography and PCT 
for predicting morbidity 
and mortality
 - PCT predicts necrosis 
with sensitivity between 
71-100% and specificity 
between 74-100%
 - Predictive performance 
of PCT higher than angi-
ography
 - PCT predicts mortality 
with sensitivity between 
25-100% and specificity 
between 6-69%
 - Included studies of mod-
erate quality
• PCT seems to have 
superior predictive 
accuracy for necrosis 
compared to other 
AP scoring systems. 
For mortality, other 
AP scoring systems 
perform better
• PCT could be used 
in early therapeutic 
window of AP to guide 
fluid resuscitation
9. Primary: To examine the 
association between 
obesity and mortality 
in AP
Secondary: To investigate 
the association between 
obesity and necrosis, 
OF, MOF and interven-
tion
 - No statistically sig-
nificant association 
between obesity and 
mortality
 - Significant association 
between obesity and 
higher RR for organ fail-
ure and multiple organ 
failure
 - No significant associa-
tion between obesity and 
necrosis or intervention
• Results can be used 
to optimize clinical 
scoring systems for 
predicting organ fail-
ure, possibly through 
recalibration
AUC: area under the receiver operating characteristic curve. AP: acute pancreatitis. CTSI: CT 
severity index. ERCP: endoscopic retrograde cholangiopancreatography. MOF: multi-organ fail-
ure. NSAID: non-steroidal anti-inflammatory drugs. OF: organ failure. PCT: perfusion CT. PEP: 
post-ERCP pancreatitis. PEPSI: post-ERCP pancreatitis severity index. RCT: randomized controlled 
trial. 
PART I: PREVENTION OF POST-ERCP PANCREATITIS
The ERCP landscape is changing towards more invasive procedures. Diagnostic ERCPs 
have been largely replaced by less invasive procedures such as endoscopic ultrasound. 
There is a big push for  more complex ERCP techniques such as cholangioscopy, that 
bear a higher complication rate 1. This trend will likely result in a rising incidence of PEP, 
which makes its prevention even more relevant. At the same time, ERCPs are increasingly 
performed in an ambulatory setting. However, a safe ambulatory practice demands 
adequate prediction of PEP. This thesis aimed to contribute to bolster evidence for areas 
that entail prevention and prognosis of PEP.
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Defining severity of post-ERCP pancreatitis
Before meaningful research can be conducted, it is necessary to adopt objective definitions 
that are related to clinically important outcomes. It ensures that investigators ‘speak the 
same language’ and thus enables comparison of studies. The consensus criteria from 1991 
2 ensured this common language, but from the beginning it was criticized for its reliance 
on length of hospital stay as determining factor in disease severity 3,4. Because of that, 
it was doubtful whether a reported reduction in PEP severity would parallel a reduction 
in morbidity and mortality. Furthermore, from a scientific perspective, the classification 
was suboptimal because it hampered comparison of PEP to AP of other aetiology, because 
this is normally defined according to the revised Atlanta criteria 5. 
In Chapter 2 we formally compared the consensus and revised Atlanta criteria for PEP 
severity. We concluded that the revised Atlanta classification is superior in predicting 
PEP-related mortality and is a better reflection of the PEP phenotype. Therefore, we 
believe the revised Atlanta classification is the preferable definition for PEP severity.
This influences PEP research and the clinical decision-making surrounding an ERCP. 
First, adopting the revised Atlanta criteria will have a profound influence on the feasibility 
of PEP studies, because severe PEP will then be an even rarer occurrence: in our PEP 
cohort, only 19 patients (5%) had severe PEP according to revised Atlanta, against 112 
(29%) if the consensus criteria are used. It is unlikely that there will ever be a trial with 
the statistical power sufficient to detect a difference in PEP severity defined according 
to revised Atlanta. Therefore, alternative methods need to be employed. An individual 
patient data meta-analysis of PEP trials is probably the only way forward to investigate 
the effect of PEP prophylactics on important (but rare) clinical outcomes like necrosis 
and organ failure 6,7. Alternatively, studies could adopt composite endpoints to increase 
the incidence of the primary outcome and with it, the power of the study. However, the 
downside is that composite endpoints can be difficult to interpret because individual 
components do not necessarily have a similar impact, direction and clinical importance 8,9. 
The clinical impact of Chapter 2 is best explained by looking at the efficacy of PEP 
prophylactics found in major PEP trials. Use of PEP prophylactics results in  relative risk 
reductions of moderate-severe PEP up to 50% 10,11. Because these studies adopted the 
consensus criteria, this mainly translates to a reduction in length of hospital stay, rather 
than a reduction in clinically important outcomes such as (persistent) organ failure 7. 
10
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Thus, on the one hand clinicians should realise that prophylactics do not necessarily 
reduce the incidence of necrosis and organ failure. On the other hand, it is important to 
know that the incidence of severe PEP is rare when using the revised Atlanta criteria. 
These arguments should be taken into account when assessing the cost-benefit ratio of 
conducting an ERCP. Furthermore, the knowledge can be used to better inform patients 
on the efficacy of prophylactic measures when obtaining informed consent for ERCP, 
especially in light of patient reported outcome measures and patient centred care 12,13. It 
must be noted that the consensus criteria are valuable from a patient perspective, since 
longer hospital stays lead to reductions in quality of life and higher odds of mortality 14–16. 
Furthermore, problems like oral refeeding are a heavy burden for patients. Because of 
that, there is perhaps a role for both systems in defining PEP severity. At the very least, 
the issues raised by this study justify reporting both classifications.
Identification of PEP risk factors
An important aspect of PEP prevention is identification of risk factors. First of all, they can 
aid clinicians in assessing the cost-benefit ratio of conducting an ERCP: do the advantages 
of ERCP outweigh the disadvantages or should I resort to less invasive procedures? Also, 
risk factor identification leads to a clear picture of what the ideal, atraumatic ERCP 
practice that avoids hazardous techniques should look like. Understanding of risk factors 
is instrumental in the design of studies focusing on measures to reduce PEP. 
To date, sixteen independent risk factors have been identified 17. Still, PEP remains the 
most frequent complication of ERCP. It is likely that genetic variations interact with other 
causes of PEP, because genetic factors such as SPINK1 and PRSS1 are associated with 
pancreatitis susceptibility 18. Furthermore, the genome is involved in the metabolization 
of NSAIDs, the most important prophylactic measure for PEP, and as such could exert an 
effect on PEP incidence 19,20. However, the precise mechanisms involved and their clinical 
relevance have not been unravelled to date. Therefore, our department is currently 
planning an international cohort study to investigate the genetic background of PEP.
Prognosticating PEP
Although we have a clear picture of which factors are related to PEP, there is still no 
general consensus as to what constitutes a high risk of PEP and how to accurately 
predict it. Because most PEP studies are conducted in a high-risk subgroup, absence 
of a standardized definition makes comparison of individual trials inaccurate 10,11,21. 
The European Society for Gastrointestinal Endoscopy (ESGE) offers a definition for 
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patients at high risk of developing PEP 17, but it is based on expert opinion rather 
than scientific enquiry. For all of the above reasons, future research should focus on 
developing a prediction model that accurately categorizes patients into low or high risk 
of PEP, preferably in a prospective, multicenter ERCP cohort. This model can be used in 
clinical practice in the decision-making process surrounding an ERCP or used for risk 
stratification in studies.
Prognosticating severe PEP
Another knowledge gap to date is how we can prognosticate severe PEP. This is important 
because data from our PEP cohort used in Chapter 2 emphasize that PEP is not a milder 
disease than AP of other aetiology, which has been suggested in a previous study 22. The 
3% mortality rate we found is similar to that of general AP and it is the highest of all 
ERCP complications 6,23. Through early prognostication it may be possible to influence 
disease course. Because PEP is a complication that develops within 2-6 hours after ERCP 
in over 70% of patients 24, swift and early risk stratification is of paramount importance. 
We therefore developed and internally validated a prediction model for severe PEP: 
the PEPSI score (Chapter 3). We used the established risk factors for PEP for model 
development, as these are implicated in PEP severity 17,25. The PEPSI score had an area 
under the curve of 0.63 and allows for disease prognostication directly after ERCP. The 
worth of PEPSI is apparent through its significant association with necrosis. The presence 
of necrosis increases the chances of a severe disease course dramatically: persistent organ 
failure is present in only 1% of patients with interstitial pancreatitis 26, compared to 33% 
of patients with necrotizing pancreatitis 27. PEPSI allows physicians to take advantage 
of the early therapeutic window in which (micro)circulatory changes may still reversible 
and necrosis could be prevented 28. If patients have a higher PEPSI score, physicians could 
start more vigorous hydration and increase the frequency of post-procedural monitoring. 
In tertiary referral centers that perform ERCPs for small community hospitals, a high 
PEPSI score could alert physicians that patients are best kept at the specialised center 
for adequate treatment of a potentially severe disease. Also, PEPSI was significantly 
associated with length of stay, which is important from both a patient and societal 
perspective 14–16. 
The multicenter setting makes our PEP cohort a reflection of the general ERCP population, 
which increases the generalizability of the PEPSI score. However, the model is limited 
by its mediocre performance. This is probably due to the fact that traditional PEP risk 
10
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factors were not statistically significant predictors of severe PEP in our cohort. It could be 
that the retrospective design we employed was liable to this: it forced us to dichotomize 
parameters, with a subsequent loss of information and possible loss of predictive power. 
Because our findings are in line with another study on this subject 29, we are fairly 
confident that higher data quality would not have changed these results. These findings 
are surprising, as they contradict the generally held belief that PEP risk factors affect 
disease severity 25. One could hypothesize that the multifactorial, immunological cascade 
underlying severe pancreatitis is less likely to be affected by early, temporary factors 
like an ERCP 30. A further limitation is that we did not use the revised Atlanta criteria to 
define PEP severity, although we showed in Chapter 2 that they are preferable. This was a 
deliberate choice, because only 19 patients would then have had severe PEP, which would 
severely limit our study’s power. 
An obvious aim for future research is the external validation of the PEPSI score. However, 
the results of Chapter 3 also highlight the need for other prognostic studies for severe 
PEP. In that respect, the directions for future research are twofold. First, it could be 
worthwhile to validate general AP scoring systems for early prognostication in PEP. An 
advantage would be that these are established prognostic models that are repeatedly 
validated. However, it is not immediately said that they have similar performance at 
the early time frame that PEP is diagnosed (most often within 2-6 hours after ERCP 31). 
Because AP in general is seldom diagnosed 2-6 hours after disease onset due to delays 
in emergency department presentation and diagnostics 32,33, the general AP scores are 
not validated in this early stage. It might be speculated that the physiological changes 
that are part of the scores (for instance, the APACHE II score 34 incorporates parameters 
such as mean arterial pressure, temperature, pH and leucocytosis) have not progressed 
far enough at this stage. Also, systems like Ranson 35 and Glasgow 36 take 48 hours to 
complete, hampering early prognostication. 
The issues raised above underline that a second line of research is worth pursuing: 
efforts should be made to identify new prognostic factors for severe PEP. As traditional 
PEP risk factors are of limited use (as we showed in Chapter 3), our attention should be 
directed to identify prognostic factors that have a (patho)physiological basis. For instance, 
trypsinogen seems to play a central role in the development and disease progression of 
PEP 37. Also, markers of systemic inflammation (such as interleukins IL-10 and IL-6) could 
prove useful as these are implicated in PEP progression as well 38–40.  
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Prophylactic measures for PEP
The other pillar on which PEP prevention rests is the use of prophylactic measures. 
Currently, rectal NSAIDs and pancreatic duct (PD) stents are advocated by both the ESGE 
and ASGE 17,41. The scientific field concerns itself mostly with optimizing these established 
prophylactics and with identifying new prophylactics. The studies in this thesis belong 
to the last. 
One of the most promising agents is periprocedural hydration. It is intended to preserve 
adequate pancreatic perfusion and tissue oxygenation during ERCP. The strategy finds its 
justification in the theory that early pancreatic microcirculatory perfusion derangements 
are correlated with severity of acute pancreatitis 42. Circumstantial evidence supporting 
this theory is that an increased level of pre-procedural blood urea nitrogen, a marker of 
haemoconcentration, has been associated with PEP development and severity 43,44.
In Chapter 4 we systematically summarized the evidence for periprocedural hydration to 
prevent PEP. In general, evidence suggests that higher volumes of periprocedural fluids 
are associated with a lower incidence of PEP and severe PEP. However, this evidence stems 
from cohort studies or small RCTs with not enough power to allow definitive statements 
on the effectiveness of periprocedural hydration. Furthermore, an important question is 
whether periprocedural hydration provides additional protection on top of established 
prophylactics, which we highlighted in Chapter 5. These knowledge gaps led us to design a 
multicenter, randomized controlled trial to investigate whether periprocedural hydration 
with lactated Ringer’s solution can prevent post-ERCP pancreatitis in 826 moderate-
high risk patients undergoing ERCP who already receive prophylactic rectal NSAIDs: 
the FLUYT trial (Chapter 6). Unfortunately, patient recruitment for the trial was not 
completed at the finalization of this PhD thesis. The results are expected in 2020. 
In the wake of the influential pilot trial by Buxbaum and colleagues 45, several RCTs have 
been published that all find a protective effect of periprocedural hydration 46,47. Is the 
FLUYT trial still necessary then? I am convinced it is. The referenced studies did not 
use rectal NSAIDs while evidence for their preventive effect is irrefutable. As argued in 
Chapter 5, it is unlikely that periprocedural hydration will replace rectal NSAIDs as (cost-
effective) measure for PEP. The question remains unanswered whether periprocedural 
hydration provides additional protection. The trials that did use rectal NSAIDs 48,49 had 
low power and the design of the hydration schedules did not allow statements on the 
10
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worth of periprocedural hydration. Therefore, the results of the FLUYT trial are still 
very much needed. 
The promising results of preliminary studies warrant the conduct of the FLUYT trial. Of 
the 28 agents that have been investigated for the prevention of PEP, at least three deserve 
high quality randomized controlled trials as well. Based on exploratory studies, their 
effectiveness is plausible and pilot randomized trials report favourable results. These 
agents are nitroglycerin (smooth muscle relaxant), somatostatin (inhibitor of pancreatic 
exocrine secretion) and nafamostat (trypsin inhibitor) 50.  
Still, there is probably much to be gained from optimizing existing prophylactic 
regimens. The first question that must be answered is whether combination therapy 
with rectal NSAIDs and PD-stents provides additional protection against PEP compared 
to monotherapy with either one alone. Preliminary studies point in the direction of 
superiority of rectal NSAID monotherapy 51,52. This requires a head-to-head comparison in 
a randomized controlled setting. A large-scale RCT on this subject is currently recruiting 
patients in the United States 53. The second question is whether the optimal dose of rectal 
NSAIDs depends on patient weight. One cohort study suggests it is 54, but to answer this 
question with certainty an RCT is needed that randomizes patients between a fixed dose 
or a weight-dependent dose. 
PART II: PREDICTION OF AP DISEASE COURSE
The first part of the thesis dealt specifically with post-ERCP pancreatitis, but 
prognostication of disease course is important in AP of other aetiologies as well. For 
clinical purposes, risk stratification can guide monitoring intensity, treatment (e.g. more 
aggressive resuscitation) or referral to tertiary care centers. From a scientific point of 
view, predictive scores provide standardised criteria for patient enrolment in randomized 
trials. In this part of the Discussion, I will first examine knowledge gaps in AP severity 
prediction. Thereafter, I will explain how the results of this thesis contribute to filling 
these gaps. 
AP severity prediction
Whereas prognostic studies specifically for PEP are mostly limited to identifying risk 
factors, prognostic studies for general AP have yielded a wide array of prognostic models: 
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at least 21 different models have been developed so far 55,56. Their predictive performance, 
expressed as area under the receiver operating characteristic curve (AUC), ranges from 
0.57 to 0.74 57. Then why is it necessary to invest even more resources in optimizing 
prognostication in AP? 
First of all, it is important to note that no scoring system is clearly superior to others. 
This could be because many systems use different configurations of the same parameter 
pool. For instance, PaO2, haematocrit, leucocyte count, age and blood urea nitrogen are 
used in at least 3 different scores. Therefore, to optimize prognostication it might be 
necessary to identify new predictors. 
Second, most scoring systems are difficult to calculate, which makes them impractical for 
clinical use. For instance, the APACHE-II score 34 incorporates 15 separate parameters into 
one comprehensive score. In addition, many parameters are not routinely measured in 
clinical practice, such as PaO2. Along the same lines, most efforts to increase the predictive 
performance of existing scoring systems came at the cost of a further reduction in 
simplicity. For instance, Mounzer combined several scoring systems to create prediction 
rules 57 and Johnson added BMI to the APACHE-II score 58. These issues highlight the need 
for simple prognostic models with high accuracy. 
Third, risk stratification to guide treatment decisions might be most effective within the 
so-called therapeutic window of AP 59. This is the (theoretical) time frame in which it is 
still possible to correct the fluid losses due to third spacing and in that way, prevent AP 
from progressing to the severe stages with necrosis and organ failure. Evidence suggests 
that aggressive resuscitation after the procedure does more harm than good 60. Because 
many scores, such as Ranson 35 and Glasgow-Imrie 36, take 48 hours to complete, they are 
less suitable for this early prognostication. 
A final point I want to mention in the discussion of optimizing AP disease prognostication 
is the current lack of impact studies. Impact studies quantify the effect of prognostic 
models on clinical practice compared to usual care. Although many studies are 
concerned with identifying prognostic factors an developing prognostic models, studies 
investigating whether prognostic models influence clinical practice are virtually absent 
55. By performing impact studies, it might be that one prognostic model will emerge as the 
best guide for clinical practice. Incidentally, this model would then be an obvious choice 
for use in research to stratify patients in randomized trials or monitor effectiveness of 
potential new treatments. 
10
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Circulatory changes and AP severity prediction
In Chapters 7 and 8 we aimed to identify new predictors for AP severity by looking at 
circulatory changes in AP. We chose this approach because (micro)circulatory changes 
are at the heart of AP pathophysiology and are implicated in disease progression 42. 
Incidentally, scores derived from circulatory changes might offer better guidance in 
hydration, the cornerstone of early AP treatment 61, because they more directly reflect 
the circulatory state of the patient.
Chapter 7 is a post-hoc analysis of prospective data in which we found an inverse 
relationship between portal system vein diameters and mortality, necrosis, infected 
necrosis, organ failure and persistent organ failure. We proposed the following consecutive 
order of events to explain our findings. Acute pancreatitis causes third spacing of fluids, 
which leads to reduced splanchnic perfusion and subsequent reduced pancreatic blood 
flow. In turn, this leads to reduced venous return. Because blood volume and vessel radius 
are tightly linked (figure 1), this results in a subsequent decrease in vein diameter 62,63. 
This could explain the association between vein diameter and development of necrotizing 
pancreatitis and organ failure. 
Figure 1: Relationship between blood flow and vessel diameter 64.
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In Chapter 8 we further explored the relationship between pancreatic blood flow and 
outcomes in AP, but now we focused on (early) microcirculatory changes within the 
pancreas. These include vasoconstriction of end arteries, pathological shunting, stasis 
of blood, increased capillary permeability and impaired lymph drainage. Ultimately, these 
processes can cause necrotizing pancreatitis at a later stage 42. Imaging techniques to 
study these microvasculature changes are perfusion computed tomography (PCT) and 
angiography. PCT analyzes tissue microcirculation through the kinetics of intravenous 
contrast 65,66. Angiography through arterial catheters detects vascular changes that 
underlie pancreatic necrosis, such as arterial vasospasms. As such, necrotizing 
pancreatitis could be predicted 67. In Chapter 8 we systematically reviewed the evidence 
for angiography and perfusion CT for predicting necrotizing AP and mortality. We found 
that the accuracy of PCT was superior to angiography. Compared to general AP scoring 
systems, the predictive accuracy of PCT was much higher for necrosis, but lower for 
mortality 56,68. 
The post-hoc analysis in Chapter 7 was exploratory in nature. The original data collection 
was not specifically designed for the research question at hand. Because of that, we 
could not establish a temporal relationship between vein diameter and necrosis or organ 
failure. A similar limitation was present in the studies included in the systematic review 
of Chapter 8: the timing of index PCT and follow-up CT was highly variable, leading to a 
wide variety in reported accuracy. These issues need to be resolved in future studies before 
the results can be implemented in disease prognostication. This requires prospective 
studies in which index imaging (CE-CT or PCT) is performed at admission and follow-up 
CT is performed at least 72-92 hours after symptom onset for detection of necrosis 61. 
In what way do the results of Chapters 7 and 8 contribute to solving the issues raised in the 
preceding paragraphs? First, the relationship between portal system vein diameters and 
clinical outcomes can be used to optimize existing radiological scoring systems for AP, 
for instance CTSI 69. Although CTSI has a high accuracy for necrosis, its prognostication 
of organ failure and mortality leaves much to be desired 56. The significant relationship 
we established between vein diameter and AP-related morbidity and mortality could 
help to solve that. This requires recalibration of CTSI through a prospective cohort study 
that assigns points to a decrease in vein diameter. Appropriate cut-off values can then 
be established. 
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With respect to PCT, this technique could act as a predictive system on its own and 
does not need further modification. The major advantage over existing (radiological) 
scores is that it can be applied at a very early stage in the disease course, because 
microcirculatory changes are present within 30 minutes of disease onset 70. Currently, 
the main argument against early CT assessment in AP patients is that it has no direct 
management complications and there is no evidence it will improve clinical outcomes 
71,72. This might be true for early CE-CT, but the early changes detectable through PCT 
makes the technique especially adept at guiding treatment choices in the early therapeutic 
window mentioned before. PCT might alter management, and with it clinical outcomes. 
This should be evaluated prospectively. With respect to radiation exposure, studies in 
PCT reported a wide variation, which hampers comparison to standard CE-CT. However, 
low-dose PCT shows promising results with a reported effective radiation dose of 3.6-4.9 
mSv, compared to 4.4-11.3 mSv for a contrast-enhanced two-phase pancreatic scan 73. 
This could justify its use for prognosticating necrotizing pancreatitis. 
The findings in Chapter 7 and 8 also contribute to our understanding of the 
pathophysiology underlying acute pancreatitis and might offer guidance in an ongoing 
debate in acute pancreatitis: How can fluid resuscitation prevent AP from progressing to 
its severest stages? Although hydration is the only treatment option early in the disease 
course of AP, there is an astounding lack of trials to guide clinicians 60. The three main 
issues with respect to hydration schedules are 1) which fluid type to use, 2) how aggressive 
resuscitation should be and 3) how treatment should be monitored. Our results make 
a case for more aggressive hydration, because our studies confirm that necrosis and 
intestinal ischaemia are key elements of disease progression 74. 
Obesity and AP severity prediction
The final chapter of this thesis, Chapter 9, investigated the effect of obesity on outcomes in 
AP. Although data suggest that obesity is associated with local and systemic complications 
as well as mortality, it is unknown if that association is independent. Also, studies to 
date had several methodological shortcomings 75. We therefore performed an individual 
patient data meta-analysis in 1302 AP patients in order to address the methodological 
limitations of former studies and in that way, provide an answer to whether obesity is 
an independent prognostic factor for outcomes in AP. Indeed, we found that obesity is 
independently associated with organ failure and multiple organ failure. However, we 
found no independent relationship between obesity and necrosis, an intervention or 
mortality. 
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The main contribution our IPDMA can offer to the body of evidence is that we were able 
to fix some of the methodological issues hampering previous studies. Most importantly, 
we could adopt stringent endpoint definitions and could account for several important 
confounders. Indeed, BMI is associated with several prognostic parameters for mortality 
in AP, including age and organ failure 75,76. We accounted for these in our analyses, making 
our results probably more reliable than standard meta-analyses on this subject 77–80. Our 
results at least highlight that obesity is an important baseline characteristic to report 
in AP. However, we still need to investigate how these findings can be used for better 
disease prognostication. Our results show that it depends on which endpoint you want 
to prognosticate. BMI is less valuable in prognosticating necrosis and mortality but is 
useful in prognosticating organ failure. This could explain why increasing the prognostic 
performance of APACHE-II by adding points for obesity (APACHE-O score) failed to better 
predict mortality 81. What our study could not answer, however, is whether general obesity 
(measured by BMI) or central obesity (measured by waist circumference) has the highest 
prognostic accuracy. Some studies suggest the latter 82. Important in this debate is the 
simplicity of BMI for clinical practice, in contrast to waist circumference, which can be 
measured in different ways 83. 
CONCLUSIVE REMARKS
Thus far, the research field of post-ERCP pancreatitis focused on identifying prophylactic 
measures and risk factors for PEP. It led to significant improvements in PEP prevention, 
mainly through the introduction of prophylactic pancreatic duct stents and rectal NSAIDs 
and the identification of numerous independent risk factors. Despite these efforts, PEP 
remains the most prevalent and most severe complication of ERCP. As for AP in general, 
we are still unable to mitigate disease severity at an early stage. Once necrosis and organ 
failure develop, the mortality remains as high as 30%. By improving the accuracy of 
predictive systems, we might be able to better target treatment and in that way influence 
the disease course. I hope this thesis provides leads for further research to optimize 
preventive strategies for PEP and improve prognostication of acute pancreatitis. 
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ENGLISH SUMMARY
This thesis is concerned with optimizing the prevention of post-endoscopic retrograde 
cholangiopancreatography (ERCP) pancreatitis (PEP) and the prognostication of the 
disease course of general acute pancreatitis (AP). In this chapter, I will summarize the 
main findings of this thesis.
PART I: PREVENTION OF POST-ERCP PANCREATITIS
PEP is the most prevalent and most severe of all ERCP complications. It is therefore pivotal 
to investigate its prevention. However, before meaningful research can be conducted 
it is necessary to adopt objective definitions that are related to clinically important 
outcomes. In Chapter 2 we compared two commonly used definitions for PEP severity 
in a cohort of 387 PEP cases: the consensus criteria and the revised Atlanta criteria. 
We found a significant difference between the two definitions: 112 patients (29%) were 
severe according to the consensus criteria, compared to only 19 patients (5%) according 
to revised Atlanta. The revised Atlanta criteria had a higher prognostic accuracy for PEP-
related mortality and reflected the PEP phenotype better. We therefore concluded that 
the revised Altanta criteria are preferable in defining PEP severity. Because PEP studies 
to date mostly used the consensus criteria, additional research is needed to evaluate the 
efficacy of prophylactic measures on outcomes such as organ failure. This is the main 
determinant of mortality in AP, but it is not included in the consensus criteria. This is 
important in the assessment of the cost-benefit ratio of ERCP and in the informed consent 
procedure for patients. Also, the incidence of severe PEP is much smaller while using 
revised Atlanta and this will have a profound influence on the feasibility of PEP studies, 
especially with regard to statistical power for severe PEP. This calls for alternative designs 
such as individual patient data meta-analyses. 
PEP remains the most detrimental complication of ERCP. Predicting at an early stage 
who will develop severe PEP may alleviate disease course through guidance of treatment 
decisions. In Chapter 3 we therefore developed a prediction model for severe PEP: the PEP 
severity index (PEPSI). With an area under the receiver operating characteristic curve 
(AUC) of 0.63 and a sensitivity of 90%, PEPSI is able to categorize patients directly after 
ERCP into high or low risk of severe PEP. PEPSI can guide clinicians in choices concerned 
with patient referral to tertiary care centers for adequate treatment of a potentially severe 
disease. Furthermore, the choice of prophylactic measures for PEP could depend on PEPSI 
score because pancreatic duct (PD) stents are thought to provide better protection against 
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severe PEP compared to rectal non-steroidal anti-inflammatory drugs (NSAIDs). Finally, 
a high PEPSI score could prompt clinicians to treat more aggressively, for instance by 
infusing higher fluid volumes. It must be stressed that the AUC of 0.63 is mediocre. This is 
probably because the traditional PEP risk factors we used in our multivariable regression 
analysis were no statistically significant predictors of severe PEP. As such, PEPSI should 
be regarded as a first step in prognosticating severe PEP. The score could be improved 
through external validation and by adding other potential predictors.
The second pillar of PEP prevention is the use of prophylactic measures. A promising 
new prophylactic agent is periprocedural hydration. It might prevent PEP by maintaining 
pancreatic microperfusion. Chapter 4 is a systematic review in which we summarized 
the evidence for periprocedural hydration. We concluded that the current literature is 
of moderate quality. Nevertheless, the studies suggest that hydration affords protection 
against PEP. Therefore, adequately powered trials are needed. Furthermore, it should 
be investigated if hydration affords additional protection on top of already established 
prophylactics such as rectal NSAIDs and PD-stents. We emphasized this in a letter-to-
the-editor (Chapter 5). Because the effectiveness of rectal NSAIDs and PD-stents is 
irrefutable, patients cannot be withheld them. Also, it must be investigated if 9-hour 
hydration schedules used in the current literature are cost-effective. These issues are 
all addressed in a multicenter randomized controlled trial: the FLUYT-trial (Chapter 
6). The primary research question is whether periprocedural hydration with lactated 
Ringer’s solution can prevent PEP in 826 moderate- to high-risk patients undergoing 
ERCP who already receive prophylactic rectal NSAIDs. Important secondary outcomes 
are the influence of periprocedural hydration on PEP severity and the cost-effectiveness 
of the approach. Unfortunately, patient enrollment for the FLUYT trial was not completed 
at the end of this thesis. Results are expected in 2020.
PART II: PREDICTION OF AP DISEASE COURSE
The second part of this thesis dealt with prognosticating the disease course of general 
AP. Prognostic scores can be used to guide monitoring intensity, treatment or referral 
to tertiary care centers. Furthermore, they provide standardized criteria for patient 
enrolment in clinical trials. 
In Chapter 7 and 8 we aimed to identify new predictors of severity by looking at circulatory 
changes in AP. Microcirculatory changes are present within 30 minutes of disease onset. 
If that is exploited in prognostic scores, it might enable clinicians to treat patients 
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within the therapeutic window of AP, in which fluid losses due to third spacing can still 
be reversed. In that way, a severe disease course might be prevented. In Chapter 7 we 
conducted a post-hoc analysis of two randomized controlled trials. In 144 patients we 
investigated the correlation between diameter of portal system veins (splenic, portal 
and superior mesenteric vein) and outcomes in AP. Indeed, we observed an inverse 
relationship between diameters of portal system veins and morbidity, and an inverse 
relationship between splenic vein diameter and mortality. These findings can be used in 
optimizing radiological scoring systems for AP, for instance the computed tomography 
(CT) severity index (CTSI). In Chapter 8 we systematically summarized the evidence for 
perfusion CT (PCT) and angiography in predicting necrotizing pancreatitis and mortality. 
Six prospective studies with 334 patients were identified. They showed that PCT had a 
higher prognostic accuracy for necrosis and mortality compared to angiography. The 
prognostic performance of PCT for necrosis was higher than most general AP scoring 
systems and could therefore be useful for clinical practice. 
In the final chapter of this thesis, Chapter 9, we investigated the effect of obesity on 
outcomes in AP. Obesity is thought to promote the inflammatory response in AP, 
causing a more severe disease course. This relationship was investigated before, but 
methodological drawbacks of previous studies precluded firm conclusions. We performed 
an individual patient data-meta-analysis (IPDMA) in 1302 AP patients to address the 
methodological issues. We found that obesity is independently associated with organ 
failure and multiple organ failure. However, we found no independent relationship 
between obesity and necrosis, an intervention or mortality. As such, these results could 
be used in prognosticating organ failure. It might be worthwhile to recalibrate existing 
scoring systems by incorporating obesity. 
CONCLUSION
Many efforts have been directed to identifying risk factors and prophylactic measures 
for PEP. These efforts led to significant improvements in PEP prevention, but it remains 
the most prevalent and most severe complication of ERCP. As for general AP, we are still 
unable to alleviate disease severity at an early stage. Once necrosis and organ failure 
develop, the mortality can be as high as 30%. By improving the accuracy of predictive 
systems, we might be able to better target treatment and in that way influence the disease 
course. I hope this thesis provides leads for further research to optimize preventive 
strategies for PEP and improve prognostication of acute pancreatitis. 
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DUTCH SUMMARY
Dit proefschrift gaat over het optimaliseren van de preventie van post-endoscopische 
retrograde cholangiopancreaticografie (ERCP) pancreatitis (PEP) en het voorspellen van 
het ziektebeloop van acute pancreatitis (AP) in het algemeen. In dit hoofdstuk zal ik de 
voornaamste bevindingen van het proefschrift samenvatten.
DEEL 1: PREVENTIE VAN POST-ERCP PANCREATITIS
PEP is de meest voorkomende en meest ernstige van alle ERCP-complicaties. Het is 
daarom belangrijk om te onderzoeken hoe PEP voorkomen kan worden. De eerste stap 
in waardevol onderzoek is echter het hanteren van objectieve definities die gerelateerd 
zijn aan belangrijke klinische uitkomstmaten. In Hoofdstuk 2 hebben we in een cohort 
van 387 patiënten met PEP twee definities voor ernst vergeleken: de consensus criteria 
en de revised Atlanta criteria. We vonden een significant verschil tussen de definities: 
112 patiënten (29%) hadden een ernstig beloop volgens de consensus criteria, tegenover 
19 patiënten (5%) als de revised Atlanta criteria gebruikt worden. De revised Atlanta 
criteria hebben een hogere prognostische accuratesse voor mortaliteit en vormen een 
betere reflectie van het fenotype van PEP. Wij concludeerden daarom dat de revised 
Atlanta criteria de voorkeur genieten boven de consensus criteria voor het definiëren 
van ernstige PEP. Echter, reeds gepubliceerde studies in het onderzoeksveld gebruiken 
tot nu toe voornamelijk de consensus criteria. Daarom is aanvullend onderzoek nodig om 
vast te stellen of PEP profylaxen ook complicaties zoals orgaanfalen kunnen voorkomen. 
Dit is namelijk de belangrijkste voorspeller van mortaliteit, maar deze is niet opgenomen 
in de consensus definitie. Het is belangrijk voor endoscopisten om te beseffen dat PEP-
profylaxen niet per se PEP-gerelateerde morbiditeit voorkomen. Dit gegeven moeten zij 
in gedachten houden als zij de voor- en nadelen van ERCP tegen elkaar afwegen. Tevens 
zou dit meegenomen moeten worden in de informed consent procedure voor patiënten 
die een ERCP ondergaan. Een tweede implicatie van onze bevindingen is dat de incidentie 
van ernstige PEP veel kleiner is bij gebruik van de revised Atlanta criteria. Om met genoeg 
statistische power een verschil in ernstige PEP aan te kunnen tonen, ontkomen we er 
daarom niet aan om alternatieve designs zoals een individual patient data meta-analysis 
(IPDMA) te gebruiken.  
PEP blijft de ernstigste complicatie van ERCP. Als artsen in een vroeg stadium 
kunnen voorspellen welke patiënten een ernstig ziektebeloop zullen ontwikkelen, dan 
kunnen ze hierop hun behandeling aanpassen. Op die manier kan het mogelijk zijn 
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om het ziektebeloop gunstig te beïnvloeden. Daarom hebben we in Hoofdstuk 3 een 
predictiemodel ontwikkeld voor ernstige PEP: de PEP severity index (PEPSI). Met een 
area under the receiver operating characteristic curve (AUC) van 0,63 en een sensitiviteit 
van 90% categoriseert de PEPSI-score patiënten in een hoog of laag risico voor ernstige 
PEP. De PEPSI-score kan clinici bijstaan bij keuzes omtrent verwijzingen naar een tertiair 
centrum voor de behandeling van een, in potentie, ernstig ziektebeeld. Tevens kunnen 
endoscopisten PEPSI gebruiken bij hun keuze voor PEP profylaxen, omdat stents in de 
ductus pancreaticus (PD) waarschijnlijk beter zijn in het voorkomen van ernstige PEP dan 
rectale non-steroidal anti-inflammatory drugs (NSAID’s). Tot slot kunnen behandelend 
artsen er bij een hoge PEPSI-score toe over gaan om een agressief vloeistofbeleid te 
voeren. Het moet gezegd worden dat de AUC van 0,63 matig is. Dit komt waarschijnlijk 
omdat traditionele risicofactoren voor PEP, die wij gebruikt hebben in onze multivariable 
regressieanalyse, geen significante voorspellers voor ernstige PEP waren. Daarom moet 
deze studie gezien worden als een eerste stap in het voorspellen van ernstige PEP. De 
PEPSI-score zal eerst extern gevalideerd moeten worden. Tevens kan de score verbeterd 
worden door er andere voorspellers aan toe te voegen.
De tweede pilaar waarop PEP-preventie rust is het gebruik van profylaxen. Een nieuw, 
veelbelovend middel om PEP te voorkomen is periprocedurele hydratie. Het zou PEP 
kunnen voorkomen doordat het de microcirculatie van het pancreas op peil houdt. In 
Hoofdstuk 4 hebben we op systematische wijze de literatuur samengevat die al over dit 
onderwerp is verschenen. We concludeerden dat de huidige literatuur slechts van matige 
kwaliteit is. Desondanks wijzen de studies die gepubliceerd zijn erop dat periprocedurele 
hydratie PEP kan voorkomen. Daarom is het nodig om gerandomiseerde onderzoeken 
van hoge kwaliteit uit te voeren. Een belangrijk aspect dat dan ook onderzocht dient te 
worden, is of hydratie bovenop reeds bestaande profylaxen, zoals rectale NSAID’s en PD-
stents, aanvullende bescherming tegen PEP geeft. Het belang van deze onderzoeksvraag 
wordt benadrukt in een letter-to-the-editor die wij schreven (Hoofdstuk 5). Wij zijn 
namelijk van mening dat wij patiënten effectieve profylaxen niet mogen onthouden. 
Tevens dient onderzocht te worden of een hydratieschema van 9 uur, zoals nu gebruikt 
wordt in de literatuur, wel kosteneffectief is. Deze zaken zullen allemaal aan bod komen 
in een multicentrische, gerandomiseerde klinische trial: de FLUYT-studie (Hoofdstuk 
6). De primaire onderzoeksvraag is of periprocedurele hydratie met Ringer’s lactaat de 
incidentie van PEP verlaagt in 826 patiënten met een matig-hoog risico op PEP die al 
profylactische rectale NSAID’s krijgen. De belangrijkste secundaire eindpunten zijn de 
invloed van periprocedurele hydratie op ernst van PEP en de kosteneffectiviteit van de 
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behandeling. De patiënteninclusie van de FLUYT-studie was helaas nog niet voltooid aan 
het einde van deze promotie. De resultaten worden verwacht in 2020.
DEEL II: VOORSPELLEN VAN HET ZIEKTEBELOOP VAN ACUTE PANCREATITIS
Het tweede deel van dit proefschrift ging over het voorspellen van het ziektebeloop van 
AP in het algemeen. Prognostische scores kunnen gebruikt worden bij het bepalen van de 
intensiteit van monitoring, de behandeling of het verwijzen naar tertiaire centra. Tevens 
bieden ze gestandaardiseerde criteria voor het includeren van patiënten in klinische trials.
In Hoofdstuk 7 en 8 hebben we gepoogd nieuwe voorspellers van ernst te identificeren 
door de circulatoire veranderingen in AP als uitgangspunt te nemen. Microcirculatoire 
veranderingen zijn namelijk binnen 30 minuten na start van de ziekte al aanwezig. Als 
dat gegeven gebruikt kan worden in prognostische scores, zouden behandelaars mogelijk 
het therapeutic window van AP kunnen benutten. Dit is het tijdsbestek waarin het 
vochtverlies naar de derde ruimte door de pancreatitis (het ‘zweten’ van het pancreas) 
nog gecompenseerd kan worden. Op die manier kan mogelijk een ernstig beloop 
voorkomen worden. Hoofdstuk 7 is een post-hoc analyse van twee gerandomiseerde 
studies. In 144 patiënten hebben we de correlatie onderzocht tussen de diameter van 
vaten in het portale systeem (vena porta, splenica en mesenterica superior) en uitkomsten 
in AP. We vonden inderdaad een omgekeerd evenredige relatie tussen diameter en 
morbiditeit. Tevens vonden we een omgekeerd evenredige relatie tussen diameter van 
de vena splenica en mortaliteit. Deze bevindingen kunnen gebruikt worden bij het 
optimaliseren van radiologische scoringssystemen, zoals de computed tomography (CT) 
severity index (CTSI). In Hoofdstuk 8 hebben we op systematische wijze de literatuur 
samengevat die gepubliceerd is over perfusie CT (PCT) en angiografie in het voorspellen 
van necrotiserende pancreatitis en mortaliteit. We includeerden zes prospectieve 
cohortstudies met 334 patiënten. Daaruit bleek dat PCT een hogere prognostische 
accuratesse had voor necrose en mortaliteit dan angiografie. De prognostische accuratesse 
van PCT voor necrose was hoger dan de meeste AP-scores en daarom zou deze gebruikt 
kunnen worden in de klinische praktijk.
In het laatste hoofdstuk van dit proefschrift, Hoofdstuk 9, onderzochten we het effect van 
obesitas op uitkomsten in AP. Verondersteld wordt dat obesitas de inflammatiereactie 
van AP verhevigt, waardoor een ernstiger ziektebeloop ontstaat. Hoewel deze relatie 
in andere studies al onderzocht is, was het door verschillende methodologische 
tekortkomingen nog niet mogelijk definitieve conclusies hieruit te trekken. Daarom 
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voerden wij een IPDMA uit in 1302 patiënten met AP. Dit gaf ons de mogelijkheid om 
de methodologische tekortkomingen van eerdere studies te corrigeren. We vonden 
dat obesitas een onafhankelijke voorspeller is voor orgaanfalen en multi-orgaanfalen. 
Echter, we vonden geen onafhankelijke relatie tussen obesitas en necrose, interventie 
of mortaliteit. Obesitas is daarom geschikt voor het voorspellen van orgaanfalen. Het 
kan waardevol zijn om reeds bestaande scoringssystemen te recalibreren door obesitas 
eraan toe te voegen. 
CONCLUSIE
Het onderzoeksveld van PEP blijft groeien, en talloze risicofactoren en profylactische 
middelen zijn inmiddels onderzocht. Dit heeft geleid tot een significante daling in PEP, 
maar het blijft nog altijd de meest voorkomende en meest ernstige complicatie van ERCP. 
Wat betreft AP in het algemeen is het nog altijd niet goed mogelijk om het ziektebeloop 
in een vroeg stadium te beïnvloeden. Als patiënten necrose en orgaanfalen ontwikkelen, 
kan de mortaliteit nog steeds oplopen tot 30%. Door de accuratesse van prognostische 
modellen te verbeteren is het wellicht mogelijk om behandelingen beter af te stemmen 
op de behoeften van de individuele patiënt. Op die manier wordt het in de toekomst 
misschien wel mogelijk om een ernstige pancreatitis te voorkomen. Ik hoop dat dit 
proefschrift aanknopingspunten biedt om de preventie van PEP en het voorspellen van 
het ziektebeloop van AP te optimaliseren. 
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Dankwoord
Allereerst wil ik alle patiënten bedanken die hun medewerking hebben verleend aan de 
studies in dit proefschrift. Ik heb er veel waardering voor dat mensen bereid zijn om mee 
te doen aan wetenschappelijk onderzoek op het moment dat ze zelf ernstig ziek zijn. 
Laat ik als tweede mijn copromotor bedanken. Erwin van Geenen himself, de schuifkoning 
die liever op een Vespa dan op de fiets naar zijn werk komt. Jij bent als geen ander in staat 
out-of-the-box te denken en op die manier tot nieuwe inzichten en onderzoeksvragen 
te komen. Je hebt me geleerd om te manoeuvreren in een competitieve wereld waarin 
iedereen zijn eigen belangen heeft. Tevens heb je me laten inzien hoe belangrijk het is 
om in een netwerk te opereren. Ik heb erg veel van je geleerd en ik zie er naar uit om over 
een paar jaar de fijne kneepjes van het ERCP-vak van je te leren. 
Uiteraard wil ik ook prof. dr. Joost Drenth, mijn promotor, bedanken. Op subtiele en 
minder subtiele wijze heb je mij continu uitgedaagd om het beste in mezelf naar boven 
te halen. Met jouw sturing heb ik me kunnen ontwikkelen op zowel wetenschappelijk 
als persoonlijk vlak. Je hebt me het belang van positief denken bijgebracht met een 
gevleugelde uitspraak die ik nooit meer zal vergeten: ‘Ik kan zeggen dat je er in je groene 
broek bescheten uit ziet, of ik kan zeggen dat je een leuk overhemd aan hebt.’ Je gaat door 
het vuur voor je promovendi en dat siert je.  
Tevens wil ik alle leden van de manscriptcommissie en corona bedanken voor de tijd die 
zij in mijn promotie hebben gestoken. 
Dan de Hoge Heren van de Pancreatitis Werkgroep Nederland, prof. dr. Paul Fockens, prof. 
dr. Marco Bruno, (inmiddels prof.) dr. Marc Besselink, dr. Hjalmar van Santvoort, prof. dr. 
Harry van Goor, prof. dr. Marja Boermeester en dr. Robert Verdonk. Al jaren zetten jullie je 
met hart en ziel in om de PWN draaiende te houden. Ik vind het bewonderenswaardig dat 
jullie zo laagdrempelig beschikbaar zijn voor advies, ook als jullie daar niet rechtstreeks 
een belang bij hebben. Voor de arts-onderzoekers zijn jullie altijd beschikbaar om (zij)
studies kritisch te bekijken en daarvoor wil ik jullie hier bedanken. Zonder een kerngroep 
zoals deze kan de PWN niet bestaan.
De oud arts-onderzoekers van de PWN verdienen hier ook zeker een plek. Sandra, bedankt 
voor de oral free paper prize op de UEGW. Stefan, Yama en Usama, dank voor jullie input 
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tijdens de vele PWN-vergaderingen. Last but not least, David da Costa. Kompaan in de 
embryonale tijd van FLUYT en daarna bij vele zijstudies. Jij bent in mijn gehele promotie 
een belangrijke sparringpartner geweest en ik heb veel geleerd van jouw doelgerichtheid, 
van je methodologische kennis en precisie en van je Engelse schrijfstijl. 
Dan de arts-onderzoekers van de PWN waarmee ik het Datacenter bemand heb. Het DC 
trio, kwartet, quintet, sextet of hoeveel het er inmiddels ook zijn. De groep die overdag 
de PWN draaiende houdt en daarnaast in de avonduren ook nog promoveert. Of die 
dan juist wakker gebeld wordt door een slaapdronken arts-assistent die een patiënt wil 
aanmelden voor registratie (niet voor een trial). En die rando’s wegwerkt zoals Sven 
kaasplankjes wegwerkt, en op de meest vreemde plekken en tijdstippen: tijdens blind 
dates, in Oostenrijkse bergen, op het vliegveld. Enfin, jullie weten wat ik bedoel. 
 - Nicolien: Bedankt voor de stoomcursus PWN die je in het begin gaf. Je hebt me de 
waarde laten inzien van doortastendheid in onderzoek en in het coördineren van 
multicenter trials. Precies, precies, precies!
 - Janneke: Juffrouw Jannie, de vrolijke noot en degene die nooit een kans laat liggen om 
een woordgrap te maken. Jij maakt onderzoek luchtig en met je positieve uitstraling 
krijg je iedereen voor je gewonnen. Bedankt voor een erg leuke tijd samen! Ik denk 
dat ik je ook ga bedanken dat je zitting hebt genomen in de corona, al weet ik, nu ik 
dit schrijf, nog niet hoezeer je me aan het spit gaat rijgen op dat moment. 
 - Bob: Ik zal nooit vergeten hoe stoïcijns jij getallen inklopte voor de IPDMA en de 100 
pagina’s Supplement. Het drukt goed je doortastendheid en doelgerichtheid uit die 
ik erg in je bewonder. Bedankt voor de gezellige tijd op het DC, voor je expertise op 
het gebied van IPDMA’s en propensity scores en voor de mannelijke noot tussen al 
het vrouwelijke geweld op het DC. Wat vind je daar nou eigenlijk zelf van?
 - Noortje: Brother-from-another-mother! Al heel snel na onze start op het DC 
verruilden wij collegialiteit voor vriendschap. We hebben elkaar op veel vlakken 
gevonden, zoals in een voorliefde voor harde en absurde grappen en Star Wars. Jij 
hebt een belangrijke bijdrage geleverd aan het plezier dat ik uit mijn promotietraject 
heb gehaald. Niet alleen in dat opzicht ben je waardevol voor me geweest. Ik heb ook 
veel van je geleerd. Ik heb zelden iemand ontmoet die zo lang en veel kan werken en 
die zo goed is in logisch redeneren (en dat toepast in communicatie naar centra, het 
bouwen van databases, het ontwerpen van studies, het houdt maar niet op). Ook heb 
ik van je geleerd dat het goed kan zijn om de confrontatie aan te gaan. Hoewel mijn 
tijd op het DC voorbij is, zal ik je blijven lastig vallen. Hopelijk durf je het aan om 
mij binnenkort op het platteland te komen bezoeken. Je weet wel, dat gebied buiten 
Amsterdam waar de meerderheid van Nederland woont. Ik kijk ernaar uit!
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 - Sven: Ik heb veel waardering voor je bodemloze nieuwsgierigheid op zowel medisch-
inhoudelijk als wetenschappelijk gebied, voor je humor en voor je werklust. En voor 
het feit dat je de ukelele bespeelt. Het is ons toch maar mooi gelukt om een paar 
maanden met z’n tweeën de PWN draaiende te houden! Als gezellige jongen uit het 
Zuiden des Lands had jij gelukkig ook altijd al om 12 uur honger. Ik heb veel van je 
geleerd en ik dank je voor een gezellig tijd. Heel veel succes met het afronden van je 
promotie, en hopelijk komen we elkaar in de kliniek weer tegen. 
 - Rens: Al lange tijd houd je als enige de CP-kant van de PWN draaiende, waarvoor 
hulde. Bedankt voor de jarenlange prettige samenwerking. 
 - Lotte: In de maanden dat we hebben samengewerkt heb ik je je leren kennen als een 
erg fijne collega, die ook nog eens verse cappuccino maakt! Dank daarvoor. Heel veel 
succes met de eindeloze lokale uitvoerbaarheid en met AXIOMA.  
 - Devica, werkpaard met pompende beats in je oren. Ook jij bedankt voor de fijne 
samenwerking en veel succes met de spechtenstudie! Mocht ik ooit nog voor je in 
de digitale rij moeten staan voor Kendrick Lamar of Beyoncé, geef dan maar een gil. 
 - Daan: de eerste tukker na Marc Besselink! Dat belooft veel goeds voor de PWN. 
Veel succes met alle studies die je nog gaat opzetten en bedankt voor de prettige 
samenwerking!
 - Hester, je was nog net niet begonnen toen ik het DC verliet, maar als ik bedenk hoe 
je als student wetenschappelijk onderzoek deed, dan kan het niet anders dan dat je 
dit project ook succesvol gaat afronden. 
Christa, veel succes en plezier bij het afronden van de FLUYT-studie. Ik heb je een 
maand bezig gezien en ben nu al uitermate blij met onze keuze voor jou. Je hebt de studie 
bijzonder snel opgepakt en dat geeft vertrouwen voor de toekomst. Ik zie ernaar uit om 
samen onderzoek te blijven doen. 
Ik wil graag de onderzoeksverpleegkundigen van FLUYT bedanken: Hadewijch, Cynthia 
en Jeroen. Zonder ondersteuning is een groot project zoals FLUYT onmogelijk. Dank 
voor al jullie hulp!
Minstens zoveel dank verdient Wietske Kievit. Het was erg fijn om met je te sparren 
over methodologische vraagstukken. Je adviezen hebben mijn studies aanzienlijk beter 
gemaakt. Maar ik zal ook nooit vergeten dat je tweede talent bij het hakken ligt. Veel 
succes bij de KNO!
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Michail Belias, I want to thank you as well. The IPDMA was, at least statistically, my most 
difficult project. Your guidance was paramount to its success. Thank you for your help. 
Tevens wil ik alle hoofdonderzoekers, arts-assistenten, afdelingsverpleegkundigen en 
endoscopieverpleegkundigen bedanken die op een manier hebben bijgedragen aan de 
FLUYT-studie. Het blijft lastig om in een klinische omgeving onderzoek op de juiste 
manier te incorporeren. Zonder jullie hulp zou FLUYT niet mogelijk zijn. 
Ook bedank ik alle co-auteurs van alle studies die ik heb uitgevoerd naast FLUYT. Die 
waren zonder jullie steun en advies niet mogelijk geweest. 
Dan de arts-onderzoekers van het Radboudumc. Dank Jos, Mark, Marten, Floor, Edgar, 
Titus, Hedwig, Yasmijn, Lauranne, Myrte, Anna, René, Ali, Lucas, Vince, Marleen, Dorian, 
Michelle, Karina, Angelique, Vera, Judith, Michiel, Kelly, Liyanne, Isabelle, Simon, Yonne, 
Lisa, Elsa, Ayla, Govert, Bram en Yannick. Wat is deze lijst belachelijk lang geworden in de 
loop van de jaren! Ik heb me altijd onderdeel van de groep gevoeld, ondanks het feit dat 
ik vaak afwezig was in verband met mijn werkzaamheden voor de PWN. Daar ben ik jullie 
dankbaar voor. Ik heb een geweldige tijd met jullie gehad en ik heb zin in de toekomst, 
waarin we collega’s worden in een klinische omgeving. Een aantal mensen wil ik speciaal 
noemen. René, bedankt dat je Limburgs bent en fervent postzegelverzamelaar. Vince, 
bedankt voor het verjongen van de afdeling met je puppygedrag. Kaat, medepromovendus 
van Erwin, bedankt voor het meedenken met al mijn onderzoeken en je steun in moeilijke 
tijden. Simon, bedankt voor de mooie tijd. Jij hebt er als geen ander voor gezorgd dat de 
afdeling mijn thuis werd. Tot slot Titus: bedankt voor het rollenspel ten tijde van mijn 
sollicitatie voor de opleiding. 
Veel dank, dames van de research unit, Sonja en Chantal, de spinnen in het web van de 
onderzoeksafdeling MDL. Bij jullie kon ik altijd terecht met (organisatorische) vragen 
omtrent onderzoek en kon ik sparren over GCP. Chantal, bedankt voor de ondersteuning 
bij het zoeken naar een researchverpleegkundige voor FLUYT. 
Veel dank ook aan het lab, in het bijzonder aan Hennie en René. Jullie zijn belangrijk 
geweest bij het onderzoek naar inflammatieparameters rondom ERCP, en jullie worden 
nog veel belangrijker bij het toekomstige onderzoek op het gebied van PEP en genetica. 
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Ik wil alle studenten bedanken die hebben bijgedragen aan de studies in dit proefschrift. 
In het bijzonder wil ik Iris Knoester bedanken, die als student belangrijk voorwerk heeft 
verricht voor de IPDMA. Ook bedank ik Nassim Bouhouch, die als bachelor student in 
zijn vrije tijd onderzoek komt doen, gewoon omdat hij dat leuk vindt. Met die instelling 
ga je het nog ver schoppen in onderzoeksland. 
Ook bedank ik mijn paranimfen. Sowieso omdat jullie mij als twee pinguïns terzijde 
stonden bij de verdediging. Maar ook omdat jullie in de afgelopen jaar gezorgd hebben 
voor steun en afleiding.
Tot slot begeef ik me naar persoonlijke sferen in mijn dankwoord. 
Allereerst mijn ouders: pap en mam, bedankt! Jullie vertrouwen in me heeft voor veel 
motivatie gezorgd. Jullie zijn op veel verschillende manieren een voorbeeld voor mij 
geweest. Met name twee zaken wil ik daarbij, in het licht van dit promotietraject, noemen: 
doorzettingsvermogen en breed blijven denken. Er is meer in de wereld dan werk en 
onderzoek. Daar heb ik veel aan gehad. Ik hou van jullie. 
Daarnaast mijn broer en zijn vriendin: Julien en Madelaine, ook uit jullie heb ik steun en 
vertrouwen gehaald tijdens dit traject. Ik heb veel bewondering voor de manier waarop 
jullie je hart volgen in je werk, ondanks het feit dat daar soms onzekerheid bij komt (of 
misschien moet ik inmiddels zeggen: kwam) kijken. Maar daarnaast ook simpelweg veel 
dank voor de afleiding waarvoor jullie zorgden in de afgelopen jaren. 
Hennie en Bart, Joost en Maartje, Christan en Marc: bedankt dat ik altijd welkom ben in 
Maastricht om bij te komen van een werkweek. Hennie en Bart, bij jullie staat de deur 
altijd open en het is heerlijk om in die hartelijkheid te vertoeven. Veel dank voor de steun 
die jullie gegeven hebben in de afgelopen jaren. Joost en Maartje, het was prettig om altijd 
bij jullie in de zaak koffie te kunnen drinken en mijn laptop te kunnen gebruiken als ik 
weer eens in het weekend moest werken. Christan en Marc, ook jullie veel dank voor de 
steun in de afgelopen jaren. 
Tot slot bedank ik Gijs, de belangrijkste persoon in mijn leven. Ik ben nog iedere dag blij 
dat ik jaren geleden (iets te veel) spraakwater met je ben gaan drinken in een restaurant 
in Nijmegen. Je verbreedt mijn wereld, doorbreekt mijn routine (al moet ik zeggen dat het 
op willekeurige momenten afspelen van Carnival Festival van de Efteling iets te veel van 
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het goede is) en in deze turbulente tijd zorgde jij voor onvoorwaardelijke steun. Daar ben 
ik je voor altijd dankbaar voor. Ik ben erg gelukkig in dit leven waarin we elkaar aanvullen: 
jij rijdt auto, ik lees de krant op de bijrijdersstoel. Jij kookt, ik eet het op. En zo kan ik nog 
wel even doorgaan. Ik hou van je en zie ernaar uit om samen oud te worden!
Xavier Smeets
Den Bosch, 24 april 2018
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Curriculum vitae
Xavier Johannes Nicolaas Marie Smeets werd op 18 maart 1989 
geboren in Heerlen (Limburg) en groeide op in Einighausen 
(hoewel de naam anders doet vermoeden, ligt ook dit dorp 
in Limburg). Hij volgde de middelbare school boven de grote 
rivieren in Nijmegen, aan het Stedelijk Gymnasium, waar hij 
in 2007 zijn diploma cum laude behaalde. Daarna besloot hij de 
noordelijke regionen van Nederland te verkennen door de studie 
Geneeskunde te volgen aan de Rijksuniversiteit Groningen. In 
2015 haalde hij daar zijn artsexamen. 
Door een gelukkige samenloop van omstandigheden kon hij daarna direct aan de slag 
als promovendus op de afdeling Maag-, Darm- en Leverziekten in het Radboudumc. 
Onder leiding van copromotor dr. Erwin van Geenen en promotor prof. dr. Joost 
Drenth coördineerde hij de landelijke FLUYT-trial, een studie bij 826 patiënten uit 20 
ziekenhuizen naar preventie van post-ERCP pancreatitis door middel van periprocedurele 
hydratie. Ook zijn verdere promotietraject stond in het teken van het voorkomen van 
acute pancreatitis, en het voorspellen van het ziektebeloop. Als arts-onderzoeker was hij 
tevens verbonden aan de Pancreatitis Werkgroep Nederland, een onderzoeksgroep die op 
nationaal en internationaal niveau onderzoek doet naar acute en chronische pancreatitis 
en tevens fungeert als adviesorgaan bij complexe casuïstiek. 
Op 1 mei 2018 startte Xavier als AIOS Interne Geneeskunde in het Jeroen Bosch Ziekenhuis 
in ’s Hertogenbosch (opleider dr. W. Smit), als onderdeel van zijn opleiding tot Maag-, 
Darm- en Leverarts. Xavier woont in ’s Hertogenbosch met zijn vriend Gijs.
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PhD Portfolio
Name PhD candidate: X.J.N.M. Smeets
Department: Gastroenterology & Hepatology
Graduate School: Radboud Institute for Molecular Life 
Sciences
PhD period: 01-04-2015 – 30-04-2018
Promotor: Prof. J.P.H. Drenth
Co-promotor: Dr. E.J.M. van Geenen
TRAINING ACTIVITIES Year(s) ECTS
Courses & workshops
BROK course 2015 1.5
RCT course Centre for Statistics in Medicine (Oxford, UK) 2015 2.5
Management for PhDs 2016 2.0
Presenting in English 2016 1.5
Scientific Integrity Course 2017 1.0
Seminars & lectures
Radboud Research Rounds 2015-2018 2.0
Ravenstein GI lectures (yearly 6x) 2015-2018 1.5
GI-Hep meetings (yearly 8x) 2015-2018 1.5
Grant Club Gastroenterology & Hepatology 2017-2018 1.0
PhD retreat Gastroenterology & Hepatology 2015-2018 3.0
Symposia & congresses
NVGE voor- en najaarsdagen (4x) 2015-2018 1.0
Pancreas day (oral presentation) 2016 1.5
UEGW (oral presentation & poster presentation) 2018 1.0
Other
MDL ontwikkelplan 2015-2018 5.0
Journal clubs Gastroenterology&Hepatology (weekly) 2015-2018 5.0
Research meetings Gastroenterology&Hepatology (weekly) 2015-2018 5.0
Coordination Dutch Pancreatitis Study Group (daily) 2015-2018 12.0
Grant writing (3x) 2015-2018 6.0
TEACHING ACTIVITIES
Lecturing
Education on acute pancreatitis in Dutch hospitals 2015-2018 3.0
Supervision of internships / other
(Co-)supervision Master student internships 2016-2018 2.0
Supervising research nurses FLUYT trial 2016-2018 2.0
TOTAL 61.0
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